StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
642 Study Matches

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) (cAMeLot-1)

Study Contact - Participate-In-This-Study1@its.jnj.com

NCT04811560
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Phase 1: * Age 2 years and above (pediatric cohort only), all other cohorts 18 years and above * Relapsed or refractory (R/R) acute leukemia and has exhausted, or is ineligible for, available therapeutic options * Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 gene (NPM1) or nucleoporin 98 gene or nucleoporin 214 gene (NUP98 or NUP214) alterations Phase: 2 * Participants greater than 18 years are eligible * Must have had an initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria and have relapsed/refractory disease * AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only For Both Phase 1 and 2: * Pretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count less than or equal to (\<=) 20\*10\^9/liter (L) and (b) renal function; For adult participants, estimated or measured glomerular filtration rate greater than equal (\>=) 30 milliliter per minute (mL/min) per four variable MDRD equation. For pediatric participants an estimated or measured glomerular filtration rate \>50 mL/min per the CKiD (Chronic Kidney Disease in Children) Schwartz formula * Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2. Pediatric participants only: Performance status \>=70 by Lansky scale (for participants less than \[\<\]16 years of age) or \>=70 Karnofsky scale (for participants \>=16 years of age) * A female of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment * Participant must agree to all protocol required contraception requirements and avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment
Exclusion Criteria:
* Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia or juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria * Active central nervous system (CNS) disease * Prior solid organ transplantation * QTc according to Fridericia's formula (QTcF) for males \>= 450 millisecond (msec) or for females \>= 470 msec. Participants with a family history of Long QT syndrome are excluded * Exclusion criteria related to stem cell transplant: a. Received prior treatment with allogenic bone marrow or stem cell transplant \<=3 months before the first dose of study treatment; b. Has evidence of graft versus host disease; c. Received donor lymphocyte infusion \<=1 month before the first dose of study treatment; d. Requires immunosuppressant therapy (exception: daily doses \<=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement) * Prior cancer immunotherapy within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)
DRUG: Bleximenib
Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
I'm interested
Share via email
Show 100 locations

Study Locations

Hide all locations
Location Contacts
Asan Medical Center Seoul,
Baylor University Medical Center Dallas, Texas
CHRU Nancy Brabois Vandœuvre-lès-Nancy,
CHU Bretonneau Tours,
CHU Lyon Sud Pierre-Bénite,
CHU de Nantes hotel Dieu Nantes,
Carmel Medical Center Haifa,
Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie Pessac,
China Medical University Hospital Taichung,
City of Hope Duarte, California
City of Hope Phoenix Goodyear, Arizona
Clinica Univ. de Navarra Pamplona,
Dana Farber Cancer Institute Boston, Massachusetts
First Affiliated Hospital Medical School of Zhejiang University Hangzhou,
Fox Chase Cancer Center Philadelphia, Pennsylvania
Fukushima Medical University Hospital Fukushima,
Fundacao Antonio Prudente A C Camargo Cancer Center São Paulo,
Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo São Paulo,
Gold Coast University Hospital Southport,
Gunmaken Saiseikai Maebashi Hospital Maebashi,
Gustave Roussy Villejuif,
Guys and St Thomas NHS Foundation Trust London,
Hadassah University Hospita Ein Kerem Jerusalem,
Henan Cancer Hospital Zhengzhou, Henan
Hokkaido University Hospital Sapporo,
Hopital Jean Minjoz Besançon,
Hopital Maisonneuve Rosemont Montreal, Quebec
Hopital Saint Louis Paris, Île-de-France Region
Hopital trousseau- APHP Paris,
Hosp Clinic de Barcelona Barcelona,
Hosp Clinico Univ de Salamanca Salamanca,
Hosp Univ Fund Jimenez Diaz Madrid,
Hosp Univ Vall D Hebron Barcelona,
Hosp. Clinico Univ. de Valencia Valencia,
Hosp. Gral. Univ. Gregorio Marañon Madrid,
Hosp. Virgen Del Rocio Seville,
Houston Methodist Hospital Houston, Texas
Institut Paoli Calmettes Marseille,
Institut Universitaire du Cancer Toulouse Oncopole Toulouse,
Institut de Cancerologie Strasbourg Europe ICANS Strasbourg,
Institute of Hematology and Blood Diseases Hospital Tianjin,
Instituto D Or de Pesquisa e Ensino São Paulo,
Instituto D Or de Pesquisa e Ensino IDOR São Paulo,
Kanazawa University Hospital Kanazawa,
Karmanos Cancer Institute Detroit, Michigan
Kobe City Medical Center General Hospital Hyōgo,
Kyushu University Hospital Fukuoka,
Leeds Teaching Hospitals NHS Trust Leeds,
Liga Norte Riograndense Contra O Cancer Natal, Rio Grande do Norte
MD Anderson Houston, Texas
Maine Health Providence, Rhode Island
Massachusetts General Hospital Boston, Massachusetts
Medical College of WI at Froedtert Milwaukee, Wisconsin
Ministerio da Saude Instituto Nacional do Cancer Rio de Janeiro,
Monash Medical Centre Clayton, Victoria
Montefiore Medical Center The Bronx, New York
NTT Medical Center Tokyo Tokyo,
NYU Langone Medical Center New York, New York
Nagoya University Hospital Nagoya, Aichi-ken
Nanfang Hospital of Southern Medical Hospital Guangzhou,
National Cancer Center Hospital East Kashiwa,
National Cheng Kung University Hospital Tainan,
National Taiwan University Hospital Taipei,
Norton Cancer Institute Louisville, Kentucky
Oregon Health and Science University Portland, Oregon
Oxford University Hospitals NHS Trust Oxfordshire,
Peking University First Hospital Beijing, Beijing Municipality
Princess Margaret Cancer Centre University Health Network Toronto, Ontario
Qilu Hospital of Shandong University Jinan, Shandong
Roswell Park Comprehensive Cancer Center Buffalo, New York
Royal Perth Hospital Perth, Western Australia
START Midwest Grand Rapids, Michigan
Samsung Medical Center Seoul,
San Antonio Methodist TX Transplant Physicians Group San Antonio, Texas
Seoul National University Hospital Seoul,
Sheba Medical Center Ramat Gan,
St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Indianapolis, Indiana
Swedish Cancer Institute Seattle, Washington
Tel Aviv Sourasky Medical Center Tel Aviv,
The Christie NHS Foundation Trust Manchester,
The Clatterbridge Cancer Centre Liverpool,
The First Affiliated Hospital of NanChang University Nanchang, Jiangxi
The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang
UCSF Benioff Children's Hospital San Francisco, California
Union Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan,
University College London Hospitals London,
University Hospital of Wales Cardiff,
University Hospitals Plymouth NHS Trust Plymouth,
University of California Irvine Medical Center Orange, California
University of California San Francisco San Francisco, California
University of Chicago Chicago, Illinois
University of Fukui Hospital Yoshida,
University of New Mexico Albuquerque, New Mexico
University of Tennessee Medical Center Knoxville, Tennessee
Vancouver Coastal Health Vancouver, British Columbia
Virginia Commonwealth University Richmond, Virginia
West China Hospital Si Chuan University Chengdu,
Yamagata University Hospital Yamagata,
Zhongda Hospital Southeast University Nanjing, Jiangsu
the First Hospital of Jilin University Changchun, Jilin

Enhancing Oral Cancer Awareness

Tamas Gal, Ph.D - Tamas.Gal@vcuhealth.org

NCT06682494
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Identify as African American as defined by the US Census * Participants must be able to read, speak, and write in English
Exclusion Criteria:
* Individuals who cannot physically or mentally participate in the research project will be excluded * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners
BEHAVIORAL: Traditional Education, BEHAVIORAL: AI-powered Chatbox
Oral Cancer, Chatbot, Patient Education, Prevention, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancers
AI-powered Chatbox, Oral cancer prevention, Socio-economic barriers
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Tamas Gal, Ph.D - (Tamas.Gal@vcuhealth.org)

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in Men With Opioid Use Disorder Who Are Taking Buprenorphine

Boehringer Ingelheim - clintriage.rdg@boehringer-ingelheim.com

NCT06628622
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Male participants, 18 to 65 years of age, both inclusively, at the time of consent
• Meet current diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) criteria for opioid use disorder, of at least moderate severity within the 12 months prior to screening
• Currently engaged in medications for opioid use disorder (MOUD) treatment with one of the following regimens:
• buprenorphine/naloxone sublingual film total daily dose ranging from 8 mg/2 mg to 24 mg/6 mg for at least 2 weeks at screening OR
• buprenorphine/naloxone sublingual tablet from 5.7 mg/1.4 mg to 17.1 mg/4.3 mg total daily dose for at least 2 weeks at screening OR
• buprenorphine sublingual tablet from 8 mg to 24 mg total daily dose for at least 2 weeks at screening OR
• on a stable dose of depot injectable buprenorphine for at least 5 weeks at screening, with at least 1 week since last depot buprenorphine injection
• Have a current MOUD prescription in accordance with inclusion criterion 4 and a positive urine drug screen for buprenorphine during screening and upon presenting for randomization to document buprenorphine use
• Willingness to abstain from using alcohol for 24 hours (h) and all other drugs of abuse for 72 h prior to Day 1 and through discharge from the trial site on Day 9
• Further inclusion criteria apply
Exclusion Criteria:

• Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, delusional disorder, or autism spectrum disorder as confirmed by the mini international neuropsychiatric interview (MINI) at the screening visit
• Moderate or severe substance use disorder other than opioid use disorder (OUD) within the 6 months prior to screening (excluding tobacco, caffeine, and moderate stimulant use)
• Severe stimulant use disorder within the 6 months prior to screening
• Any other psychiatric disorder that is not currently stable in symptoms and treatment. Stable is defined as having no significant changes in symptom acuity or treatment (medication or psychotherapy treatment) in the 8 weeks prior to randomization
• Score of ≥20 on the Montgomery-Åsberg Depression Rating Scale (MADRS)
• Positive results on a urine drug screen for ≥3 drugs (not counting buprenorphine or TCAs) at screening. In the case of a positive drug screen for 1 or 2 agents, if the participant does not meet the exclusion criteria regarding substance use disorder for these compounds, they may be included if the investigator determines that use will not be an impediment to trial participation or accurate data collection
• Any positive result on a urine drug screen (not counting buprenorphine, TCAs, or cannabis) at admission to the trial site on Day -1
• Intoxication at screening or randomization, as determined by clinical exam and breathalyzer
• Further exclusion criteria apply
DRUG: BI 1356225, DRUG: Placebo
Opioid Use Disorder
I'm interested
Share via email
Show 5 locations

Study Locations

Hide all locations
Location Contacts
Collaborative Neuroscience Research, LLC, Los Alamitos Los Alamitos, California Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Hassman Research Institute-Marlton-66897 Marlton, New Jersey Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of California Los Angeles Los Angeles, California Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Virginia Commonwealth University Richmond, Virginia Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
iResearch Atlanta Decatur, Georgia Boehringer Ingelheim - (unitedstates@bitrialsupport.com)

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (OMAHA-003)

Toll Free Number - Trialsites@msd.com

NCT06136624
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology. * Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening * Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI). * Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA) * Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment * Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<1.7 nM) * Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization * Has had prior treatment with PARPi or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment * Has received prior 177Lu-PSMA-617 or were deemed ineligible to receive 177Lu-PSMA-617 treatment by the investigator or refused 177Lu-PSMA-617 treatment * Participants who have not received cabazitaxel can be enrolled if they are ineligible for cabazitaxel treatment as determined by the investigator or have refused treatment * If participant received first generation anti-androgen therapy before screening, the participant has evidence of disease progression \>4 weeks since the last flutamide treatment and \>6 weeks since the last bicalutamide or nilutamide treatment * Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for ≥ 4 weeks before the date of randomization * Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening. * Participants who can produce sperm must agree to the following during the study treatment period and for at least 7 days after the last dose of opevesostat, for at least 30 days after the last dose of abiraterone acetate, and for at least 3 months after the last dose of enzalutamide: EITHER be abstinent OR must agree to use male condom
Exclusion Criteria:
* Has a gastrointestinal disorder that might affect absorption * Has a history of pituitary dysfunction * Has poorly controlled diabetes mellitus * Has clinically significant abnormal serum potassium or sodium level * Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events * Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization * Has a history of clinically significant ventricular arrhythmias * Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization * Has undergone major surgery, including local prostate intervention (except prostate biopsy), within 28 days before the date of randomization, and has not recovered from the toxicities and/or complications * Participants who have not adequately recovered from major surgery or have ongoing surgical complications * Has used herbal or medicinal products that may have hormonal anti-prostate cancer activity and/or are known to decrease prostate-specific Antigen (PSA) (eg, saw palmetto, megesterol acetate, citrus pectin polysaccharide) within 4 weeks before the date of randomization * Has received radium-223 or lutetium-177 within 4 weeks before the date of randomization, or has not recovered to Grade ≤1 or baseline from AEs due to radium-223 or lutetium-177 administered more than 4 weeks before the date of randomization * Has received treatment with 5-αreductase inhibitors (eg, finasteride or dutasteride), estrogens, or cyproterone within 4 weeks before the date of randomization * Has received colony-stimulating factors within 28 days before the date of randomization * Has received a whole blood transfusion in the last 120 days before the date of randomization. Packed red blood cells and platelet transfusions are acceptable if not given within 28 days of the date of randomization * Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention as follows: enzalutamide or apalutamide within 3 weeks or abiraterone acetate + prednisone or darolutamide within 2 weeks * Has a "superscan" bone scan * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has an active infection requiring systemic therapy * Has concurrent active HBV or known active HCV infection * Has a history of long QTc syndrome * Has any of the following at Screening Visit: hypotension (systolic BP \<110 mm Hg) or uncontrolled hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥90 mm Hg, in 2 out of 3 recordings with optimized antihypertensive therapy) * Is unable to swallow capsules/tablets * Is currently being treated with cytochrome 450-inducing antiepileptic drugs for seizures * Participants on an unstable dose of thyroid hormone therapy within 6 months before the start of the study intervention * Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Systemic use of the following medications within 2 weeks before the first dose of study intervention: strong CYP3A4 inducers (eg, avasimibe, carbamazepine, lumacaftor, phenobarbital, rifampicin, rifapentine, or St John's Wort); P-gp inhibitors (eg, erythromycin, clarithromycin, rifampicin, ketoconazole, itraconazole, posaconazole, artesunate-pyronaridine, ritonavir, indinavir, nelfinavir, atazanavir, glecaprevir-pibrentasvir, simeprevir, ledipasvir-sofosbuvir, verapamil, diltiazem, dronedarone, propafenone, quinidine, cyclosporine, valspodar, or milk thistle \[Silybum marianum\]) * Use of aldosterone antagonist (eg, spironolactone, eplerenone) and phenytoin within 4 weeks before the start of the study intervention
DRUG: Opevesostat, DRUG: Abiraterone acetate, DRUG: Enzalutamide, DRUG: Hydrocortisone, DRUG: Fludrocortisone acetate, DRUG: Prednisone, DRUG: Dexamethasone
Prostate Cancer Metastatic
I'm interested
Share via email
Show 281 locations

Study Locations

Hide all locations
Location Contacts
A. C. Camargo Cancer Center ( Site 0310) São Paulo, São Paulo
AHN Allegheny General Hospital ( Site 0001) Pittsburgh, Pennsylvania
Ad-Vance Medical Research-Research ( Site 1353) Ponce,
Addenbrooke's Hospital ( Site 1605) Cambridge, Cambridgeshire
Affiliated hospital of Jiangnan university ( Site 0434) Wuxi, Jiangsu
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1477) Uppsala, Uppsala County
Akershus Universitetssykehus-Onkologisk avdeling ( Site 1227) Lørenskog, Akershus
Akita University Hospital ( Site 0904) Akita,
Aliada-Oncologìa ( Site 1257) Lima,
Amsterdam UMC, locatie VUmc ( Site 1156) Amsterdam, North Holland
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1552) Ankara,
Anschutz Cancer Pavilion ( Site 0046) Aurora, Colorado
Asahikawa Medical University Hospital ( Site 0901) Asahikawa, Hokkaido
Asan Medical Center-Oncology ( Site 1402) Songpagu, Seoul
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205) Buenos Aires, Buenos Aires F.D.
Atlantic Health System Morristown Medical Center ( Site 0115) Morristown, New Jersey
Avera Cancer Institute - Pierre ( Site 0118) Pierre, South Dakota
Avera Cancer Institute - Yankton ( Site 0117) Yankton, South Dakota
Avera Cancer Institute- Research ( Site 0094) Sioux Falls, South Dakota
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 0752) Kecskemét, Bács-Kiskun county
Baltimore Veterans Affairs Medical Center ( Site 0069) Baltimore, Maryland
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1554) Adana,
Beijing Cancer hospital-Urinary Surgery ( Site 0395) Beijing, Beijing Municipality
Beijing Friendship Hospital Affiliate of Capital University ( Site 0396) Beijing, Beijing Municipality
Bell Land General Hospital ( Site 0913) Sakai, Osaka
Blue Ridge Cancer Care ( Site 0004) Roanoke, Virginia
Bradford Hill Norte ( Site 0357) Antofagasta,
Bradfordhill-Clinical Area ( Site 0351) Santiago, Region M. de Santiago
Bruce W. Carter Veterans Affairs Medical Center ( Site 0082) Miami, Florida
CIO - Centro de Inmuno-Oncología de Occidente ( Site 1103) Guadalajara, Jalisco
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0632) Rennes, Ille-et-Vilaine
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 0630) Nîmes, Gard
Centre Hospitalier de l'Université de Montréal ( Site 0326) Montreal, Quebec
Centre Hospitalier de la Côte Basque ( Site 0633) Bayonne, Pyrenees-Atlantiques
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328) Greenfield Park, Quebec
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0629) Clermont-Ferrand, Puy-de-Dome
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327) Québec, Quebec
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329) Sherbrooke, Quebec
Centro de Investigacion Clinica de Oaxaca ( Site 1109) Oaxaca City,
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1302) Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Chang Gung Medical Foundation-Linkou Branch-Medical Oncology ( Site 1504) Taoyuan District,
Charing Cross Hospital-Oncology Research ( Site 1606) London, Hammersmith and Fulham
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0679) Berlin,
China Medical University Hospital-Department of Urology ( Site 1503) Taichung,
Chongqing Three Gorges Central Hospital's ( Site 0426) Chongqing, Chongqing Municipality
Chongqing University Cancer Hospital ( Site 0416) Chongqing, Chongqing Municipality
Chulalongkorn University ( Site 1530) Bangkok, Bangkok
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0501) Bogotá, Bogota D.C.
Clinica Universidad Catolica del Maule-Oncology ( Site 0355) Talca, Maule Region
Clinical Research Chile SpA ( Site 0358) Valdivia, Los Ríos Region
Clínica Imbanaco S.A.S ( Site 0509) Cali, Valle del Cauca Department
Clínica Sánchez Ferrer ( Site 1261) Trujillo, La Libertad
Clínica de Neoplasias Litoral ( Site 0305) Itajaí, Santa Catarina
Colorado Clinical Research ( Site 0067) Lakewood, Colorado
Complexo Hospitalario Universitario de Ourense ( Site 1426) Ourense, Orense
Comprehensive Cancer Centers of Nevada ( Site 0010) Las Vegas, Nevada
Cross Cancer Institute ( Site 0332) Edmonton, Alberta
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0758) Debrecen,
Dubbo Hospital ( Site 0235) Dubbo, New South Wales
Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203) Dunedin, Otago
ETZ Elisabeth-Internal Medicine ( Site 1160) Tilburg, North Brabant
Ehime University Hospital ( Site 0918) Tōon, Ehime
Emek Medical Center ( Site 0830) Afula,
FALP ( Site 0353) Santiago, Region M. de Santiago
Faculty of Medicine - Khon Kaen University ( Site 1526) Muang, Changwat Khon Kaen
Faculty of Medicine Siriraj Hospital ( Site 1531) Bangkok, Bangkok
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0555) Olomouc, Olomoucký kraj
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0554) Ostrava, Moravskoslezský kraj
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551) Prague, Praha 5
Filios Alta Medicina ( Site 1106) Monterrey, Nuevo León
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436) Huaian, Jiangsu
Florida Cancer Specialists - South ( Site 7003) Fort Myers, Florida
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0877) Milan, Lombardy
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1151) Schiedam, South Holland
Fred Hutchinson Cancer Center ( Site 0013) Seattle, Washington
Fudan University Shanghai Cancer Center-Urology department ( Site 0376) Shanghai, Shanghai Municipality
Fukushima Medical University Hospital ( Site 0933) Fukushima,
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204) Mendoza,
Fundación Cardiovascular de Colombia ( Site 0503) Piedecuesta, Santander Department
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1430) Valencia, Valenciana, Comunitat
Fundación Valle del Lili ( Site 0505) Cali, Valle del Cauca Department
Gifu University Hospital ( Site 0910) Gifu,
Greenebaum Comprehensive Cancer Center ( Site 0049) Baltimore, Maryland
Gulhane Egitim Arastirma Hastanesi ( Site 1558) Ankara,
Gustave Roussy ( Site 0626) Villejuif, Val-de-Marne
HELIOS Kliniken Schwerin ( Site 0694) Schwerin, Mecklenburg-Vorpommern
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1428) Seville,
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1551) Ankara,
Hadassah Medical Center ( Site 0833) Jerusalem,
Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1164) The Hague, South Holland
Henry Ford Hospital ( Site 0015) Detroit, Michigan
Hiroshima University Hospital ( Site 0916) Hiroshima,
Hokkaido University Hospital ( Site 0931) Sapporo, Hokkaido
Hospital Aleman-Oncology ( Site 0207) Buenos Aires,
Hospital Británico de Buenos Aires-Oncology ( Site 0202) Ciudad Autónoma de Buenos Aires, Buenos Aires
Hospital Felicio Rocho ( Site 0317) Belo Horizonte, Minas Gerais
Hospital Jerez de la Frontera ( Site 1427) Jerez de la Frontera, Cadiz
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1078) Kuala Lumpur,
Hospital Lucus Augusti-Oncology ( Site 1432) Lugo,
Hospital Mario Penna ( Site 0309) Belo Horizonte, Minas Gerais
Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320) Vitória, Espírito Santo
Hospital Sultan Ismail ( Site 1081) Johor Bahru, Johor
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1433) Madrid, Madrid, Comunidad de
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1431) Madrid, Madrid, Comunidad de
Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314) Curitiba, Paraná
Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308) Bragança Paulista, São Paulo
Hospital of the University of Occupational and Environmental Health, Japan ( Site 0921) Kitakyushu, Fukuoka
Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388) Shanghai, Shanghai Municipality
Hubei Cancer Hospital-Urinary surgery ( Site 0406) Wuhan, Hubei
Hunan Cancer Hospital ( Site 0405) Changsha, Hunan
Hôpital Européen Georges Pompidou ( Site 0628) Paris,
IC La Serena Research ( Site 0356) La Serena, Coquimbo Region
IMAT S.A.S ( Site 0504) Montería, Departamento de Córdoba
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 1256) Lima,
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 1254) Lima,
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 0879) Meldola, Emilia-Romagna
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0627) Strasbourg, Alsace
Instituto Alexander Fleming-Alexander Fleming ( Site 0206) Buenos Aires, Buenos Aires F.D.
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 1258) Concepción, Departamento de Junín
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201) Mar del Plata, Buenos Aires
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1555) Istanbul,
James J. Peters VA Medical Center ( Site 0088) The Bronx, New York
Jiangxi Cancer Hospital ( Site 0386) Nanchang, Jiangxi
Kagawa University Hospital ( Site 0917) Kita, Kagawa-ken
Kagoshima University Hospital ( Site 0929) Kagoshima,
Kaiser Permanente Riverside Medical Center ( Site 0099) Riverside, California
Kanazawa Medical University Hospital ( Site 0909) Mukai-awagasaki, Ishikawa-ken
Kansai Medical University Hospital ( Site 0912) Hirakata, Osaka
Karolinska Universitetssjukhuset Solna ( Site 1478) Stockholm, Stockholm County
Klinikum Wels-Grieskirchen GmbH ( Site 0279) Wels, Upper Austria
Kobe University Hospital ( Site 0914) Kobe, Hyōgo
Kuopion Yliopistollinen Sairaala ( Site 0603) Kuopio, Northern Savonia
Kurume University Hospital ( Site 0920) Kurume, Fukuoka
Kyushu University Hospital ( Site 0919) Fukuoka,
M Health Fairview Clinics and Surgery Center ( Site 0019) Minneapolis, Minnesota
MEDICAL COLLEGE OF WISCONSIN ( Site 0020) Milwaukee, Wisconsin
Macquarie University-MQ Health Clinical Trials Unit ( Site 0234) Macquarie University, New South Wales
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0553) Brno, Brno-mesto
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1310) Siedlce, Masovian Voivodeship
Meander Medisch Centrum ( Site 1157) Amersfoort, Utrecht
Medical Care and Research SA de CV ( Site 1108) Mérida, Yucatán
Medische Centrum Leeuwarden ( Site 1172) Leeuwarden, Provincie Friesland
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280) Graz, Styria
Meir Medical Center. ( Site 0832) Kfar Saba,
Memorial Ankara Hastanesi-Medical Oncology ( Site 1557) Ankara,
Metro-Minnesota Community Clinical Oncology ( Site 0014) Saint Louis Park, Minnesota
Miyazaki Prefectural Miyazaki Hospital ( Site 0927) Miyazaki,
Nagano Municipal Hospital ( Site 0932) Nagano,
Nanbu Tokushukai Hospital ( Site 0930) Shimajiri, Okinawa
Nanchong Central Hospital-urology ( Site 0422) Nanchong, Sichuan
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377) Nanjing, Jiangsu
Nara Medical University Hospital ( Site 0915) Kashihara, Nara
National Cancer Centre Singapore ( Site 1377) Singapore, Central Singapore
National Cancer Institute ( Site 1079) Putrajaya, Putrajaya
National Cheng Kung University Hospital-Urology ( Site 1502) Tainan,
National Hospital Organization Kumamoto Medical Center ( Site 0924) Kumamoto,
National Hospital Organization Nagasaki Medical Center ( Site 0923) Ōmura, Nagasaki
National Hospital Organization Oita Medical Center ( Site 0925) Ōita,
National Taiwan University Hospital-Urology ( Site 1506) Taipei,
National University Hospital ( Site 1376) Singapore, Central Singapore
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1153) Amsterdam, North Holland
Nograd Varmegyei Szent Lazar Korhaz-Onkologia es Sugarterapias Osztaly ( Site 0761) Salgótarján, Nógrád megye
Obras Sociais Irma Dulce ( Site 0302) Salvador, Estado de Bahia
Ochsner Clinic Foundation ( Site 0108) New Orleans, Louisiana
Odense Universitetshospital-Department of oncology ( Site 0579) Odense, Region Syddanmark
Oncosalud-Clinical Research ( Site 1260) Lima,
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276) Linz, Upper Austria
Oregon Health and Science University ( Site 0028) Portland, Oregon
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 0756) Budapest, Pest County
Ospedale San Raffaele-Oncologia Medica ( Site 0876) Milan,
Pan American Center for Oncology Trials - Ciudadela ( Site 1351) San Juan,
Peking University First Hospital-Urology ( Site 0390) Beijing, Beijing Municipality
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230) Melbourne, Victoria
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354) Santiago, Region M. de Santiago
Prince of Wales Hospital ( Site 0730) Shatin,
Princess Alexandra Hospital-Cancer Care Serices ( Site 0237) Brisbane, Queensland
Princess Margaret Cancer Centre ( Site 0330) Toronto, Ontario
Puerto Rico Medical Research Center LLC ( Site 1354) Hato Rey,
Queen Mary Hospital ( Site 0727) Hong Kong,
Quemex Medical and Research ( Site 1112) Mexico City, Mexico City
Rabin Medical Center ( Site 0828) Petah Tikva,
Radboudumc-Medical Oncology ( Site 1152) Nijmegen, Gelderland
Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) Charleston, South Carolina
Rambam Health Care Campus-Oncology Division ( Site 0826) Haifa,
Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1316) Grudziądz, Kuyavian-Pomeranian Voivodeship
Rigshospitalet ( Site 0576) Copenhagen, Capital Region
Rutgers Cancer Institute of New Jersey ( Site 0033) New Brunswick, New Jersey
SCRI Oncology Partners ( Site 7000) Nashville, Tennessee
Saga-Ken Medical Centre Koseikan ( Site 0922) Saga, Saga-ken
Sahlgrenska Universitetssjukhuset ( Site 1479) Gothenburg, Västra Götaland County
Samsun Medical Park Hastanesi-medical oncology (1560) Samsun, Dilek Erdem - (dilekgurgenyatagi@yahoo.com)
Samsung Medical Center ( Site 1405) Seoul,
Sanatorio Parque ( Site 0208) Rosario, Santa Fe Province
Sapporo Medical University Hospital ( Site 0902) Sapporo, Hokkaido
Sarawak General Hospital-Radiotherapy Unit ( Site 1076) Kuching, Sarawak
Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408) Hefei, Anhui
Seoul National University Hospital-Oncology ( Site 1401) Seoul,
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1404) Seoul,
Sheba Medical Center ( Site 0827) Ramat Gan,
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0502) Valledupar, Cesar Department
Songklanagarind hospital ( Site 1527) Hat Yai, Changwat Songkhla
Southwest Hospital of Third Military Medical University ( Site 0420) Chongqing, Chongqing Municipality
Spaarne Gasthuis - Hoofddorp-Oncology ( Site 1170) Hoofddorp, North Holland
St. Olavs Hospital-Kreftklinikken ( Site 1231) Trondheim, Sor-Trondelag
St. Vincent's University Hospital ( Site 0802) Dublin, Dublin
Stanford Cancer Center ( Site 0036) Palo Alto, California
Suining Central Hospital ( Site 0437) Suining, Sichuan
Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413) Guangzhou, Guangdong
Sunnybrook Research Institute ( Site 0331) Toronto, Ontario
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1318) Kielce, Świętokrzyskie Voivodeship
Sykehuset Østfold Kalnes ( Site 1228) Sarpsborg, Østfold fylke
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1303) Koszalin, West Pomeranian Voivodeship
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1553) Istanbul,
Taipei Veterans General Hospital ( Site 1505) Taipei,
Tallaght University Hospital ( Site 0801) Dublin,
Tampereen yliopistollinen sairaala ( Site 0604) Tampere, Pirkanmaa
Tan Tock Seng Hospital-Medical Oncology ( Site 1378) Singapore, Central Singapore
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201) Tauranga, Bay of Plenty
Texas Oncology - Central/South Texas ( Site 8003) Austin, Texas
Texas Oncology - DFW ( Site 8001) Dallas, Texas
Texas Oncology - Gulf Coast ( Site 8002) The Woodlands, Texas
The Beatson West of Scotland Cancer Centre ( Site 1603) Glasgow, Glasgow City
The Christie NHS Foundation Trust ( Site 1608) Manchester,
The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414) Fuzhou, Fujian
The First Affiliated Hospital of Chongqing Medical University ( Site 0427) Chongqing, Chongqing Municipality
The First Affiliated Hospital of Guangzhou Medical University ( Site 0412) Guangzhou, Guangdong
The First Affiliated Hospital of Ningbo University ( Site 0383) Ningbo, Zhejiang
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379) Wenzhou, Zhejiang
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393) Xi'an, Shaanxi
The First Affiliated hospital of Xiamen University-Urology ( Site 0415) Xiamen, Fujian
The First Hospital of Jiaxing-urology ( Site 0380) Jiaxing, Zhejiang
The Jikei University Hospital ( Site 0907) Minato, Tokyo
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336) Ottawa, Ontario
The Royal Cornwall Hospital ( Site 1610) Truro, England
The Second Affiliated Hospital Of Kunming Medical University ( Site 0429) Kunming, Yunnan
The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394) Xi'an, Shaanxi
The Second Hospital of Tianjin Medical University ( Site 0391) Tianjin, Tianjin Municipality
The Third People's Hospital of Chengdu (CDTPH) ( Site 0428) Chengdu, Sichuan
The University of Osaka Hospital ( Site 0911) Suita, Osaka
Tianjin Medical University Cancer Institute & Hospital ( Site 0392) Tianjin, Tianjin Municipality
Toho University Sakura Medical Center ( Site 0906) Sakura, Chiba
Tongji Hospital Tongji Medical,Science & Technology ( Site 0407) Wuhan, Hubei
Turku University Hospital-Department of Oncology ( Site 0601) Turku, Southwest Finland
Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0705) Hamburg,
University College London Hospital ( Site 1612) London, London, City of
University Hospitals Cleveland Medical Center ( Site 0043) Cleveland, Ohio
University Malaya Medical Centre ( Site 1077) Lembah Pantai, Kuala Lumpur
University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095) Omaha, Nebraska
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) Orange, California
University of Chicago Medical Center ( Site 0045) Chicago, Illinois
University of Colorado Health - Highlands Ranch Hospital ( Site 0111) Highlands Ranch, Colorado
University of Colorado Health - Lone Tree Medical Center ( Site 0112) Lone Tree, Colorado
University of Illinois at Chicago ( Site 0105) Chicago, Illinois
University of Iowa ( Site 0047) Iowa City, Iowa
University of Kentucky Chandler Medical Center ( Site 0048) Lexington, Kentucky
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051) Miami, Florida
University of Miyazaki Hospital ( Site 0926) Miyazaki,
University of Virginia Health System ( Site 0054) Charlottesville, Virginia
Universitätsklinikum Bonn-Klinik und Poliklinik für Urologie und Kinderurologie ( Site 0680) Bonn, North Rhine-Westphalia
Universitätsklinikum Jena-Klinik und Poliklinik für Urologie ( Site 0682) Jena, Thuringia
Universitätsklinikum Münster - Albert Schweitzer Campus-Klinik für Urologie ( Site 0678) Münster, North Rhine-Westphalia
Universitätsklinikum Schleswig-Holstein-Klinik für Urologie ( Site 0691) Lübeck, Schleswig-Holstein
VA Portland Health Care System ( Site 0058) Portland, Oregon
VCU Health Adult Outpatient Pavillion ( Site 0061) Richmond, Virginia
Vejle Sygehus ( Site 0578) Vejle, Region Syddanmark
VieCuri Medisch Centrum ( Site 1173) Venlo, Limburg
Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062) St Louis, Missouri
West China Hospital, Sichuan University-Urology Surgery ( Site 0417) Chengdu, Sichuan
Westmead Hospital ( Site 0232) Westmead, New South Wales
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 1304) Torun, Kuyavian-Pomeranian Voivodeship
Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419) Ürümqi, Xinjiang
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064) New Haven, Connecticut
Yantai Yuhuangding Hospital ( Site 0397) Yantai, Shandong
Yokohama City University Medical Center ( Site 0908) Yokohama, Kanagawa
Yunnan Province Cancer Hospital ( Site 0418) Kunming, Yunnan
Zachodniopomorskie Centrum Onkologii ( Site 1311) Szczecin, West Pomeranian Voivodeship
Zhejiang Cancer Hospital ( Site 0435) Hangzhou, Zhejiang
Zhejiang Provincial People's Hospital-Urology ( Site 0378) Hangzhou, Zhejiang
Zhongshan Hospital of Fudan University (0430) Shanghai, Shangai Jianming Guo - (guo.jianming@zs-hospital.sh.cn)
Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1163) Sittard-Geleen, Limburg
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0696) Munich, Bavaria

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

ctrrecruit@vcu.edu

NCT06096844
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* STEP 1 REGISTRATION * Patient must be ≥ 70 years of age * Patient must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with PD-L1 Tumor Proportion Score (TPS) range of 1-49% * Patient must have Stage IIIB, IIIC or IV disease and not be candidates for combined chemo-radiation. NOTE: Prior chemo-radiation therapy (RT) for stage III with recurrence is allowed * Patient must have a tumor that is negative for EGFR mutation/ALK translocations or other actionable first line mutations in which patients would receive first-line oral tyrosine kinase inhibitors * Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 * Patient must agree not to father children while on study and for 6 months after the last dose of protocol treatment * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible * Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained within 14 days prior to Step 1 registration) * Platelets ≥ 75,000/uL (obtained within 14 days prior to Step 1 registration) * Hemoglobin (Hgb) ≥ 8.0 g/dL (obtained within 14 days prior to Step 1 registration) * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to Step 1 registration) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3.0 × institutional ULN (obtained within 14 days prior to Step 1 registration) * Creatinine clearance (CrCL) ≥ 45 mL/min (estimated using Cockcroft-Gault method with actual body weight or measured) (obtained within 14 days prior to Step 1 registration) * Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months of Step 1 registration are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have undetectable HCV viral * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patient must be English or Spanish speaking to be eligible for the QOL component of the study * NOTE: Sites cannot translate the associated GA or QOL forms * Patient must not have symptomatic central nervous system disease (CNS) metastases. Patients with a clinical history of CNS metastases or cord compression are eligible if they have been definitively treated and are clinically stable for at least 14 days prior to Step 1 registration and off all steroids for at least 24 hours prior to Step 1 registration. Patients with asymptomatic CNS metastases are eligible * Patient must not have had any prior cytotoxic chemotherapy regimen for metastatic disease. Chemotherapy given in the setting of adjuvant therapy or locally advanced disease is allowed as long as treatment was completed, and they have fully recovered from treatment related adverse events prior to Step 1 registration * Patient must not have had any prior immunotherapy for metastatic disease. Immunotherapy given in the setting of adjuvant therapy or locally advanced disease is allowed as long as treatment was completed greater than 6 months prior to Step 1 registration * Patient must not have a history of uncontrolled autoimmune conditions with the following exceptions, which are allowed: alopecia, vitiligo, rheumatoid arthritis, psoriasis/psoriatic arthritis, Hashimoto's thyroiditis, lupus, inflammatory bowel disease * Patient must not be on immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal and/or topical steroids are eligible * Patient must have baseline imaging done assessing all measurable or non-measurable sites of disease within 45 days prior to Step 1 registration * Investigator must declare their intended chemotherapy regimen should their patient be randomized to Arm B (doublet versus\[vs\] singlet) * STEP 2 RANDOMIZATION * Patient must have completed the baseline Geriatric Assessment (GA) after Step 1 registration and prior to Step 2 randomization
DRUG: Carboplatin, PROCEDURE: Computed Tomography, PROCEDURE: Magnetic Resonance Imaging, DRUG: Nab-paclitaxel, DRUG: Paclitaxel, BIOLOGICAL: Pembrolizumab, DRUG: Pemetrexed, PROCEDURE: Positron Emission Tomography, OTHER: Questionnaire Administration
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
I'm interested
Share via email
Show 312 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Adena Regional Medical Center Chillicothe, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin
Aspirus Medford Hospital Medford, Wisconsin Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Regional Cancer Center Wausau, Wisconsin
Asplundh Cancer Pavilion Willow Grove, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Aultman Health Foundation Canton, Ohio Site Public Contact - (ClinicalReserachDept@aultman.com)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
Bellin Memorial Hospital Green Bay, Wisconsin
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Bronson Battle Creek Battle Creek, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bryn Mawr Hospital Bryn Mawr, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
CTCA at Southeastern Regional Medical Center Newnan, Georgia
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan Site Public Contact - (connie.szczepanek@crcwm.org)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana Farber-Merrimack Valley Methuen, Massachusetts
Dana-Farber Cancer Institute at Boston Medical Center - Brighton Brighton, Massachusetts
Dana-Farber Cancer Institute at Foxborough Foxborough, Massachusetts
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Milford, Massachusetts
Dana-Farber/Brigham and Women's Cancer Center at South Shore South Weymouth, Massachusetts
Dartmouth Cancer Center - North Saint Johnsbury, Vermont Site Public Contact - (cancer.research.nurse@hitchcock.org)
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Durham VA Medical Center Durham, North Carolina Site Public Contact - (VHADURcancertrials@va.gov)
ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania Megan A. Baumgart - (megan_baumgart@urmc.rochester.edu)
Edwards Comprehensive Cancer Center Huntington, West Virginia Site Public Contact - (Christina.Cole@chhi.org)
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Genesee Hematology Oncology PC Flint, Michigan
Genesis Healthcare System Cancer Care Center Zanesville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
George Washington University Medical Center Washington D.C., District of Columbia
Glens Falls Hospital Glens Falls, New York
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
Guthrie Medical Group PC-Robert Packer Hospital Sayre, Pennsylvania
HaysMed Hays, Kansas
Highlands Oncology Group Springdale, Arkansas Site Public Contact - (research@hogonc.com)
Highlands Oncology Group - Fayetteville Fayetteville, Arkansas Site Public Contact - (research@hogonc.com)
Highlands Oncology Group - Rogers Rogers, Arkansas Site Public Contact - (research@hogonc.com)
Holy Cross Hospital Silver Spring, Maryland Site Public Contact - (eileen.georgi@holy-cross.com)
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Inspira Medical Center Mullica Hill Mullica Hill, New Jersey
Jefferson Cherry Hill Hospital Cherry Hill, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Jefferson Torresdale Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Kaiser Permanente Downtown Commons Sacramento, California Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Fresno Orchard Plaza Fresno, California
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii Site Public Contact - (shelley.a.clark@kp.org)
Kaiser Permanente San Leandro San Leandro, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fremont Fremont, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Modesto Modesto, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Roseville Roseville, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Francisco San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California Site Public Contact - (Kpoct@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California Site Public Contact - (Kpoct@kp.org)
Kansas City Veterans Affairs Medical Center Kansas City, Missouri
Knox Community Hospital Mount Vernon, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Lafayette Family Cancer Center-EMMC Brewer, Maine
Lake Regional Hospital Osage Beach, Missouri Site Public Contact - (clinicaltrials@lakeregional.com)
Lancaster General Ann B Barshinger Cancer Institute Lancaster, Pennsylvania Site Public Contact - (nctn@pennmedicine.upenn.edu)
Langlade Hospital and Cancer Center Antigo, Wisconsin Site Public Contact - (Juli.Alford@aspirus.org)
Lankenau Medical Center Wynnewood, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Lawrence Memorial Hospital Lawrence, Kansas
Licking Memorial Hospital Newark, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Loyola University Medical Center Maywood, Illinois
Malcom Randall Veterans Administration Medical Center Gainesville, Florida Site Public Contact - (trials@cancer.ufl.edu)
Marshfield Medical Center - Minocqua Minocqua, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic Health System-Eau Claire Clinic Eau Claire, Wisconsin
Mayo Clinic Health Systems-Mankato Mankato, Minnesota
Medical University of South Carolina Charleston, South Carolina
Memorial Hospital Marysville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Memorial Hospital East Shiloh, Illinois
Mercy Cancer Center-West Lakes Clive, Iowa Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy Health - Perrysburg Hospital Perrysburg, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Health - Saint Anne Hospital Toledo, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Hospital Coon Rapids, Minnesota
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Medical Center - Des Moines Des Moines, Iowa Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercyhealth Hospital and Cancer Center - Janesville Janesville, Wisconsin Site Public Contact - (oncologyclinicaltrials@mhemail.org)
MetroHealth Medical Center Cleveland, Ohio Site Public Contact - (ababal@metrohealth.org)
Miami Valley Cancer Care and Infusion Greenville, Ohio
Miami Valley Hospital Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Michigan Healthcare Professionals Pontiac Pontiac, Michigan Site Public Contact - (Emily.Crofts@trinity-health.org)
Minnesota Oncology - Burnsville Burnsville, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Moffitt Cancer Center Tampa, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center - McKinley Campus Tampa, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center at Wesley Chapel Wesley Chapel, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center-International Plaza Tampa, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
Montefiore Medical Center - Moses Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Einstein Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Mount Carmel Grove City Hospital Grove City, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
MyMichigan Medical Center Saginaw Saginaw, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
MyMichigan Medical Center Tawas Tawas City, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
New Ulm Medical Center New Ulm, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Northwest Cancer Center - Hobart Hobart, Indiana
Northwest Cancer Center - Main Campus Crown Point, Indiana
Northwest Cancer Center - Valparaiso Valparaiso, Indiana Site Public Contact - (CancerResearch@COMHS.org)
Northwest Oncology LLC Dyer, Indiana
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
Oncology Hematology Associates of Saginaw Valley PC Saginaw, Michigan
Paoli Memorial Hospital Paoli, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Memorial Hospital Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
Penn Medicine Princeton Health Plainsboro, New Jersey Site Public Contact - (PennCancerTrials@careboxhealth.com)
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania Site Public Contact - (CTO@hmc.psu.edu)
Premier Blood and Cancer Center Dayton, Ohio
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProHealth Waukesha Memorial Hospital Waukesha, Wisconsin
Ralph H Johnson VA Medical Center Charleston, South Carolina Site Public Contact - (ashley.salvo@va.gov)
Rapid City Regional Hospital Rapid City, South Dakota Site Public Contact - (research@monument.health)
Reading Hospital West Reading, Pennsylvania
Reading Hospital McGlinn Cancer Institute at Phoenixville Phoenixville, Pennsylvania
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Riddle Memorial Hospital Media, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Rush-Copley Medical Center Aurora, Illinois Site Public Contact - (RCMC_Cancer_Research@rush.edu)
SIH Cancer Institute Carterville, Illinois Site Public Contact - (clinical.research@sih.net)
SSM Health Good Samaritan Mount Vernon, Illinois
SUNY Upstate Medical Center-Community Campus Syracuse, New York
Sacred Heart Hospital Pensacola, Florida Site Public Contact - (eebrou@ascension.org)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Catherine Hospital Indianapolis, Indiana Site Public Contact - (ecog.rss@jimmy.harvard.edu)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint Francis Regional Medical Center Shakopee, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Mary Medical Center Hobart, Indiana Site Public Contact - (CancerResearch@COMHS.org)
Saint Mary's Oncology/Hematology Associates of West Branch West Branch, Michigan
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Salina Regional Health Center Salina, Kansas Site Public Contact - (mleepers@srhc.com)
Sanford Bismarck Medical Center Bismarck, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Joe Lueken Cancer Center Bemidji, Minnesota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Roger Maris Cancer Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Sheboygan Physicians Group Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Sinai Hospital of Baltimore Baltimore, Maryland
Siteman Cancer Center at Christian Hospital St Louis, Missouri
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri
Siteman Cancer Center-South County St Louis, Missouri
Southern Illinois University School of Medicine Springfield, Illinois
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Springfield Regional Cancer Center Springfield, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Stamford Hospital/Bennett Cancer Center Stamford, Connecticut
State University of New York Upstate Medical University Syracuse, New York
Stony Brook University Medical Center Stony Brook, New York
Strecker Cancer Center-Belpre Belpre, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The Community Hospital Munster, Indiana
The Dana-Farber Cancer Institute at Londonderry Londonderry, New Hampshire Site Public Contact - (ecog.rss@jimmy.harvard.edu)
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The Mark H Zangmeister Center Columbus, Ohio Site Public Contact - (Jeffh@columbusccop.org)
The University of Kansas Cancer Center - Olathe Olathe, Kansas Site Public Contact - (OlatheCCResearch@kumc.edu)
ThedaCare Cancer Care - Berlin Berlin, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - New London New London, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Shawano Shawano, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Waupaca Waupaca, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Cancer Center Appleton, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Medical Center - Neenah Neenah, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Tufts Medical Center Boston, Massachusetts Site Public Contact - (ContactUsCancerCenter@TuftsMedicalCenter.org)
UF Health Cancer Institute - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
UMass Memorial Medical Center - University Campus Worcester, Massachusetts
UT Southwestern Clinical Center at Richardson/Plano Richardson, Texas Site Public Contact - (Suzanne.cole@utsouthwestern.edu)
UT Southwestern Simmons Cancer Center - RedBird Dallas, Texas Site Public Contact - (canceranswerline@utsouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Fort Worth Fort Worth, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
UW Health Carbone Cancer Center Rockford Rockford, Illinois Site Public Contact - (lkline@uwhealth.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University Health Truman Medical Center Kansas City, Missouri
University of Illinois Chicago, Illinois
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - Briarcliff Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center-Overland Park Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Clinical Research Center Fairway, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
University of Rochester Rochester, New York
University of Virginia Cancer Center Charlottesville, Virginia
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
Upper Valley Medical Center Troy, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Upstate Cancer Center at Oswego Oswego, New York Site Public Contact - (McDowelE@upstate.edu)
Upstate Cancer Center at Verona Verona, New York Site Public Contact - (McDowelE@upstate.edu)
VA Palo Alto Health Care System Palo Alto, California
VCU Health Tappahannock Hospital Tappahannock, Virginia Site Public Contact - (klcampbell@vcu.edu)
VCU Massey Cancer Center at Stony Point Richmond, Virginia Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Veterans Affairs Connecticut Healthcare System-West Haven Campus West Haven, Connecticut
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Washington University School of Medicine St Louis, Missouri
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
White River Junction Veteran Administration Medical Center White River Junction, Vermont
William E Kahlert Regional Cancer Center/Sinai Hospital Westminster, Maryland
Wilmot Cancer Institute at Webster Webster, New York Site Public Contact - (WCICTOresearch@urmc.rochester.edu)
Women's Diagnostic Center - Munster Munster, Indiana Site Public Contact - (mnicholson@comhs.org)

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

ctrrecruit@vcu.edu

NCT03606967
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must have a histologically confirmed diagnosis of metastatic invasive triple negative breast cancer. Patients with clinical and/or radiologic suspicion of metastatic TNBC can be consented prior to this confirmation. * Estrogen receptor (ER) and progesterone receptor (PR) less than Allred score of 3 OR less than 1% positive staining cells in the invasive component of the tumor. * HER2 negative by fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) staining 0 or 1+. * PD-L1 negative by a Clinical Laboratory Improvement Act (CLIA) approved laboratory using compatible assays appropriate for treatment decisions. * Patients may have measurable or evaluable disease. * Patients must be willing to undergo biopsy and have accessible lesions for a new biopsy, or they must have sufficient tissue available from a biopsy performed for standard of care (specifications below). If patient does not have enough archived tissue available, a new biopsy is required. A tumor specimen obtained from relapsed metastatic or locally advanced disease (if applicable) must be submitted. Acceptable samples include core needle biopsies for deep tumor tissue (minimum 4 cores) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. Formalin-fixed, paraffin-embedded (FFPE) tumor specimens in paraffin blocks are preferred; FFPE tumor tissue sections on slides may be provided if sufficient material (15 x 10μ- unstained) is available. Fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. * No prior therapy for metastatic TNBC. Patients who have received taxane-based adjuvant therapy are required to have a disease-free interval of at least 12 months after completion of taxane therapy. * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of durvalumab (MEDI4736) and tremelimumab in combination with neoantigen vaccine in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 60%). * Body weight \> 30 kg. * Must have a life expectancy of at least 12 weeks. * Absolute neutrophil count \>= 1,500/mcL. * Platelets \>= 100,000/mcL. * Hemoglobin \>= 9.0 g/dL. * Serum bilirubin =\< 1.5 x institutional upper limit of normal. * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =\< 5 x institutional upper limit of normal. * Calculated creatinine clearance \> 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance. * Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). * Women \>= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). * The effects of durvalumab (MEDI4736) and tremelimumab and neoantigen vaccine on the developing human fetus are unknown. For this reason and because these agents may be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 180 days after completion of durvalumab (MEDI4736) and tremelimumab. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. * Human immunodeficiency virus (HIV)-positive patients are eligible provided they have a negative viral load, CD4 count \> 250, and are on a stable antiretroviral regimen. * Ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity who have a close caregiver or legal guardian are also eligible with the consent of the caregiver/guardian.
Exclusion Criteria:
* Patients who are not considered to be candidates for carboplatin + gemcitabine for first line therapy of their metastatic triple negative breast cancer are not eligible. * Patients who have had chemotherapy, radiotherapy (to more than 30% of the bone marrow), or biologic therapy within 30 days (42 days for nitrosoureas or mitomycin C) prior to entering the study. * Patients who have received prior immunotherapy for metastatic disease. * Patients who have not recovered from grade \>= 2 adverse events due to prior anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. * Patients with grade \>= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician. * Patients with stable endocrinological adverse events (AEs), (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus), must have been on a stable dose of supplemental therapy for at least 2 weeks before screening to be eligible for this study. * Patients who are receiving any other investigational agents or who have received an investigational agent within the last 30 days. * Receipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumab (MEDI4736) and tremelimumab. * Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment. * Major surgical procedure within 28 days prior to the first dose of durvalumab (MEDI4736) and tremelimumab. Local surgery of isolated lesions for palliative intent is acceptable. * Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (MEDI4736) or tremelimumab. The following are exceptions to this criterion: * Intranasal, inhaled, topical steroids or local steroid injections (e.g. intra-articular injection) * Systemic corticosteroids at physiological doses which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid * Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication). * Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab (MEDI4736) and tremelimumab. Known allergy, or history of serious adverse reaction to vaccines, such as anaphylaxis, hives or respiratory difficulty. * Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) \>= 470 ms calculated from 3 electrocardiograms (ECGs) (within 15 minutes at 5 minutes apart). * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, evidence of any acute or chronic viral illness or disease, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because durvalumab (MEDI4736) and tremelimumab has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with durvalumab (MEDI4736) and tremelimumab, breastfeeding should be discontinued if the mother is treated with durvalumab (MEDI4736) and tremelimumab. These potential risks may also apply to other agents used in this study. A negative serum pregnancy test is required no more than 7 days before study entry. * Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * History of pneumonitis or interstitial lung disease. * History of active primary immunodeficiency. * Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and tuberculosis \[TB\] testing in line with local practice), hepatitis B (known positive hepatitis B virus \[HBV\] surface antigen \[HBsAg\] result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA). * The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: * Patient has undergone potentially curative therapy for all prior malignancies. * Patients have been considered disease free for at least 1 year (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix). * Patients with a strong likelihood of non-adherence (such as difficulties in adhering to follow-up schedule due to geographic distance from the treatment facility) should not be knowingly registered. * History of allogeneic organ transplantation.
PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, DRUG: Carboplatin, PROCEDURE: Computed Tomography, BIOLOGICAL: Durvalumab, DRUG: Gemcitabine Hydrochloride, PROCEDURE: Magnetic Resonance Imaging, DRUG: Nab-paclitaxel, BIOLOGICAL: Personalized Synthetic Long Peptide Vaccine, DRUG: Poly ICLC, BIOLOGICAL: Sacituzumab Govitecan, BIOLOGICAL: Tremelimumab
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
I'm interested
Share via email
Show 30 locations

Study Locations

Hide all locations
Location Contacts
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Site Public Contact - (jhcccro@jhmi.edu)
Moffitt Cancer Center Tampa, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center - McKinley Campus Tampa, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center at Wesley Chapel Wesley Chapel, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center-International Plaza Tampa, Florida Site Public Contact - (ClinicalTrials@moffitt.org)
NYP/Weill Cornell Medical Center New York, New York
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California
UCHealth University of Colorado Hospital Aurora, Colorado
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Texas Medical Branch Galveston, Texas Site Public Contact - (clinical.research@utmb.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Wake Forest University Health Sciences Winston-Salem, North Carolina
Wake Forest University at Clemmons Clemmons, North Carolina
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Yale University New Haven, Connecticut

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com - Clinical.Trials@bms.com

NCT06003426
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria * Subjects with IPF aged ≥ 40 years at the time of signing the informed consent. * Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia. * If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening. * If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening. * Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test. * Men who are sexually active with women of childbearing potential agree to use male barrier contraception. Exclusion Criteria * History of stroke or transient ischemic attack within 3 months prior to screening. * Participants who exhibit symptoms of heart failure at rest. * Participants who have a current malignancy or a previous malignancy with less than 2 years free of recurrence or a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations. * Other protocol-defined Inclusion/Exclusion criteria apply.
DRUG: BMS-986278, DRUG: BMS-986278 Placebo
Idiopathic Pulmonary Fibrosis
BMS-986278, LPA1 antagonist, IPF, Pulmonary fibrosis
I'm interested
Share via email
Show 504 locations

Study Locations

Hide all locations
Location Contacts
"Corfu General Hospital ""St. IRINI""" Corfu,
"General Hospital of Thessaloniki ""G. Papanikolaou""" Pylaia-Chortiatis, B
"Ospedale ""Gian Battista Morgagni - Luigi Pierantoni"" di Forli" Forlì,
ACE Hospital & Research Center Pune, Maharashtra
AORN - Ospedali dei Colli Ospedale V. Monaldi Napoli,
Aarhus University Hospital Aarhus N,
Accellacare US Inc. of Wilmington Wilmington, North Carolina
Ajou University Hospital Suwon,
All India Institute of Medical Sciences (AIIMS) - New Delhi New Delhi, National Capital Territory of Delhi
Alliance Pulmonary Group Guaynabo, PR
Amsterdam UMC - Locatie VUMC - Pulmonale Hypertensie (PH) Kenniscentrum Amsterdam,
AnMed Health Oglesby Center - AnMed Health Pulmonary and Sleep Medicine Anderson, South Carolina
Anhui Medical University - Anhui Chest Hospital Hefei, AH
Anhui Medical University - The Second Hospital - Hematological Research Center Hefei, Anhui
Anhui Provincial Hospital Hefei, Anhui
Ankara Universitesi Tip Fakultesi Hastaneleri - Cebeci Hastanesi Ankara,
Asan Medical Center (AMC) Songpa-gu, Seoul
Aso Iizuka Hospital Iizuka-shi,
Assistance Publique Hopitaux de Marseille - Hopital Nord Marseille,
Asst Papa Giovanni XXIII Bergamo, Bg
Asthma Bhawan Jaipur, Rajasthan
Athens Medical Center Marousi, Attica
Avanza Medical Research Center Pensacola, Florida
Azienda Ospedaliera San Paolo Milan,
Azienda Ospedaliera Universitaria - Universita di Sassari Sassari,
Azienda Ospedaliero - Universitaria di Modena Policlinico Modena, Emilia-Romagna
Azienda Ospedaliero Universitaria Pisana Pisa,
Azienda Ospedaliero Universitaria delle Marche Ancona,
Azienda Ospedaliero-Universitaria Careggi Florence,
Baylor College of Medicine Medical Center - Pulmonary, Critical Care, and Sleep Medicine Houston, Texas
Baylor University Medical Center at Dallas Dallas, Texas
Beijing Chaoyang Hospital, Capital Medical University Beijing, Beijing Municipality
Beijing Friendship Hospital, Capital Medical University Beijing,
Bioreuma Concepción, Bio Bio
Brightshores Health System Owen Sound, Ontario
Burlington Lung Clinic Burlington, Ontario
C.I.C. Joliette Saint-Charles-Borromée, Quebec
C.I.C. Mauricie Inc. Trois-Rivières, Quebec
CEC Centros Estudios Clinicos Santiago, RM
CEMEC - Centro Multidisciplinar de Estudos Clínicos São Bernardo do Campo, São Paulo
CENRESIN - Centro Respiratorio Integral Quillota, Región de Valparaíso
CHRU de Tours - Hôpital Bretonneau Tours,
CHU Dijon - Hôpital François Mitterrand Dijon,
CHU Hopitaux de Bordeaux - Hopital Haut-Leveque Pessac,
CHU UCL Namur - Mont-Godinne Yvoir, Namur
CHU de Brest - Hôpital Cavale Blanche Brest,
CHU de Nantes - Hôpital Nord Laennec Nantes, Pays de la Loire Region
Carmel Medical Center Haifa,
Center Hospital of the National Center for Global Health and Medicine Shinjyu-Ku,
Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes) Grenoble, Auvergne-Rhône-Alpes
Centre Hospitalier Universitaire d'Angers Angers, Maine-et-Loire
Centre Hospitalier Universitaire de Liege - Sart Tilman Liège,
Centre Hospitalier de L'Universite de Montreal (CHUM) Montreal, Quebec
Centro Medico Santa Maria Barra Mansa, Rio de Janeiro
Centro Medico de Enfermedades Respiratorias Florida, B
Centro Respiratorio Quilmes Quilmes, Provincia de Buenos Aires, B
Centro de Estudos de Pneumologia da Faculdade de Medicina do ABC (CEPFMABC) Santo André, São Paulo
Centro de Investigacion Clinica de Oaxaca (CICLO) Oaxaca City, Oaxaca
Centro de Investigacion Curico Curicó, Maule Region
Centro de Investigaciones Metabólicas (CINME) Buenos Aires,
Centro de Investigación Clínica Chapultepec S.A. de C.V. Morelia, Michoacán
Centro de Investigación del Maule Talca,
Centrum Medycyny Oddechowej Bialystok, Podlaskie Voivodeship
Chang Gung Medical Foundation - Kaohsiung Branch Kaohsiung City, Kao-Hsiung
Changhua Christian Hospital Changhua County,
Chiba University Hospital Chiba, Chiba,
China Medical University Hospital Taichung,
Christiana Care Pulmonary Associates - Newark Newark, Delaware
Clinica 25 de Mayo Mar del Plata, B
Clinica Providencia San Miguel, LIM
Clinica Universidad de Navarra Madrid,
Clinica Universidad de los Andes Santiago, RM
Clinical Research Specialists, LLC - Kissimmee Kissimmee, Florida
Cliniques Universitaires Saint-Luc Brussels,
Clínica Universidad de Navarra -Madrid Madrid,
Clínica de día Jockey Salud Lima, LIM
Coastal Pulmonary & Critical Care, P.L.C. St. Petersburg, Florida
Connolly Hospital Blanchardstown Dublin,
Consultorios Médicos del Buen Ayre Capital Federal,
David Geffen School of Medicine at UCLA Los Angeles, California
Diex Recherche - Trois-Rivieres Trois-Rivières, Quebec
Dokuz Eylul Universitesi Tip Fakultesi Pasaport,
Duke University Medical Center Durham, North Carolina
Ege Universitesi Tip Fakultesi Hastanesi (Ege University Medical Faculty Hospital) Izmir,
Erasmus MC - Centrum voor Interstitiele Longziekten Rotterdam, South Holland
Erciyes University School of Medicine Kayseri,
Escola Paulista de Medicina São Paulo,
Fachkrankenhaus Coswig GmbH Coswig,
Far Eastern Memorial Hospital Taipei,
Fiona Stanley Hospital Murdoch, Western Australia
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan, Lombardy
Fondazione IRCCS Policlinico San Matteo Pavia,
Fondazione IRCCS San Gerardo dei Tintori Monza,
Fondazione Policlinico Universitario Agostino Gemelli Roma,
Fortis Hospital Mohali Mohali, Punjab
Fundacion Enfisema - Instituto Ave Pulmo Mar del Plata, Buenos Aires
Fundacion Respirar Buenos Aires,
Fundacion Santa Fe de Bogota Bogotá,
Fundacion Scherbovsky Mendoza, M
Gachon University - Gil Medical Center Incheon,
Gallipoli Medical Research Centre - Clinical Trials Unit (CTU) Greenslopes, Queensland
Gentofte Hospital Hellerup,
Getwell Hospital and Research Institute - Lungs Care Nagpur, Maharashtra
Giromed Institute, SLP Barcelona,
Grant Medical Foundation - Ruby Hall Clinic Pune,
Green City Hospital Bhopal, Madhya Pradesh
Guy's and St Thomas' NHS Foundation Trust - Royal Brompton Hospital London, Greater London
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz Győr,
HELIOS Klinikum Emil von Behring Berlin, State of Berlin
Hadassah Medical Center (HMC) - Hadassah University Hospital (HUH) - Ein Kerem Jerusalem,
Hamamatsu University Hospital Shizuoka, Hamamatsu,
Hangzhou First People's Hospital Hangzhou,
Harmony Medical Research Institute, Inc Hialeah, Florida
Health SURA Calle 100 Bogotá, DC
Health SURA Chipichape Santiago de Cali, VAC
Helsinki University Hospital Heart and Lung Center Helsinki, Etelae-Suomen Laeaeni
Henan provincial people's hospital Zhengzhou, HA
Hiroshima Prefectural Hospital Hiroshima, Hirohima-ken
Hopital Avicenne Bobigny,
Hopitaux Universitaires de Geneve (HUG) Geneva, Canton of Geneva
Hospices Civils de Lyon Bron, Auvergne-Rhône-Alpes
Hospital Alemao Oswaldo Cruz (HAOC) - Centro de Oncologia (Oncology Center) São Paulo,
Hospital CUF Tejo Lisbon,
Hospital Clinic de Barcelona Barcelona,
Hospital Clinico San Carlos Madrid,
Hospital Clinico Universitario Madrid,
Hospital Dia do Pulmão Blumenau, Santa Catarina
Hospital Ernesto Dornelles (HED) Porto Alegre, Rio Grande do Sul
Hospital Madre Teresa Belo Horizonte, Minas Gerais
Hospital Nacional Cayetano Heredia Lima,
Hospital Universitari de Bellvitge (IDIBELL) Barcelona,
Hospital Universitario Central de Asturias Oviedo,
Hospital Universitario Fundacion Jimenez Diaz Madrid,
Hospital Universitario La Paz Madrid,
Hospital Universitario Marqués de Valdecilla Santander,
Hospital Universitario Puerta De Hierro - Majadahonda Majadahonda, M
Hospital Universitario de La Princesa Madrid,
Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) Belo Horizonte, Minas Gerais
Hospital de Santa Marta Lisbon,
Huadong Hospital Affiliated to Fudan University Shanghai,
Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital Cottingham, Yorkshire and the Humber
Hôpital Bichat - Claude-Bernard Paris,
Hôpital Larrey Toulouse,
Ibamedica Santa Fe,
Inje University Busan Paik Hospital Busan,
Inje University Haeundae Paik Hospital Busan,
Inje University Ilsan Paik Hospital Goyang-si,
Inselspital - Universitaetsklinik Bern für Pneumologie Bern, Canton of Bern
Inspiration Research Toronto, Ontario
Institute for Respiratory Health Nedlands, Western Australia
Institute of Science Tokyo Hospital Tokyo, Bunkyo-ku,
Instituto De Enfermedades Respiratorias E Investigacion Medica (IERIM) San Juan Bautista, Buenos Aires
Instituto Medico DAMIC Córdoba, Córdoba Province
Instituto Medico INSARES SA Mendoza, M
Instituto Medico de la Fundacion de Estudios Clínicos Rosario, S
Instituto Neumologico del Oriente Floridablanca, Santander Department
Instituto de Seguridad Social del Estado de Mexico y Municipios (ISSEMYM) - Centro Medico Toluca Metepec, Edo De Mexico
Investigaciones en Patologias Respiratorias San Miguel de Tucuman, Tucumán, T
Istanbul Universitesi - Istanbul Tip Fakultesi (ITF) Hastanesi Topkapı,
Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT) Palermo,
Jehangir Clinical Development Center Pune, Maharashtra
Jichi Medical University Hospital Shimotsuke,
Jizankai Medical Foundation Tsuboi Cancer Center Hospital Koriyama-shi, Fukushima
Juntendo University Hospital Bunkyo-ku, Tokyo
K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre Belagavi, Karnataka
Kameda Medical Center - Kameda Clinic Kamogawa-shi, Chiba
Kanagawa Cardiovascular and Respiratory Center Kanagawa, Yokohama,
Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City,
Kaplan Medical Center Rehovot,
Kepler Universitatsklinikum Linz, Upper Austria
Kindai University Hospital Ōsaka-sayama,
King George's Medical University Lucknow, Uttar Pradesh
Klinikum der Universitat Munchen Munich, Bavaria
Kobe City Medical Center General Hospital Hyōgo,
Krankenhaus Hietzing Vienna,
Krankenhaus der Augustinerinnen- Klinik fuer Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin Cologne, Northwest
Kurume University Hospital Kurume-shi, Fukuoka
Kyorin University Hospital Mitaka-shi, Tokyo
Kyushu University Hospital Fukuoka,
Lankenau Medical Center Wynnewood, Pennsylvania
Layrek Clinical Research Tulsa, Oklahoma
Leeds Teaching Hospitals NHS Trust Leeds,
Local Institution - 0001 Lenexa, Kansas
Local Institution - 0006 São Paulo,
Local Institution - 0008 Munster, Northwest
Local Institution - 0014 Salt Lake City, Utah
Local Institution - 0016 Lima, LIM
Local Institution - 0020 Badalona, Barcelona
Local Institution - 0032 Pittsburgh, Pennsylvania
Local Institution - 0043 Changchun, Jilin
Local Institution - 0055 Lima,
Local Institution - 0060 Gainesville, Florida
Local Institution - 0063 Brno, JM
Local Institution - 0070 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0071 L'Hospitalet Del Llobregat, Barcelona [Barcelona]
Local Institution - 0076 Villejuif, Val-de-Marne
Local Institution - 0078 Monterrey, Nuevo León
Local Institution - 0080 Iowa City, Iowa
Local Institution - 0081 Lille, Nord
Local Institution - 0082 Vienna,
Local Institution - 0087 Marseille, Bouches-du-Rhône
Local Institution - 0091 Victoria, British Columbia
Local Institution - 0094 Evanston, Illinois
Local Institution - 0100 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0104 Atlanta, Georgia
Local Institution - 0112 Buenos Aires,
Local Institution - 0115 Busan, Pusan-Kwangyǒkshi
Local Institution - 0116 Deagu, Taegu-Kwangyǒkshi
Local Institution - 0133 Milano, MI
Local Institution - 0136 Buenos Aires,
Local Institution - 0141 Aguascalientes, AGU
Local Institution - 0148 Katowice,
Local Institution - 0156 Piura, PIU
Local Institution - 0157 Valencia, Comunidad Valencia
Local Institution - 0162 Monterrey, Nuevo Leon
Local Institution - 0163 Córdoba, VER
Local Institution - 0179 Jasper, Alabama
Local Institution - 0182 Chicago, Illinois
Local Institution - 0190 Buffalo, New York
Local Institution - 0192 Milwaukee, Wisconsin
Local Institution - 0195 Springfield, Massachusetts
Local Institution - 0203 Exeter, South West
Local Institution - 0208 Edmonton, Alberta
Local Institution - 0212 Talcahuano, BI
Local Institution - 0217 Sherbrooke, Quebec
Local Institution - 0219 Exeter, South West
Local Institution - 0223 La Tronche, Isère
Local Institution - 0234 Mérida, YUC
Local Institution - 0245 Nagpur, Maharashtra
Local Institution - 0248 Guadalajara, JAL
Local Institution - 0253 Melbourne, Victoria
Local Institution - 0277 Uppsala, Uppsala Län [se-03]
Local Institution - 0280 Helsinki,
Local Institution - 0281 Oulu, North Ostrobothnia
Local Institution - 0293 Darlinghurst, New South Wales
Local Institution - 0296 Zhengzhou Shi, Henan
Local Institution - 0303 Murdoch, Western Australia
Local Institution - 0308 Paris,
Local Institution - 0310 Milano, MI
Local Institution - 0311 Lille CEDEX,
Local Institution - 0312 Incheon,
Local Institution - 0315 Caen,
Local Institution - 0316 Deogyang-Gu, Goyang-Si,
Local Institution - 0317 Kitakyushu-shi, Fukuoka-Ken
Local Institution - 0327 Sapporo, Hokkaido
Local Institution - 0329 Okayama,
Local Institution - 0340 Olomouc,
Local Institution - 0357 Gosford, New South Wales
Local Institution - 0376 Yinchuan,
Local Institution - 0381 London, LND
Local Institution - 0384 Koblenz, Rhineland-Palatinate
Local Institution - 0387 Linz,
Local Institution - 0390 Zagreb, City of Zagreb
Local Institution - 0392 Sofia,
Local Institution - 0397 Chaïdári, Attikí
Local Institution - 0399 Athens, Attikí
Local Institution - 0401 Miami, Florida
Local Institution - 0412 A Coruña, A Coruña [La Coruña]
Local Institution - 0413 Guadalajara,
Local Institution - 0422 Ankara,
Local Institution - 0423 Kitakyushu-shi, Fukuoka
Local Institution - 0427 Singapore, Central Singapore
Local Institution - 0432 George Town, Pulau Pinang
Local Institution - 0435 Louisville, Kentucky
Local Institution - 0439 Dammam, Eastern Province
Local Institution - 0443 Box Hill, Victoria
Local Institution - 0444 Hermosillo, Sonora
Local Institution - 0445 Riyadh, Riyadh Region
Local Institution - 0446 Buenos Aires,
Local Institution - 0447 Santiago,
Local Institution - 0448 Guadalajara, Jalisco
Local Institution - 0449 Ampang, Selangor
Local Institution - 0450 Tulsa, Oklahoma
Local Institution - 0451 Keçiören/Ankara,
Local Institution - 0452 Atlanta, Georgia
Local Institution - 0453 Lembah Pantai, Kuala Lumpur
Local Institution - 0454 Pilea Chortiatis, Thessaloniki
Local Institution - 0455 Seongnam,
Local Institution - 0460 Graz, Styria
Local Institution - 0462 Auckland,
Local Institution - 0463 Hermosillo, Sonora
Local Institution - 0464 Pilea Chortiatis, Thessaloniki
Local Institution - 0465 Tacoma, Washington
Local Institution - 0466 Pittsburgh, Pennsylvania
Local Institution - 0467 Darlinghurst, New South Wales
Local Institution - 0468 Santiago,
Local Institution - 0469 Rock Hill, South Carolina
Local Institution - 0471 Coimbatore, Tamil Nadu
Local Institution - 0474 Chermside, Queensland
Local Institution - 0475 Eiheiji-cho,Yoshida-gun, Fukui
Local Institution - 0476 Engenho Velho da Federação, Salvador
Local Institution - 0487 Solna, Stockholms Län [se-01]
Local Institution - 0489 Seville,
Local Institution - 0493 Rome, Lazio
Local Institution - 0494 Guadalajara, Jalisco
Local Institution - 0499 Groningen,
Local Institution - 0500 Leiden, South Holland
Local Institution - 0501 Newport Beach, California
Local Institution - 0504 Halle, Saxony-Anhalt
Loyola University Health System Maywood, Illinois
Lungenfachklinik Immenhausen Immenhausen,
MICS Centrum Medyczne Bydgoszcz Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Marengo CIMS Hospital Ahmedabad, Gujarat
Massachusetts General Hospital Boston, Massachusetts
Mater Misericordiae Limited South Brisbane,
Matsusaka Municipal Hospital Matsusaka-shi, Mie-ken
Max Super Specialty Hospital, Saket - West Block - A Unit of Max Healthcare Institute Limited New Delhi, National Capital Territory of Delhi
McGovern Medical School - UT Physicians - Pulmonary Medicine - Texas Medical Center Location Houston, Texas
MedStar Georgetown University Hospital Washington D.C., District of Columbia
Medical University of South Carolina- College of Medicine Charleston, South Carolina
Medicos Internistas de Caldas Manizales, CL
Mercy St. Vincent Medical Center Toledo, Ohio
Meris Clinical Research Brandon, Florida
Metroplex Pulmonary and Sleep Center McKinney, Texas
Midland Healthcare & Research Center Lucknow,
Monteregie Centre de Recherche Greenfield Park, Quebec
Myongji Hospital Goyang-si, Gyeonggi-do
NHS Lothian - Royal Infirmary of Edinburgh Edinburgh, EDH
NHS Tayside Dundee, DND
NZOZ Przychodnia Vitamed Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Nagasaki University Hospital Nagasaki, Nagasaki
Nagoya University Hospital Nagoya, Aichi-ken
Nanfang Hospital of Southern Medical University Guangzhou, Guangdong
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School Nanjing, JS
National Hospital Organization - Okinawa National Hospital Ginowan-Shi, Okinawa
National Hospital Organization Himeji Medical Center Himeji, Hyōgo
National Hospital Organization Ibarakihigashi National Hospital Naka-gun, Gunma
National Hospital Organization Kinki-Chuo Chest Medical Center Osaka, Sakai,
National Hospital Organization Kyushu Medical Center Fukuoka,
National Jewish Health Denver, Colorado
National Taiwan University Hospital - The National Center of Excellence for Clinical Trial Taipei,
National Taiwan University Hospital Yun-Lin Branch Yunlin County,
Nilratan Sircar (NRS) Medical College & Hospital Kolkata, West Bengal
Nippon Medical School Hospital Bunkyo-ku, Tokyo
North Bristol NHS Trust - Southmead Hospital Bristol Bristol, BST
Northern Westchester Hospital Mount Kisco, New York
Northwestern Memorial Hospital Evanston, Illinois
Norton Pulmonary Specialists Louisville, Kentucky
OSF Saint Francis Medical Center Peoria, Illinois
OU Health Sciences Center - OU Health Physicians - Cardiology, Pulmonary & Vascular Medicine Clinic Oklahoma City, Oklahoma
Ocala Lung & Critical Care Ocala, Florida
Odense Universitetshospital - Svendborg Sygehus Odense C, Region Syddanmark
Omega Research Consultants LLC DeBary, Florida
Oregon Health & Science University - Pulmonary Clinic Portland, Oregon
Ospedale Colonnello D'Avanzo Foggia Foggia,
Ospedale Policlinico di Siena Siena,
Our Lady of Lourdes Hospital - Drogheda Drogheda, LH
Oxford University Hospitals NHS Trust - Churchill Hospital Oxford, Oxfordshire
Papworth Hospital NHS Foundation Trust Cambridge, Cambridgeshire
Peking Union Medical College Hospital Beijing, Beijing Municipality
Peking University Shenzhen Hospital Shenzhen,
Peninsula Health - Frankston Hospital Frankston, Victoria
Penn Medicine - Perelman Center for Advanced Medicine Philadelphia, Pennsylvania
Penn State Milton S. Hershey Medical Center Hershey, Pennsylvania
Peterborough City Hospital Peterborough,
Policlínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro Rio de Janeiro, Rio de Janeiro
Praxis fur Pneumologie Marburg, HE
Pulmonary Group of Central Florida, LLC - Leesburg Leesburg, Florida
Pulmonary Specialists of the Palm Beaches Loxahatchee Groves, Florida
Pulmonology, Sleep, Asthma & Allergy Center of Dublin Dublin, Georgia
Qilu Hospital of Shandong University Jinan, Shandong
Quebec Heart and Lung Institute Quebec,
Rabin Medical Center - Hasharon Hospital Petah Tikva,
Rambam Health Care Campus - Pulmonology Haifa,
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine - South Branch Shanghai, SH
Renmin Hospital of Wuhan University Wuhan,
Respira Salud Clinica Integral Godoy Cruz, M
Royal Adelaide Hospital Adelaide,
Royal Prince Alfred Hospital Camperdown, New South Wales
Rush University Medical Center - Rush Pulmonary and Critical Care Medicine - Professional Building Chicago, Illinois
SALK - Universitatsklinik Fur Pneumologie/ Lungenheilkunde Landeskrankenhaus Salzburg, Salzburger Land
Saiseikai Kumamoto Hospital Kumamoto,
Santa Casa de Misericórdia de Porto Alegre - Hospital Sao Jose Porto Alegre, Rio Grande do Sul
Santiago Clinic Hospital (Hospital Clínico Universitario de Santiago -CHUS) Santiago de Compostela, Galicia
Sapporo Medical University Hospital Sapporo, Hokkaid
Scripps Clinic Torrey Pines La Jolla, California
Semmelweis Egyetem Pulmonologiai Klinika Budapest,
Seoul National University Bundang Hospital Seongnam-si,
Seoul National University Hospital Seoul,
Servicios de Salud IPS Suramericana S.A.S - IPS Sura Industriales Medellín Medellín, ANT
Shanghai Jiao Tong University - Shanghai Chest Hospital Shanghai, SH
Shanghai Jiaotong University Affiliated Sixth People's Hospital Shanghai,
Shanghai Pulmonary Hospital Shanghai,
Shengjing Hospital of China Medical University Shenyang, Liaoning
Shenyang Chest Hospital Shenyang, Liaoning
Shenzhen People's Hospital Shenzhen,
Shimane University Hospital Izumo-Shi,
Shree Hospital and Critical Care Centre Nagpur, MH
Shri Guru Ram Rai (SGRR) Institute of Medical and Health Sciences - Shri Mahant Indiresh Hospital Dehradun, Uttarakhand
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital Chengdu,
SoonChunHyang University Bucheon Hospital Bucheon-si,
SoonChunHyang University Seoul Hospital Yongsan-gu, Seoul
South Texas Veterans Health Care System - Audie L. Murphy VA Hospital San Antonio, Texas
Southeastern Research Center Winston-Salem, North Carolina
St Francis Sleep Allergy & Lung Institute Clearwater, Florida
St. Antonius Ziekenhuis Nieuwegein,
St. John's Medical College Bangalore,
St. Joseph's Healthcare Hamilton Hamilton, Ontario
St. Joseph's Hospital and Medical Center Phoenix, Arizona
St. Paul's Hospital Vancouver, British Columbia
St. Vincent's University Hospital Dublin,
Stanford University School of Medicine Stanford, California
Steward St. Elizabeth Medical Center Boston, Massachusetts
Synergy Respiratory & Cardiac Care Sherwood Park, Alberta
T.C.S.B. Süreyyapasa Gögüs Hastaliklari Egitim Ve Arastirma Hastanesi Maltepe,
TC Saglik Bakanlig -Izmir Dr.Suat Seren Gogus Hastaliklari Ve Cerrahisi Egitim Arastirma Hastanesi Izmir,
Taichung Veterans General Hospital Taichung,
Taipei Veterans General Hospital Taipei,
Tel Aviv Sourasky Medical Center Tel Aviv,
Temple University Hospital (TUH) - Temple Lung Center (TLC) Philadelphia, Pennsylvania
Tenri Hospital Tenri,
The Affiliated Hospital of Inner Mongolia Medical University Hohhot, Inner Mongolia
The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu
The Catholic University of Korea, Bucheon St. Mary's Hospital Bucheon-si, Gyeonggi-do
The First Affiliated Hospital of Guangzhou Medical University Guangzhou,
The First Affiliated Hospital of Nanchang University - Xianghu District Nanchang, JX
The First Affiliated Hospital of Ningbo University Ningbo,
The First Affiliated Hospital of Soochow University Suzhou, Jiangsu
The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan
The First Affiliated Hospital, Sun Yat-sen University Guangzhou, Guangdong
The First Hospital of China Medical University Shenyang, Liaoning
The Jikei University Hospital Tokyo,
The Lung Centre Vancouver, British Columbia
The Lung Research Center Chesterfield, Missouri
The Ohio State University Wexner Medical Center Columbus, Ohio
The Prince Charles Hospital Chermside, Queensland
The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang
The Second Hospital of Hebei Medical University Shijiazhuang, Hebei
The Second Xiangya Hospital of Central South University Changsha, Hunan
The Third Hospital of Hebei Medical University Shijiazhuang,
The University of Alabama at Birmingham Birmingham, Alabama
The University of Chicago Medicine Chicago, Illinois
Thomas Jefferson University Hospital - Jane and Leonard Korman Lung Center Philadelphia, Pennsylvania
Thoraxklinik-Heidelberg gGmbH Heidelberg,
Thoraxzentrum Bezirk Unterfranken Münnerstadt, Bavaria
Tianjin Chest Hospital Tianjin, Tianjin Municipality
Tianjin Medical University General Hospital Tianjin, Tianjin Municipality
Toho University - Omori Medical Center Tokyo,
Tokyo Medical University Hospital Shinjuku-Ku, Tokyo
Toranomon Hospital Tokyo, Minato-ku,
Tosei General Hospital Aichi, Seto,
Turun Yliopistollinen Keskussairaala (TYKS) Turku, Laensi-Suomen Laeaeni
UC Irvine Medical Center Orange, California
UPMC - Dorothy P. and Richard P. Simmons Center for Interstitial Lung Diseases (ILD) Pittsburgh, Pennsylvania
UZ Leuven Leuven,
Ulsan University Hospital (UUH) Dong-gu, Ulsan
Uludag Universitesi Tip Fakultesi (Uludag University Faculty of Medicine) Bursa,
Unidade Local de Saude de Gaia/Espinho, EPE Vila Nova de Gaia,
Unidade Local de Saude de Loures - Odivelas, E. P. E. Loures,
Unidade Local de Saude de Santa Maria, EPE - Hospital Pulido Valente Lisbon,
Unidade Local de Saude de Santo Antonio, E.P.E. Porto,
Unidade Local de Saude de Sao Joao, EPE - Hospital de Sao Joao Porto,
Unidade Local de Saúde do Algarve, EPE Faro,
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei
Unity Hospital Fridley, Minnesota
Universitaetsklinikum Essen - Ruhrlandklinik Essen, North Rhine-Westphalia
Universitaetsklinikum Freiburg - Klinik fuer Pneumologie Freiburg I. Breisgau, Baden-Wurttemberg
Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Pneumologie Leipzig,
University General Hospital Attikon Athens,
University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital Birmingham, BIR
University Hospitals Birmingham NHS Foundation Trust - New Queen Elizabeth Hospital Birmingham Birmingham,
University of California UC Davis Medical Center Sacramento, California
University of California, San Francisco Medical Center- Pulmonary Practice San Francisco, California
University of Cincinnati College of Medicine Cincinnati, Ohio
University of Colorado Anschutz Medical Campus - Department of Family Medicine Aurora, Colorado
University of Florida (UF) Health Shands Hospital Gainesville, Florida
University of Fukui Hospital Yoshida,
University of Iowa Hospitals and Clinics Iowa City, Iowa
University of Kansas Medical Center (KUMC) Kansas City, Kansas
University of Maryland - Marlene and Stewart Greenebaum Cancer Center Baltimore, Maryland
University of Michigan Ann Arbor, Michigan
University of Patras - Rio Regional University Hospital Rio,
University of South Florida Tampa, Florida
University of Southern California (USC) - Keck School of Medicine (KSOM) - Transplant Clinic Los Angeles, California
University of Texas Southwestern Medical Center - Pulmonary Specialty Clinic Dallas, Texas
University of Thessaly- General University Hospital of Larissa Larissa,
University of Ulsan College of Medicine - Ulsan University Hospital (UUH) Dong-Gu,
University of Utah, University Hospital Salt Lake City, Utah
University of Washington Medical Center Seattle, Washington
Universitätsklinikum Hamburg-Eppendorf (UKE) Hamburg,
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz,
Universitätsspital Basel Basel,
Uniwersytecki Szpital Kliniczny Nr. 1 im. Norberta Barlickiego Lodz,
Uniwersyteckie Centrum Kliniczne Gdansk,
VCU Medical Center Richmond, Virginia
Vanderbilt Lung Institute - One Hundred Oaks Nashville, Tennessee
Velocity Clinical Research Germany GmbH Ahrensburg,
Vivantes Klinikum Neukolln Berlin,
Vzw Az Groeninge Kortrijk,
WM Clinica Pneumologica Sociedade Simples LTDA Porto Alegre, Rio Grande do Sul
Warminsko-Mazurskie Centrum Chorób Pluc w Olsztynie Olsztyn, Warmian-Masurian Voivodeship
Washington University School of Medicine in St. Louis St Louis, Missouri
West China Hospital, Sichuan University Chengdu, Sichuan
Western Washington Medical Group (WWMG) - Everett - Silver Lake Medical Center Location Everett, Washington
Westmead Hospital Westmead, New South Wales
Wiener Gesundheitsverbund - Klinik Floridsdorf Vienna,
Wonkwang University Hospital Iksansi,
Wuxi People's Hospital Wuxi,
Xi'an International Medical Center Hospital Xi'an,
Yale New Haven Hospital New Haven, Connecticut
Yichang Central People's Hospital - Xiling Campus Yichang Shi, HE
Yonsei University Health System, Severance Hospital Seoul,
Zuyderland Medisch Centrum, Sittard-Geleen Heerlen,
hospital Italiano de Buenos Aires CABA,

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Iovance Biotherapeutics https://www.tilvance-301.com - Clinical.Inquiries@iovance.com

NCT05727904
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
• In the investigator's assessment, the participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of \> 6 months.
• Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
• Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
• Participants must have adequate organ function.
• Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
• Participants who are \> 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
Exclusion Criteria:

• Participant has melanoma of uveal/ocular origin.
• Participant has symptomatic untreated brain metastases.
• Participant received more than 1 prior line of therapy.
• Participant received prior therapy for metastatic disease
• Participants with a BRAF V600 mutation-positive tumor received prior adjuvant/neoadjuvant ICI therapy only
• Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
• Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
• Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated \>1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
• Participant has a history of allogeneic cell or organ transplant. Other protocol defined inclusion/exclusion criteria could apply.
BIOLOGICAL: Lifileucel plus Pembrolizumab, BIOLOGICAL: Pembrolizumab with Optional Crossover Period
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Tumor Infiltrating Lymphocytes, TIL, Metastatic Melanoma, Unresectable Melanoma, Cell Therapy, Cellular Immuno-therapy, IL-2, Non-myeloablative lymphodepletion (NMALD), Check point inhibitor, Melanoma, Lifileucel, Stage III Melanoma, Stage IV Melanoma, Skin cancer, Skin cancer types, Malignant melanoma, Autologous Adoptive Cell Therapy, Autologous Adoptive Cell Transfer, LN-144, Pembrolizumab, Pembro, Adjuvant/Neo-adjuvant, BRAF/MEK, ICI, BRAF v600, Immune checkpoint inhibitor, Tumor infiltrating T-cells, TILVANCE, TILVANCE-301
I'm interested
Share via email
Show 72 locations

Study Locations

Hide all locations
Location Contacts
Allegheny Health Network Pittsburgh, Pennsylvania
Azienda Ospedaliera Universitaria Senese Siena, Si
Azienda Ospedaliero Universitaria Pisana Pisa,
Baptist Cancer Center Memphis, Tennessee
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center Detroit, Michigan
Beaston West of Scotland Canter Centre Glasgow,
Bundang Medical Center - CHA University Seongnam-si, Gyeonggi-do
California Pacific Medical Center San Francisco, California
Centre Hospitalier Universitaire Vaudois Lausanne Lausanne, Canton of Vaud
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu Nantes,
Centre Hospitalier de l'Université de Montréal Montreal,
Centro di Riferimento Oncologico IRCCS Aviano, Friuli-Venezia Giulia
City of Hope Duarte, California
Clinica Universitaria de Navarra Pamplona,
Consorcio Hospital General Universitario de Valencia Valencia,
Dartmouth-Hitchcock Medical Center (DHMC) - Norris Cotton Cancer Center Lebanon, New Hampshire
Fiona Stanley Hospital Murdoch, Western Australia
Flinders Medical Centre Bedford Park,
Freeman Hospital High Heaton,
Greenslopes Private Hospital Greenslopes, Queensland
Guy's Hospital London,
Hadassah Medical Center Jerusalem,
Henry Ford Health Detroit, Michigan
Hopital Saint Louis Paris, Île-de-France Region
Hospital 12 de Octubre Madrid,
Hospital Clinic de Barcelona Barcelona,
Hospital General Universitario Gregorio Marañon Madrid,
Hospital Regional Universitario de Malaga - Hospital General Malaga, Málaga
Hospital Universitari Vall dHebron Barcelona,
Hospital Universitario Madrid Sanchinarro - CIOCC Madrid,
Hospital Universitario Marqués de Valdecilla Santander,
Hospital Universitario Quironsalud Madrid Pozuelo de Alarcón,
Hospital Universitario Ramon y Cajal Madrid,
Hospital Universitario Virgen Macarena Seville,
ICO l'Hospitalet - Hospital Duran i Reynals Barcelona,
Institut Paoli Calmettes Marseille,
Instituto Oncologico Rosell Barcelona,
Istituto Europeo Di Oncologia Milan,
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Napoli,
Istituto Romagnolo per lo Studio dei Tumori Meldola, Forli Cesena
Klinikum rechts der Isar der Technischen Universitat Munchen München, Bavaria
MD Anderson Cancer Center at Cooper Camden, New Jersey
National Cancer Institute Putrajaya,
Nederlands Kanker Instituut Amsterdam,
Ohio State University Columbus, Ohio
Oncology Hematology Care Cincinnati, Ohio
Orlando Health Cancer Institute Orlando, Florida
Peter MacCallum Cancer Centre Melbourne, Victoria
Princess Margaret Cancer Centre Toronto, Ontario
Queen Elizabeth Hospital Birmingham Birmingham,
Royal Marsden Hospital London,
SCRI Oncology Partners Nashville, Tennessee
Sahlgrenska Universitetssjukhuset Gasteborg,
Sarah Cannon Research Institute UK London,
Seoul National University Hospital Seoul,
Severance Hospital, Yonsei University Health System Seoul,
Sheba Medical Center Ramat Gan,
St. Luke's Cancer Center - Anderson Easton, Pennsylvania
Swedish Cancer Institute Seattle, Washington
Tel Aviv Sourasky Medical Center Tel Aviv,
USC Norris Comprehensive Cancer Center Los Angeles, California
Universitair Ziekenhuis Brussel - Oncologisch Centrum Jette,
Universitatsklinikum Hamburg-Eppendorf Hamburg,
University of Alabama at Birmingham: The Kirklin Clinic Birmingham, Alabama
University of Colorado Cancer Center Aurora, Colorado
University of Illinois Hospital & Health Sciences System Chicago, Illinois
University of Kansas Kansas City, Kansas
University of Louisville - James Graham Brown Cancer Center Louisville, Kentucky
Universitätsklinikum Carl Gustav Carus Dresden,
Universitätsklinikum Schleswig-Holstein - Campus Lübeck Lübeck, Schleswig-Holstein
Virginia Commonwealth University Richmond, Virginia
Westmead Hospital Westmead, New South Wales

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

ctrrecruit@vcu.edu

NCT05987241
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* PRE-REGISTRATION: Histologically confirmed muscle-invasive urothelial carcinoma of the urethra, bladder, ureter or renal pelvis * PRE-REGISTRATION: Variant histology, including neuroendocrine differentiation, sarcomatoid, micropapillary, glandular, trophoblastic, Mullerian, is allowed if urothelial cancer is predominant histology (any amount of squamous differentiation is allowed provided the tumor is not a pure squamous cell cancer) * PRE-REGISTRATION: Patient must have had radical surgery (i.e., cystectomy and lymph node dissection or nephroureterectomy or ureterectomy) ≥ 3 weeks, but ≤ 12 weeks prior to pre-registration. Patients who have had a partial cystectomy as definitive therapy are not eligible * PRE-REGISTRATION: No gross cancer at the surgical margins. Microscopic invasive urothelial carcinoma at the surgical margins (i.e., "positive margins") are allowed. Carcinoma in situ (CIS) at margins is considered negative margins * PRE-REGISTRATION: No evidence of residual cancer or metastasis after radical cystectomy or nephroureterectomy or ureterectomy (imaging is not required prior to pre-registration but is required prior to registration) * PRE-REGISTRATION: Have undergone a radical cystectomy nephroureterectomy, or ureterectomy with pathological evidence of urothelial carcinoma at high risk of recurrence as described in one of the two scenarios below (i or ii). The 7th edition of American Joint Committee on Cancer (AJCC) staging will be utilized.: * (i) Patients who have not received neoadjuvant systemic therapy: pT3-pT4\* or pT0/x-pT4/N+ on radical surgery (i.e., cystectomy, nephroureterectomy, or ureterectomy) and are not eligible for adjuvant cisplatin chemotherapy * (i) Patients ineligible for cisplatin due to at least one of the following criteria and reason for ineligibility should be documented: * (i) Creatinine Clearance (using Cockcroft-Gault): \< 60 mL/min * (i) Common Terminology Criteria for Adverse Events (CTCAE) version 5, grade \>= 2 audiometric hearing loss * (i) CTCAE version 5, grade \>= 2 or above peripheral neuropathy * New York Heart Association Class III heart failure * (i) Eastern Cooperative Oncology Group (ECOG) performance status = 2 * (i) Patients who are eligible for cisplatin may be candidates if they refuse adjuvant cisplatin-based chemotherapy, despite being informed by the investigator about the treatment options. The patient's refusal must be documented. * (i) Patients with pT2N0 urothelial cancer on radical surgery specimen (without prior neoadjuvant systemic therapy) with ctDNA(+) Signatera results based on an assay performed post-radical surgery as part of routine care outside of the study may proceed with pre-registration but require confirmation of ctDNA(+) Signatera testing on repeat "central testing" in the context of A032103 testing. Patients with pT2N0 with central testing not confirming ctDNA(+) will not be eligible for A032103 (Note: this is distinct from patients with ypT2N0 who are eligible based on ii). * (ii) Patients who received neoadjuvant systemic therapy: ypT2-T4a and/or ypN+ on radical surgery (i.e., cystectomy. , nephroureterectomy, or ureterectomy) pathology specimen. Neoadjuvant systemic therapy may have included cisplatin-based chemotherapy, cisplatin-based chemotherapy plus PD-1/PD-L1 blockade, or enfortumab vedotin plus PD-1/PD-L1 blockade * PRE-REGISTRATION: Available tumor tissue for central Signatera testing to be submitted at pre-registration. Central testing is defined as testing performed as part of the A032103 study prior to registration and is provided by the study and not routine standard commercial testing. Patients who have already had local Signatera testing performed as part of routine care will require repeat central testing as part of the A032103 study to be eligible for registration/randomization. Tumor tissue from the radical surgery specimen is preferred over tissue from prior diagnostic biopsy specimen (e.g., transurethral resection of bladder tumor specimen) * PRE-REGISTRATION: Age \>= 18 years * PRE-REGISTRATION: ECOG Performance Status 0-2 * PRE-REGISTRATION: Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects * PRE-REGISTRATION: No postoperative/adjuvant systemic therapy after radical surgery * PRE-REGISTRATION: No adjuvant radiation after radical surgery * PRE-REGISTRATION: No treatment with any other type of investigational agent =\< 4 weeks before pre-registration * PRE-REGISTRATION: Not have ever received prior treatment with LAG-3 blockade * PRE-REGISTRATION: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * PRE-REGISTRATION: Absolute Neutrophil Count (ANC) \>= 1,200/mm\^3 * PRE-REGISTRATION: Platelet count \>= 100,000/mm\^3 * PRE-REGISTRATION: Hemoglobin \>= 8 g/dL * PRE-REGISTRATION: Creatinine =\< 1.5 x upper limit of normal (ULN) or calculated (calc.) creatinine clearance \> 30 mL/min (using either Cockcroft-Gault formula or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation * PRE-REGISTRATION: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 x ULN * PRE-REGISTRATION: Total bilirubin =\< 1.5 x upper limit of normal (ULN) (except in patients with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL) * PRE-REGISTRATION: For women of childbearing potential only: A negative urine or serum pregnancy test done =\< 14 days prior to pre-registration is required * PRE-REGISTRATION: Not currently requiring hemodialysis * PRE-REGISTRATION: No current or prior history of myocarditis * PRE-REGISTRATION: No grade ≥ 3 immune related adverse event with prior PD-1/PD-L1 blockade * PRE-REGISTRATION: No active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens- Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease. * PRE-REGISTRATION: Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. * PRE-REGISTRATION: Patients with rheumatoid arthritis and other arthropathies, Sjögren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible. * PRE-REGISTRATION: No current pneumonitis or prior history of non-infectious pneumonitis that required steroids within the previous 5 years. * PRE-REGISTRATION: No known active hepatitis B (e.g., hepatitis B surface antigen \[HBsAg\] reactive) or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected). * PRE-REGISTRATION: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * PRE-REGISTRATION: Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible. * PRE-REGISTRATION: No concurrent antineoplastic therapy. * PRE-REGISTRATION: No current immunosuppressive agents (with the exception of corticosteroids as described below). * PRE-REGISTRATION: No condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of pre-registration (with the exception of steroid pre-medications for contrast allergies). Inhaled or topical steroids and adrenal replacement doses \< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. * REGISTRATION: Patient must have had radical cystectomy and lymph node dissection or nephroureterectomy or ureterectomy =\< 18 weeks prior to registration. * REGISTRATION: Must have evaluable ctDNA Signatera assay result (i.e., ctDNA\[+\]or ctDNA\[-\]) based on test performed as part of central testing at pre-registration to A032103. Central testing is defined as testing performed as part of the A032103. Local/commercial testing results may not be used for registration to A032103 * Cisplatin-ineligible (or cisplatin-declining) patients with a pT2N0 urothelial cancer on cystectomy or nephroureterectomy or ureterectomy who were pre-registered based on routine standard care ctDNA(+) Signatera testing must have confirmed ctDNA(+) Signatera testing on central testing. If central Signatera testing yields a ctDNA(-) result, these patients are ineligible. NOTE: This is a distinct consideration from patients with ypT2-4 and/or ypN+ urothelial cancer (i.e., patients who had received neoadjuvant cisplatin-based chemotherapy) who are eligible with either ctDNA(+) or ctDNA(-) central Signatera testing * REGISTRATION: All patients must have confirmed disease-free status defined as no measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or definitive non-measurable radiographic metastatic disease, within 60 days prior to registration. Patients with equivocal nodes less than 15 mm in short axis, or \< 10 mm in long axis for non-lymph node lesions, not considered by the investigator to represent malignant disease will be eligible. Attempts should be made to resolve the etiology of equivocal lesions with complementary imaging (e.g., PET scan) or biopsy. * REGISTRATION: No major surgery =\< 3 weeks before registration. * REGISTRATION: No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette- Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist \[registered trademark\]) are live attenuated vaccines and are not allowed. Coronavirus disease 2019 (COVID-19) vaccines are not live vaccines and are allowed * REGISTRATION: No change since registration in clinical condition and/or laboratory tests that would impact the safety of nivolumab +/- relatlimab administration in the opinion of the treating investigator * COHORT B, ARM 4 PATIENTS INITIATING NIVOLUMAB AFTER CONVERSION OF ctDNA ASSAY FROM ctDNA(-) to ctDNA (+): * Patient must have converted to ctDNA(+) during serial monitoring performed centrally in the setting of the A032103 study * COHORT B, ARM 4 PATIENTS INITIATING NIVOLUMAB AFTER CONVERSION OF ctDNA ASSAY FROM ctDNA(-) to ctDNA (+): * No evidence of metastatic disease on the most recent scheduled imaging assessment as outlined in the study calendar (no repeat imaging is necessary specifically at the time of the conversion from ctDNA\[-\] to ctDNA\[+\]). * COHORT B, ARM 4 PATIENTS INITIATING NIVOLUMAB AFTER CONVERSION OF ctDNA ASSAY FROM ctDNA(-) to ctDNA (+): * No change in clinical condition and/or laboratory tests that would impact the safety of nivolumab administration in the opinion of the treating investigator * COHORT B, ARM 4 PATIENTS INITIATING NIVOLUMAB AFTER CONVERSION OF ctDNA ASSAY FROM ctDNA(-) to ctDNA (+): * =\< 6 weeks from reporting of ctDNA(+) result to site (not from the date sample was drawn).
PROCEDURE: Biospecimen Collection, OTHER: cfDNA or ctDNA Measurement, PROCEDURE: Computed Tomography, PROCEDURE: Cystoscopy, PROCEDURE: Magnetic Resonance Imaging, BIOLOGICAL: Nivolumab, OTHER: Questionnaire Administration, BIOLOGICAL: Relatlimab
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
I'm interested
Share via email
Show 474 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Addison Gilbert Hospital Gloucester, Massachusetts
AdventHealth Orlando Orlando, Florida Site Public Contact - (FH.Cancer.Research@flhosp.org)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Sherman Hospital Elgin, Illinois
Allegiance Health Jackson, Michigan Site Public Contact - (CTOResearch@hfhs.org)
AnMed Health Cancer Center Anderson, South Carolina Site Public Contact - (rhonda.ballew@anmedhealth.org)
Arthur J E Child Comprehensive Cancer Centre Calgary, Alberta Site Public Contact - (ctsucontact@westat.com)
Asplundh Cancer Pavilion Willow Grove, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Atrium Health Cleveland/LCI-Cleveland Shelby, North Carolina
Atrium Health Lincoln/LCI-Lincolnton Lincolnton, North Carolina
Atrium Health Pineville/LCI-Pineville Charlotte, North Carolina
Atrium Health Stanly/LCI-Albemarle Albemarle, North Carolina
Atrium Health Union/LCI-Union Monroe, North Carolina
Atrium Health University City/LCI-University Charlotte, North Carolina
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BCCA-Vancouver Cancer Centre Vancouver, British Columbia
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Banner University Medical Center - Tucson Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
Baptist Health Louisville Louisville, Kentucky Site Public Contact - (Cbcresearch@bhsi.com)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Ben Taub General Hospital Houston, Texas
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Beth Israel Deaconess Medical Center Boston, Massachusetts
Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care Winchester, Massachusetts
Beverly Hospital Beverly, Massachusetts
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bon Secours Memorial Regional Medical Center Mechanicsville, Virginia
Bon Secours Richmond Community Hospital Richmond, Virginia
Bon Secours Saint Francis Medical Center Midlothian, Virginia
Bon Secours Saint Mary's Hospital Richmond, Virginia
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Bronson Battle Creek Battle Creek, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado Site Public Contact - (protocols@AllianceNCTN.org)
Cancer Center at Saint Joseph's Phoenix, Arizona Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Cancer Centers of Southwest Oklahoma Research Lawton, Oklahoma
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan Site Public Contact - (connie.szczepanek@crcwm.org)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Central Vermont Medical Center/National Life Cancer Treatment Berlin Corners, Vermont
Coborn Cancer Center at Saint Cloud Hospital Saint Cloud, Minnesota Site Public Contact - (coborncancercenter@centracare.com)
Columbus Oncology and Hematology Associates Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Columbus Oncology and Hematology Associates Inc Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Cross Cancer Institute Edmonton, Alberta
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana-Farber Cancer Institute Boston, Massachusetts
Dana-Farber Cancer Institute at Boston Medical Center - Brighton Brighton, Massachusetts
Dana-Farber Cancer Institute at Foxborough Foxborough, Massachusetts
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Milford, Massachusetts
Dana-Farber/Brigham and Women's Cancer Center at South Shore South Weymouth, Massachusetts
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Delaware Health Center-Grady Cancer Center Delaware, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Doctors Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Dublin Methodist Hospital Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Duke Cancer Center Cary Cary, North Carolina Site Public Contact - (NCTNStudyTeam@dm.duke.edu)
Duke Cancer Center Raleigh Raleigh, North Carolina Site Public Contact - (NCTNStudyTeam@dm.duke.edu)
Duke University Medical Center Durham, North Carolina
Edward Hospital/Cancer Center Naperville, Illinois
Edward Hospital/Cancer Center?Plainfield Plainfield, Illinois Site Public Contact - (Cancerresearch@edward.org)
Elmhurst Memorial Hospital Elmhurst, Illinois Site Public Contact - (Jrohde@emhc.org)
Emory Johns Creek Hospital Johns Creek, Georgia Site Public Contact - (m.lisa.hwang@emory.edu)
Emory Saint Joseph's Hospital Atlanta, Georgia
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
FirstHealth of the Carolinas-Moore Regional Hospital Pinehurst, North Carolina Site Public Contact - (jcwilliams@firsthealth.org)
Genesee Hematology Oncology PC Flint, Michigan
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
George Washington University Medical Center Washington D.C., District of Columbia
Glens Falls Hospital Glens Falls, New York
Grady Health System Atlanta, Georgia
Grady Memorial Hospital Delaware, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Grant Medical Center Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Hackensack University Medical Center Hackensack, New Jersey
Hartford HealthCare - Saint Vincent's Medical Center Bridgeport, Connecticut
Hartford Healthcare - Fairfield Fairfield, Connecticut Site Public Contact - (CancerResearchSupport@hhchealth.org)
Hartford Hospital Hartford, Connecticut
HaysMed Hays, Kansas
Helen F Graham Cancer Center Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Hennepin County Medical Center Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Henry Ford Hospital Detroit, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Medical Center-Columbus Novi, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford West Bloomfield Hospital West Bloomfield, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Highlands Oncology Group Springdale, Arkansas Site Public Contact - (research@hogonc.com)
Highlands Oncology Group - Fayetteville Fayetteville, Arkansas Site Public Contact - (research@hogonc.com)
Highlands Oncology Group - Rogers Rogers, Arkansas Site Public Contact - (research@hogonc.com)
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana Site Public Contact - (iutrials@iu.edu)
Ingalls Memorial Hospital Harvey, Illinois Site Public Contact - (clinicaltrials@ingalls.org)
Iowa Methodist Medical Center Des Moines, Iowa
Jefferson Cherry Hill Hospital Cherry Hill, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Jefferson Torresdale Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Site Public Contact - (jhcccro@jhmi.edu)
Kaiser Permanente - Panorama City Panorama City, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente Downtown Commons Sacramento, California Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Fresno Orchard Plaza Fresno, California
Kaiser Permanente Los Angeles Medical Center Los Angeles, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii Site Public Contact - (shelley.a.clark@kp.org)
Kaiser Permanente San Leandro San Leandro, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente South Bay Harbor City, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente West Los Angeles Los Angeles, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Anaheim Anaheim, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Baldwin Park Baldwin Park, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Bellflower Bellflower, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Fontana Fontana, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Franklin Denver, Colorado Site Public Contact - (KPCOIHRClinicalResearch@kp.org)
Kaiser Permanente-Fremont Fremont, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Irvine Irvine, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Lone Tree Lone Tree, Colorado Site Public Contact - (KPCOIHRClinicalResearch@kp.org)
Kaiser Permanente-Modesto Modesto, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Ontario Ontario, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Riverside Riverside, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Rock Creek Lafayette, Colorado Site Public Contact - (KPCOIHRClinicalResearch@kp.org)
Kaiser Permanente-Roseville Roseville, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Diego Zion San Diego, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-San Francisco San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Marcos San Marcos, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Woodland Hills Woodland Hills, California Site Public Contact - (clinical.trials@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California Site Public Contact - (Kpoct@kp.org)
Kansas City Veterans Affairs Medical Center Kansas City, Missouri
Karmanos Cancer Institute at McLaren Greater Lansing Lansing, Michigan Site Public Contact - (ctoadmin@karmanos.org)
Keck Medicine of USC Koreatown Los Angeles, California
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Lafayette Family Cancer Center-EMMC Brewer, Maine
Lahey Hospital and Medical Center Burlington, Massachusetts Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lahey Medical Center-Peabody Peabody, Massachusetts Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lancaster General Ann B Barshinger Cancer Institute Lancaster, Pennsylvania Site Public Contact - (nctn@pennmedicine.upenn.edu)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York Site Public Contact - (CancerTrials@nyulangone.org)
Lawrence Memorial Hospital Lawrence, Kansas Site Public Contact - (Stephanie.Norris@LMH.ORG)
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Levine Cancer Institute - Huntersville Huntersville, North Carolina
Levine Cancer Institute - Rutherford Forest City, North Carolina
Levine Cancer Institute - Union West Matthews, North Carolina
Levine Cancer Institute-Ballantyne Charlotte, North Carolina
Levine Cancer Institute-Gaston Gastonia, North Carolina
Levine Cancer Institute-Rock Hill Rock Hill, South Carolina
Levine Cancer Institute-SouthPark Charlotte, North Carolina
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
London Regional Cancer Program London, Ontario
Los Angeles General Medical Center Los Angeles, California
Louisiana Hematology Oncology Associates LLC Baton Rouge, Louisiana Site Public Contact - (clinicalresearch@marybird.com)
Lyndon Baines Johnson General Hospital Houston, Texas
MU Health - University Hospital/Ellis Fischel Cancer Center Columbia, Missouri
MU Health Care Goldschmidt Cancer Center Jefferson City, Missouri
Maimonides Medical Center Brooklyn, New York
Malcom Randall Veterans Administration Medical Center Gainesville, Florida Site Public Contact - (trials@cancer.ufl.edu)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mary Bird Perkins Cancer Center - Metairie Metairie, Louisiana
Mary Greeley Medical Center Ames, Iowa
McFarland Clinic - Ames Ames, Iowa Site Public Contact - (ksoder@mcfarlandclinic.com)
McFarland Clinic - Boone Boone, Iowa
McFarland Clinic - Jefferson Jefferson, Iowa
McFarland Clinic - Marshalltown Marshalltown, Iowa
McFarland Clinic - Trinity Cancer Center Fort Dodge, Iowa
McLaren Cancer Institute-Bay City Bay City, Michigan Site Public Contact - (ctoadmin@karmanos.org)
McLaren Cancer Institute-Northern Michigan Petoskey, Michigan Site Public Contact - (ctoadmin@karmanos.org)
MedStar Georgetown University Hospital Washington D.C., District of Columbia
Medical Center of the Rockies Loveland, Colorado
Medical College of Wisconsin Milwaukee, Wisconsin
Medical Oncology Hematology Consultants PA Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Medical University of South Carolina Charleston, South Carolina Site Public Contact - (hcc-clinical-trials@musc.edu)
Medstar Washington Hospital Center Washington D.C., District of Columbia
Memorial Hospital East Shiloh, Illinois Site Public Contact - (dschwab@wustl.edu)
Memorial Hospital West Pembroke Pines, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida Site Public Contact - (OHR@mhs.net)
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Nassau Uniondale, New York
Memorial Sloan Kettering Westchester Harrison, New York
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Mercy Medical Center - Des Moines Des Moines, Iowa Site Public Contact - (cancerresearch@mercydesmoines.org)
Miami Cancer Institute Miami, Florida
Michael E DeBakey VA Medical Center Houston, Texas
Midstate Medical Center Meriden, Connecticut
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Monmouth Medical Center Southern Campus Lakewood, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Montefiore Medical Center-Einstein Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Mount Sinai Chelsea New York, New York Site Public Contact - (CCTO@mssm.edu)
Mount Sinai Comprehensive Cancer Center at Aventura Aventura, Florida
Mount Sinai Hospital New York, New York Site Public Contact - (CCTO@mssm.edu)
Mount Sinai Medical Center Miami Beach, Florida
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
MyMichigan Medical Center Saginaw Saginaw, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
MyMichigan Medical Center Tawas Tawas City, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
NYP/Weill Cornell Medical Center New York, New York
NYU Langone Hospital - Long Island Mineola, New York
Nebraska Medicine-Bellevue Bellevue, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
Nebraska Medicine-Village Pointe Omaha, Nebraska
New Hampshire Oncology Hematology PA-Concord Concord, New Hampshire
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
Northside Hospital Atlanta, Georgia Site Public Contact - (ClinicalTrials@northside.com)
Northside Hospital - Duluth Duluth, Georgia Site Public Contact - (Clinical.trials@northside.com)
Northside Hospital - Gwinnett Lawrenceville, Georgia Site Public Contact - (Clinical.trials@northside.com)
Northwestern Medicine Cancer Center Delnor Geneva, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois Site Public Contact - (cancertrials@northwestern.edu)
Northwestern Medicine Oak Brook Oak Brook, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern Medicine Orland Park Orland Park, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan Site Public Contact - (WI_research_admin@hshs.org)
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
OhioHealth Mansfield Hospital Mansfield, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Marion General Hospital Marion, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth O'Bleness Hospital Athens, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Pickerington Methodist Hospital Pickerington, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Westerville Medical Campus/Westerville Cancer Center Westerville, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Oklahoma Cancer Specialists and Research Institute-Tulsa Tulsa, Oklahoma
Oncology Hematology Associates of Saginaw Valley PC Saginaw, Michigan
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Pocono Medical Center East Stroudsburg, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Poudre Valley Hospital Fort Collins, Colorado
Presbyterian Kaseman Hospital Albuquerque, New Mexico Site Public Contact - (WBurman@phs.org)
Presbyterian Rust Medical Center/Jorgensen Cancer Center Rio Rancho, New Mexico Site Public Contact - (WBurman@phs.org)
Prisma Health Cancer Institute - Butternut Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Easley Easley, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Faris Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Greer Greer, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Seneca Seneca, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Greenville Memorial Hospital Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProHealth Waukesha Memorial Hospital Waukesha, Wisconsin
ProMedica Flower Hospital Sylvania, Ohio Site Public Contact - (PCIOncResearch@promedica.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Reading Hospital West Reading, Pennsylvania
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Riverside Methodist Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Robert Wood Johnson University Hospital Somerset Somerville, New Jersey Site Public Contact - (Siby.Varughese@rwjbh.org)
Rochester General Hospital Rochester, New York Site Public Contact - (tia.derosa@rochestergeneral.org)
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint John's Cancer Institute Santa Monica, California
Saint Mary's Oncology/Hematology Associates of West Branch West Branch, Michigan
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Salina Regional Health Center Salina, Kansas Site Public Contact - (mleepers@srhc.com)
Sanford Bismarck Medical Center Bismarck, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Joe Lueken Cancer Center Bemidji, Minnesota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Roger Maris Cancer Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Sibley Memorial Hospital Washington D.C., District of Columbia Site Public Contact - (jquiver1@jhmi.edu)
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Westerly Westerly, Rhode Island Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Long Ridge Stamford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Derby Care Center Derby, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut Site Public Contact - (canceranswers@yale.edu)
Solinsky Center for Cancer Care Manchester, New Hampshire
Southern Illinois University School of Medicine Springfield, Illinois
Southern Ocean County Medical Center Manahawkin, New Jersey
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Stanford Cancer Institute Palo Alto Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
Swedish Covenant Hospital Chicago, Illinois
The Hospital of Central Connecticut New Britain, Connecticut
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The New York Hospital Medical Center of Queens Flushing, New York Site Public Contact - (ctsucontact@westat.com)
The University of Kansas Cancer Center - Olathe Olathe, Kansas Site Public Contact - (OlatheCCResearch@kumc.edu)
The West Clinic - Wolf River Germantown, Tennessee
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UC San Diego Moores Cancer Center La Jolla, California Site Public Contact - (cancercto@ucsd.edu)
UCHealth Greeley Hospital Greeley, Colorado Site Public Contact - (protocols@AllianceNCTN.org)
UCHealth Highlands Ranch Hospital Highlands Ranch, Colorado
UCHealth Lone Tree Health Center Lone Tree, Colorado Site Public Contact - (protocols@AllianceNCTN.org)
UCHealth University of Colorado Hospital Aurora, Colorado
UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California
UF Health Cancer Institute - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
UPMC Altoona Altoona, Pennsylvania Site Public Contact - (protocols@AllianceNCTN.org)
UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania Site Public Contact - (ClinicalResearchServices@upmc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania Site Public Contact - (ClinicalResearchServices@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania Site Public Contact - (klitchfield@PINNACLEHEALTH.org)
UPMC Western Maryland Cumberland, Maryland
UPMC-Passavant Hospital Pittsburgh, Pennsylvania
UPMC-Saint Clair Hospital Cancer Center Pittsburgh, Pennsylvania
UPMC-Saint Margaret Pittsburgh, Pennsylvania
USC / Norris Comprehensive Cancer Center Los Angeles, California
USC Norris Oncology/Hematology-Newport Beach Newport Beach, California
UT Southwestern Clinical Center at Richardson/Plano Richardson, Texas Site Public Contact - (Suzanne.cole@utsouthwestern.edu)
UT Southwestern Simmons Cancer Center - RedBird Dallas, Texas Site Public Contact - (canceranswerline@utsouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Fort Worth Fort Worth, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
UW Health Carbone Cancer Center Rockford Rockford, Illinois Site Public Contact - (lkline@uwhealth.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Unity Park Ridge Campus Rochester, New York Site Public Contact - (protocols@AllianceNCTN.org)
University Health Network-Princess Margaret Hospital Toronto, Ontario Site Public Contact - (clinical.trials@uhn.on.ca)
University Health Truman Medical Center Kansas City, Missouri
University of Arizona Cancer Center-North Campus Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
University of Arizona Cancer Center-Orange Grove Campus Tucson, Arizona
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Chicago Medicine-Orland Park Orland Park, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio Site Public Contact - (cancer@uchealth.com)
University of Cincinnati Cancer Center-West Chester West Chester, Ohio Site Public Contact - (cancer@uchealth.com)
University of Illinois Chicago, Illinois
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - Briarcliff Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center at North Kansas City Hospital North Kansas City, Missouri
University of Kansas Cancer Center-Overland Park Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan - Brighton Center for Specialty Care Brighton, Michigan
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
University of Michigan Rogel Cancer Center Ann Arbor, Michigan Site Public Contact - (CancerAnswerLine@med.umich.edu)
University of Mississippi Medical Center Jackson, Mississippi
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Rochester Rochester, New York
University of Vermont Medical Center Burlington, Vermont Site Public Contact - (rpo@uvm.edu)
University of Vermont and State Agricultural College Burlington, Vermont Site Public Contact - (rpo@uvm.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
VCU Community Memorial Health Center South Hill, Virginia Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Veteran's Affairs Medical Center - Saint Louis St Louis, Missouri Site Public Contact - (protocols@AllianceNCTN.org)
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Virginia Mason Medical Center Seattle, Washington Site Public Contact - (cancerresearch@virginiamason.org)
Wake Forest University Health Sciences Winston-Salem, North Carolina
Wake Forest University at Clemmons Clemmons, North Carolina
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Waterloo Regional Health Network Kitchener, Ontario Site Public Contact - (research@wrhn.ca)
Wayne State University/Karmanos Cancer Institute Detroit, Michigan Site Public Contact - (ctoadmin@karmanos.org)
Weisberg Cancer Treatment Center Farmington Hills, Michigan Site Public Contact - (ctoadmin@karmanos.org)
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
West Virginia University Charleston Division Charleston, West Virginia
Wilmot Cancer Institute at Webster Webster, New York Site Public Contact - (WCICTOresearch@urmc.rochester.edu)
Yale University New Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)
Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

ctrrecruit@vcu.edu

NCT06317649
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient must be ≥ 60 years of age or adults ˂ 60 who in the opinion of the treating physician are better served by azanucleoside-based therapy rather than intensive, cytarabine-based induction based on clinical status (i.e., performance status, age \> 75 years), organ dysfunction, or disease biology * Patient must have a morphologically confirmed diagnosis of AML according to the World Health Organization (WHO) 2016 classification excluding acute promyelocytic leukemia (APL) with PML-RARA, AML with RUNX1-RUNX1T1, or AML with CBFB-MYH11 * Patient must have no prior therapy for AML with the exception of hydroxyurea and all-trans retinoic acid (ATRA), or leukapheresis. Patients with cytarabine-based emergency therapy prior to the start of therapy on this trial are eligible * Patient must have no prior therapy with hypomethylating agents or FLT3 inhibitors * Patient must have the FLT3-ITD or D835 mutation based on MyeloMATCH Master Screening and Reassessment Protocol (MSRP) * Patient must be assigned to this protocol by the myeloMATCH MSRP * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. * All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patient of childbearing potential and/or sexually active patients must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 30 days after the last dose of venetoclax for all patients and for 6 months after the last dose of gilteritinib for patients of childbearing potential and for 4 months after the last dose of gilteritinib for male patients with partners of childbearing potential. Patient must not breastfeed during treatment and for 2 months after treatment ends * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible * Total bilirubin 2X ≤ institutional upper limit of normal (ULN) (unless thought to be elevated due to disease involvement or Gilbert's syndrome) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3.0 x institutional ULN * Either measured or estimated by Cockcroft-Gault equation * Creatinine clearance of ≥ 30 mL/min/1.73m\^2 * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration/randomization are eligible for this trial * Patients must not have a baseline corrected QT interval ≥ 480 msec using Fredericia correction (QTcF). NOTE: Since older patients are at risk for prolonged QTc and many will require supportive care with agents that affect the QTc, an ECG is recommended if clinically indicated. If the QTc is prolonged, they should be treated on tier advancement process (TAP) instead of EA02 * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patient must not have the medical necessity for ongoing treatment with a strong CYP3A4 inducing drug * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Patients must not have an active or uncontrolled infection
DRUG: Azacitidine, PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Bone Marrow Biopsy, DRUG: Gilteritinib, DRUG: Venetoclax
Acute Myeloid Leukemia
I'm interested
Share via email
Show 207 locations

Study Locations

Hide all locations
Location Contacts
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Allegiance Health Jackson, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Alta Bates Summit Medical Center-Herrick Campus Berkeley, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Augusta University Medical Center Augusta, Georgia Site Public Contact - (ga_cares@augusta.edu)
Banner University Medical Center - Tucson Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
Baptist Cancer Center-Grenada Grenada, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Ben Taub General Hospital Houston, Texas
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Cedars Sinai Medical Center Los Angeles, California
Centro Comprensivo de Cancer de UPR San Juan, Site Public Contact - (ecog.rss@jimmy.harvard.edu)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Cotton O'Neil Cancer Center / Stormont Vail Health Topeka, Kansas
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana-Farber Cancer Institute Boston, Massachusetts
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Duke University Medical Center Durham, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Edward Hines Jr VA Hospital Hines, Illinois
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fred Hutchinson Cancer Center Seattle, Washington
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Genesee Hematology Oncology PC Flint, Michigan
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
George E Wahlen Department of Veterans Affairs Medical Center Salt Lake City, Utah
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
Hawaii Cancer Care - Westridge ‘Aiea, Hawaii Site Public Contact - (info@hawaiicancercare.com)
Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii Site Public Contact - (i.webster@hawaiicancercare.com)
Henry Ford Hospital Detroit, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Medical Center-Columbus Novi, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford West Bloomfield Hospital West Bloomfield, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Kaiser Permanente Downtown Commons Sacramento, California Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Fresno Orchard Plaza Fresno, California
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii Site Public Contact - (shelley.a.clark@kp.org)
Kaiser Permanente San Leandro San Leandro, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fremont Fremont, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Modesto Modesto, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Roseville Roseville, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Francisco San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California Site Public Contact - (Kpoct@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California Site Public Contact - (Kpoct@kp.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
LSU Health Baton Rouge-North Clinic Baton Rouge, Louisiana Site Public Contact - (research@ololrmc.com)
Lahey Hospital and Medical Center Burlington, Massachusetts Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lahey Medical Center-Peabody Peabody, Massachusetts Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Loyola University Medical Center Maywood, Illinois
MaineHealth Cancer Care and IV Therapy - Brunswick Brunswick, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Cancer Care and IV Therapy - South Portland South Portland, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Maine Medical Center - Portland Portland, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Medical College of Wisconsin Milwaukee, Wisconsin
Medical University of South Carolina Charleston, South Carolina Site Public Contact - (hcc-clinical-trials@musc.edu)
Memorial Hospital East Shiloh, Illinois Site Public Contact - (dschwab@wustl.edu)
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mid Coast Hospital Brunswick, Maine Site Public Contact - (ctsucontact@westat.com)
Mills Health Center San Mateo, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
North Shore University Hospital Manhasset, New York
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
Northwell Health/Center for Advanced Medicine Lake Success, New York
Northwestern Medicine Cancer Center Delnor Geneva, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois Site Public Contact - (cancertrials@northwestern.edu)
Northwestern Medicine Orland Park Orland Park, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Our Lady of The Lake Baton Rouge, Louisiana
Our Lady of the Lake Physician Group Baton Rouge, Louisiana Site Public Contact - (research@ololrmc.com)
Pali Momi Medical Center ‘Aiea, Hawaii
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania Site Public Contact - (CTO@hmc.psu.edu)
Phoebe Putney Memorial Hospital Albany, Georgia Site Public Contact - (ga_cares@augusta.edu)
Prisma Health Cancer Institute - Butternut Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Easley Easley, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Faris Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Greer Greer, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Seneca Seneca, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Reading Hospital West Reading, Pennsylvania
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Rhode Island Hospital Providence, Rhode Island
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Barnabas Medical Center Livingston, New Jersey Site Public Contact - (joanne.loeb@rwjbh.org)
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
San Juan City Hospital San Juan,
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Southern Illinois University School of Medicine Springfield, Illinois
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
State University of New York Upstate Medical University Syracuse, New York
Straub Clinic and Hospital Honolulu, Hawaii
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The Valley Hospital - Luckow Pavilion Paramus, New Jersey Site Public Contact - (clinicaltrialsresearch@valleyhealth.com)
ThedaCare Regional Cancer Center Appleton, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Tufts Medical Center Boston, Massachusetts Site Public Contact - (ContactUsCancerCenter@TuftsMedicalCenter.org)
UCSF Medical Center-Parnassus San Francisco, California
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University of Arizona Cancer Center-North Campus Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Clinical Research Center Fairway, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Rochester Rochester, New York
University of Tennessee - Knoxville Knoxville, Tennessee
University of Vermont Medical Center Burlington, Vermont Site Public Contact - (rpo@uvm.edu)
University of Vermont and State Agricultural College Burlington, Vermont Site Public Contact - (rpo@uvm.edu)
University of Washington Medical Center - Montlake Seattle, Washington
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Health System Ridgewood Campus Ridgewood, New Jersey Site Public Contact - (clinicaltrialsresearch@valleyhealth.com)
Veterans Affairs Connecticut Healthcare System-West Haven Campus West Haven, Connecticut
Wake Forest University Health Sciences Winston-Salem, North Carolina
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
William S Middleton VA Medical Center Madison, Wisconsin
Yale University New Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

ctrrecruit@vcu.edu

NCT06422806
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient must be \>= 18 years of age * Patient must have a confirmed histopathologic diagnosis of dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Because UPS can sometimes exist in a spectrum among related diagnoses, the following additional diagnostic will be allowed, but not limited to: * Pleomorphic sarcoma with inflammation or with limited areas of differentiation * Pleomorphic sarcoma with giant cells * Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes) * Myxofibrosarcoma * Poorly differentiated sarcoma not otherwise specified (NOS) * Undifferentiated spindle cell sarcoma * Poorly differentiated spindle cell sarcoma NOS Any of these subtypes may have areas of focal myogenic differentiation * Patient must have metastatic or unresectable sarcoma * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: * Has achieved menarche at some point * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 6 months after the last dose of doxorubicin for patients of child bearing potential and for 3 months after the last dose of doxorubicin for male patients with partners of child bearing potential. Males with pregnant partners should use condoms during doxorubicin treatment and for at least 10 days after the last dose of doxorubicin. Contraception measures must also continue for 4 months after the last dose of pembrolizumab for patients of child bearing potential * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible * Patient must have a left ventricular ejection fraction (LVEF) \> 50% by either MUGA scan or echocardiogram obtained within 28 days prior to randomization * Absolute neutrophil count (ANC) ≥ 1,500 cells/uL (must be obtained ≤ 7 days prior to protocol randomization) * Platelets ≥ 75,000 cells/uL (must be obtained ≤ 7 days prior to protocol randomization) * Total bilirubin \< 1.2 mg/dL (must be obtained ≤ 7 days prior to protocol randomization) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 × institutional upper limit of normal (ULN) (must be obtained ≤ 7 days prior to protocol randomization) * Creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (must be obtained ≤ 7 days prior to protocol randomization) * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Patient must not have a history of or active interstitial lung disease * Patient must have measurable disease. Baseline imaging must include a chest computed tomography (CT). Imaging should be inclusive of all measurable and non-measurable disease and must be obtained within 28 days prior to randomization. Imaging must be available for uploading to Transfer of Images and Data (TRIAD) * NOTE: CT with (w/) contrast preferred, chest CT without contrast is acceptable, CT portion of positron emission tomography (PET) may be acceptable. Magnetic resonance imaging (MRI) is acceptable for measuring other sites of disease * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Patient must not have had prior treatment with an anthracycline * Patient must not have a diagnosis of clinically significant immunodeficiency or an autoimmune disorder requiring the patient to use systemic steroid chronically, or systemic steroids within 7 days prior to randomization * Patient must not have a known history of active TB (Bacillus Tuberculosis) * Patient must not have a known hypersensitivity to doxorubicin or pembrolizumab or any of their excipients * Patients who have received prior chemotherapy, targeted small molecule therapy or radiation therapy must have recovered from the prior therapy at the time of randomization * Patient must have recovered adequately from any prior major surgery prior to randomization * Patient must not have had prior pericardial or mediastinal radiation * Patient must not have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA4 agent * Patient must not have an autoimmune or other disease that requires the use of daily corticosteroids of \> 10 mg of prednisone (or equivalent). Patients who are on an active steroid taper at the time of randomization must finish prior to beginning study treatment. Patients who require inhaled or topical steroids are eligible
PROCEDURE: Biospecimen Collection, PROCEDURE: Diagnostic Imaging Testing, DRUG: Doxorubicin, PROCEDURE: Echocardiography Test, PROCEDURE: Multigated Acquisition Scan, BIOLOGICAL: Pembrolizumab
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
I'm interested
Share via email
Show 232 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Outpatient Center - Aurora Aurora, Illinois Site Public Contact - (ncorp@aah.org)
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Allegheny General Hospital Pittsburgh, Pennsylvania
Allegiance Health Jackson, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Arthur J E Child Comprehensive Cancer Centre Calgary, Alberta Site Public Contact - (ctsucontact@westat.com)
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
Banner University Medical Center - Tucson Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
Beebe Health Campus Rehoboth Beach, Delaware Site Public Contact - (research@beebehealthcare.org)
Beebe South Coastal Health Campus Millville, Delaware Site Public Contact - (research@beebehealthcare.org)
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Broadlawns Medical Center Des Moines, Iowa
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado Site Public Contact - (ecog.rss@jimmy.harvard.edu)
CancerCare Manitoba Winnipeg, Manitoba Site Public Contact - (ctu_web@cancercare.mb.ca)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Cedars Sinai Medical Center Los Angeles, California
Centralia Oncology Clinic Centralia, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cleveland Clinic Foundation Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Cross Cancer Institute Edmonton, Alberta
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana-Farber Cancer Institute Boston, Massachusetts
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Duke University Medical Center Durham, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Edward Hospital/Cancer Center Naperville, Illinois
Edward Hospital/Cancer Center?Plainfield Plainfield, Illinois Site Public Contact - (Cancerresearch@edward.org)
Elmhurst Memorial Hospital Elmhurst, Illinois Site Public Contact - (Jrohde@emhc.org)
Emory University Hospital Midtown Atlanta, Georgia
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fox Chase Cancer Center Philadelphia, Pennsylvania
Helen F Graham Cancer Center Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Henry Ford Hospital Detroit, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Medical Center-Columbus Novi, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford West Bloomfield Hospital West Bloomfield, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana
Ingalls Memorial Hospital Harvey, Illinois Site Public Contact - (clinicaltrials@ingalls.org)
Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario
Kaiser Permanente Downtown Commons Sacramento, California Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Fresno Orchard Plaza Fresno, California
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii Site Public Contact - (shelley.a.clark@kp.org)
Kaiser Permanente San Leandro San Leandro, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fremont Fremont, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Modesto Modesto, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Roseville Roseville, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Francisco San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California Site Public Contact - (Kpoct@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California Site Public Contact - (Kpoct@kp.org)
Keck Medicine of USC Koreatown Los Angeles, California
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Los Angeles General Medical Center Los Angeles, California Site Public Contact - (uscnorrisinfo@med.usc.edu)
Louisiana Hematology Oncology Associates LLC Baton Rouge, Louisiana Site Public Contact - (clinicalresearch@marybird.com)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic Hospital in Arizona Phoenix, Arizona
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
Medical Center of the Rockies Loveland, Colorado
Medical College of Wisconsin Milwaukee, Wisconsin
Medical Oncology Hematology Consultants PA Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Medical University of South Carolina Charleston, South Carolina Site Public Contact - (hcc-clinical-trials@musc.edu)
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Nassau Uniondale, New York
Miami Valley Cancer Care and Infusion Greenville, Ohio
Miami Valley Hospital Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Montefiore Medical Center - Moses Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Einstein Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Nebraska Medicine-Bellevue Bellevue, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
Nebraska Medicine-Village Pointe Omaha, Nebraska
Northwell Health/Center for Advanced Medicine Lake Success, New York
Northwestern Medicine Cancer Center Delnor Geneva, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois Site Public Contact - (cancertrials@northwestern.edu)
Northwestern Medicine Orland Park Orland Park, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario
Pan American Center for Oncology Trials LLC San Juan,
Pennsylvania Hospital Philadelphia, Pennsylvania Site Public Contact - (PennCancerTrials@careboxhealth.com)
Poudre Valley Hospital Fort Collins, Colorado
Premier Blood and Cancer Center Dayton, Ohio
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProHealth Waukesha Memorial Hospital Waukesha, Wisconsin
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon
Saint Anthony Regional Hospital Carroll, Iowa Site Public Contact - (sbenson@iora.org)
Sanford Bismarck Medical Center Bismarck, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Joe Lueken Cancer Center Bemidji, Minnesota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Roger Maris Cancer Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Sidney and Lois Eskenazi Hospital Indianapolis, Indiana
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Long Ridge Stamford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Derby Care Center Derby, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut Site Public Contact - (canceranswers@yale.edu)
Southern Illinois University School of Medicine Springfield, Illinois
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Stanford Cancer Institute Palo Alto Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UCHealth Greeley Hospital Greeley, Colorado Site Public Contact - (ecog.rss@jimmy.harvard.edu)
UCHealth University of Colorado Hospital Aurora, Colorado
UCSF Medical Center-Mission Bay San Francisco, California Site Public Contact - (cancertrials@ucsf.edu)
UChicago Medicine Northwest Indiana Crown Point, Indiana Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UF Health Cancer Institute - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UI Healthcare Mission Cancer and Blood - Fort Dodge Fort Dodge, Iowa Site Public Contact - (trials@missioncancer.com)
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Coral Springs Coral Springs, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Hollywood Hollywood, Florida
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
USC / Norris Comprehensive Cancer Center Los Angeles, California
USC Norris Oncology/Hematology-Newport Beach Newport Beach, California
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
University Health Network-Princess Margaret Hospital Toronto, Ontario Site Public Contact - (clinical.trials@uhn.on.ca)
University of Arizona Cancer Center-North Campus Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Chicago Medicine-Orland Park Orland Park, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia North Miami, Florida Site Public Contact - (kginnity@med.miami.edu)
University of Michigan Rogel Cancer Center Ann Arbor, Michigan Site Public Contact - (CancerAnswerLine@med.umich.edu)
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
Upper Valley Medical Center Troy, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
VA Palo Alto Health Care System Palo Alto, California
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Yale University New Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Reference Study ID Number: CO44657 https://forpatients.roche.com/ - global-roche-genentech-trials@gene.com

NCT06065748
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent * Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing) * Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing * Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after \>/=12 months or off-treatment within 12 months of completion. Prior use of adjuvant CDK4/6i is allowed (if relapse occurred \>/=12 months since completion). * No prior systemic anti-cancer therapy for advanced disease * Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 * For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment
Exclusion Criteria:
* Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer * Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents * Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term * Active cardiac disease or history of cardiac dysfunction * Clinically significant history of liver disease
DRUG: Giredestrant, DRUG: Fulvestrant, DRUG: Abemaciclib, DRUG: Palbociclib, DRUG: Ribociclib, DRUG: LHRH Agonist, DIAGNOSTIC_TEST: FoundationOne Liquid CDx Assay (F1LCDx)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
oral Selective Estrogen Receptor Degrader (SERD), CDK4/6 inhibitor (CDK4/6i), ESR1 mutation
I'm interested
Share via email
Show 351 locations

Study Locations

Hide all locations
Location Contacts
?wi?tokrzyskie Centrum Onkologii Kielce,
A.O. Universitaria Di Parma Parma, Emilia-Romagna
A.O. Universitaria S. Maria Della Misericordia Di Udine Udine, Friuli Venezia Giulia
A.O.U. Maggiore della Carità Novara, Piedmont
ASST degli Spedali Civili di Brescia Brescia,
AZ St Maarten Campus Leopoldstr Mechelen,
Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit Philadelphia, Pennsylvania
AdventHealth Altamonte Altamonte Springs, Florida
Advocate Lutheran General Hospital Park Ridge, Illinois
Allan Blair Cancer Centre Regina, Saskatchewan
Alliance Cancer Specialists Bensalem, Pennsylvania
Amethyst Cluj Cluj County,
Ankara City Hospital Ankara,
Ann B. Barshinger Cancer Institute Lancaster, Pennsylvania
Anticancer Hospital Ag. Savas Athens,
Aretaieio Hospital of Athens Athens,
Asan Medical Center Seoul,
Asante Rogue Regional Medical Center Medford, Oregon
Asst Di Cremona Cremona, Lombardy
Asst Papa Giovanni XXIII Bergamo, Bg
Astera Cancer Care East Brunswick East Brunswick, New Jersey
Aurora BayCare Medical Center Green Bay, Wisconsin
Aurora St Lukes Medical Center Milwaukee, Wisconsin
Avera Cancer Institute Sioux Falls, South Dakota
Avera Cancer Institute - Aberdeen Aberdeen, South Dakota
Azienda Ospedaliera Universitaria Careggi Florence,
Azienda Ospedaliera Universitaria Federico II Napoli, Campania
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati Avellino, Campania
B-A-Z Vármegyei Központi Kórház és Egyetemi Oktatókórház Miskolc,
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji Bakirkoy / Istanbul,
Baptist Health Hamburg Lexington, Kentucky
Baptist Health Lexington Lexington, Kentucky
Baptist Health Louisville Louisville, Kentucky
Barwon Health Geelong, Victoria
Beijing Cancer Hospital Beijing, Beijing Municipality
Brown University Health Providence, Rhode Island
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH Mönchengladbach,
Bács-Kiskun Vármegyei Oktatókórház Kecskemét, Bács-Kiskun county
CEDOES - Diagnóstico e Pesquisa Vitória, Espírito Santo
CENEIT Oncologicos Mexico City,
CHU de Liège (Sart Tilman) Liège,
CHU de Quebec - Hopital du Saint-Sacrement Québec, Quebec
CHVNG/E_Unidade 1 Vila Nova de Gaia,
CISSS Chaudière-Appalaches Lévis, Quebec
CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital Chicoutimi, Quebec
Cancer Care Center of O'Fallon O'Fallon, Illinois
Cancer Center, Sun Yat-sen University of Medical Sciences Guangzhou,
Cancer Research SA Adelaide, South Australia
Cancer Specialists of North Florida Jacksonville, Florida
Cancercare Port Elizabeth,
Cancercare Rondebosch Oncology Cape Town,
Capital Health Regional Medical Center Pennington, New Jersey
Celan S.A. Guatemala City,
Centre Cancerologie Grand Montpellier Montpellier,
Centre Eugene Marquis Rennes,
Centre Francois Baclesse Caen,
Centre Hospitalier Regional de Trois-Rivieres Trois-Rivières, Quebec
Centre Hospitalier Saint Louis La Rochelle,
Centre Hospitalier de L'Universite de Montreal (CHUM) Montreal, Quebec
Centre Jean Perrin Clermont-Ferrand,
Centre Leon Berard Lyon,
Centre Oscar Lambret Lille,
Centro De Cancer Universidad Catolica Santiago,
Centro Medico Integral de Cancerologia CEMIC Salcajá,
Centro Medico monte Carmelo Arequipa,
Centro Oncologico MD Anderson Internacional Madrid,
Centro Oncologico Riojano Integral (CORI) La Rioja,
Centro Oncológico Korben Ciudad Autonoma Buenos Aires,
Centro Oncológico de Excelencia San Juan,
Centro de Atencion Oncologica Viva S de RL de CV Mexico City, Mexico CITY (federal District)
Centro de Investigacion Clinica de Oaxaca Oaxaca City, Oaxaca
Centro de Investigaciones Médicas y Desarrollo LC S.R.L Buenos Aires,
Centro de Oncología de Precisión Santiago,
Centrul de Oncologie Oncohelp Timișoara,
Centrul de Oncologie Sfantul Nectarie Craiova,
Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli Lublin,
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka Bydgoszcz,
China Medical University Hospital Taichung,
Christchurch Hospital Christchurch,
Chulabhorn Hospital Bangkok,
Chulalongkorn Hospital Bangkok,
Clinica Alivia sucursal Coyoacan Mexico City,
Clinica CIMCA San José,
Clinica Colsanitas S.A. sede Clinica Universitaria Colombia Bogotá D.C.,
Clinica Internacional, Sede San Borja Lima,
Clinica Peruana Americana Trujillo,
Clinica San Antonio;Investigaciones Trujillo S.A.C. Trujillo,
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda São Paulo, São Paulo
Clinique Ste-Elisabeth Namur,
Cliniques Universitaires St-Luc Brussels,
Clínica Puerto Montt Port Montt, Los Lagos Region
Clínica Santa Beatriz Lima,
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico Jaén,
Comprehensive Hematology Oncology St. Petersburg, Florida
Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre Mississauga, Ontario
Crio - Centro Regional Integrado de Oncologia Fortaleza, Ceará
Cross Cancer Institute Edmonton, Alberta
DONAU ISAR Klinikum Deggendorf Deggendorf,
Dana Farber Cancer Institute Boston, Massachusetts
Duke Women Cancer Care Raleigh, North Carolina
European Interbalkan Medical Center Thessaloniki,
Ewha Womans University Mokdong Hospital Seoul,
Florida Cancer Specialists - Broadway Fort Myers, Florida
Florida Cancer Specialists - EAST - SCRI - PPDS West Palm Beach, Florida
Florida Cancer Specialists - Tampa Tampa, Florida
Frederick Health Hospital Frederick, Maryland
Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality
Fujian Medical University Union Hospital Fuzhou, Fujian
Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo Bogota, D.C.,
GHdC Site Les Viviers Charleroi,
Gangnam Severance Hospital Seoul,
Georgetown University Medical Center Washington D.C., District of Columbia
Goztepe Prof.Dr. Suleyman Yalcin City Hospital Kadiköy,
Grady Health System Atlanta, Georgia
Grant Medical Foundation, Ruby Hall Clinic Pune, Maharashtra
Grupo Angeles Guatemala City,
Guangxi Cancer Hospital of Guangxi Medical University Nanning,
Gustave Roussy Villejuif,
Gynonco Düsseldorf, MVZ Medical Center GmbH Düsseldorf,
HCA Midwest Division Kansas City, Missouri
Hacettepe Uni Medical Faculty Hospital Sihhiye/Ankara,
Hadassah Ein Karem Hospital Jerusalem,
Harbin Medical University Cancer Hospital Harbin, Heilongjiang
HealthCare Global Enterprises Limited Banglore, Karnataka
Henry Ford Hospital Detroit, Michigan
Hopital Jean Minjoz Besançon,
Hopital regional de saint jerome Saint-Jérôme, Quebec
Hospital A. C. Camargo São Paulo, São Paulo
Hospital Aleman CABA,
Hospital Amaral Carvalho Jaú, São Paulo
Hospital Araujo Jorge Goiânia, Goiás
Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia Valencia,
Hospital Goyeneche Arequipa,
Hospital Juan Ramon Jimenez Huelva,
Hospital Moinhos de Vento Porto Alegre, Rio Grande do Sul
Hospital Nacional Arzobispo Loayza Lima,
Hospital Nossa Senhora da Conceicao Porto Alegre, Rio Grande do Sul
Hospital Provincial del Centenario Rosario, Santa Fe Province
Hospital Quiron de Madrid Pozuelo de Alarcón, Madrid
Hospital Sao Domingos Bequimão,
Hospital Sao Lucas - PUCRS Porto Alegre, Rio Grande do Sul
Hospital Sírio-Libanês São Paulo, São Paulo
Hospital Sírio-Libanês São Paulo, São Paulo
Hospital Universitari Dexeus - Grupo Quironsalud Barcelona,
Hospital Universitari Vall d'Hebron Barcelona,
Hospital Universitario Virgen Macarena Seville,
Hospital Universitario Virgen de la Arrixaca El Palmar,
Hospital Universitario Virgen del Rocio Seville,
Hospital Zambrano Hellion TecSalud Monterrey, Nuevo León
Hospital da Luz Lisbon,
Hospital de Cancer de Barretos Barretos, São Paulo
Hospital de Jerez de la Frontera Jerez de la Frontera, Cadiz
Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal Madrid,
Hospital de S. Francisco Xavier Lisbon,
Hospital do Cancer de Pernambuco - HCP Recife, Pernambuco
Hospital do Câncer de Londrina Londrina, Paraná
Hospital las Higueras Concepción, Región Bio Bio
Hospital Álvaro Cunqueiro Vigo, Pontevedra
Hsin-Chu Branch of National Taiwan University Hospital Hsinchu,
Hubei Cancer Hospital Wuhan, Hubei
Humanitas Centro Catanese Di Oncologia Misterbianco (CT), Sicily
Hunan Cancer Hospital Changsha, Hunan
I.R.S.T Srl IRCCS Meldola, Emilia-Romagna
ICIMED Instituto de Investigación en Ciencias Médicas San José,
ICO Paul Papin Angers,
INTEGRA Cancer Institute Guatemala City,
IOV - Istituto Oncologico Veneto - IRCCS Padua, Veneto
IPO de Coimbra Coimbra,
IPO do Porto Porto,
IPS Salud SURA Chipichape Cali Cali,
IUCT Oncopole Toulouse,
Icegclinic Santiago,
Icon Cancer Centre Gleneagles Singapore,
Inst. de Oncologia Angel H. Roffo Buenos Aires,
Institut Catala d?Oncologia Hospital Germans Trias i Pujol Badalona, Barcelona
Institut Jean Godinot Reims,
Institut Sainte Catherine Avignon,
Institute of Oncology Ljubljana Ljubljana,
Instituto D'Or de Pesquisa e Ensino Rio de Janeiro,
Instituto Nacional Del Cancer Santiago,
Instituto Nacional de Enfermedades Neoplasicas Lima,
Instituto Peruano de Oncología y Radioterapia Lima,
Instituto Regional de Enfermedades Neoplasicas - IREN Norte Trujillo,
Instituto Valenciano Oncologia Valencia,
Instituto de Oncología de Rosario Rosario,
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucharest,
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca Cluj-Napoca,
Institutul Regional de Oncologie Iasi Iași,
Instytut "Centrum Zdrowia Matki Polki" ?ód?,
Irccs Istituto Nazionale Dei Tumori (Int) Milan, Lombardy
Istituto Clinico Humanitas Rozzano,
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE Napoli, Campania
JPS Oncology & Infusion Center Fort Worth, Texas
Jinan Central Hospital Jinan, Shandong
Kaiser Permanente - Harbor City Harbor City, California
Katip Celebi University Ataturk Training and Research Hospital Izmir,
Kliniken Essen-Mitte Essen,
Koo Foundation Sun Yat-Sen Cancer Center Taipei,
Korea University Anam Hospital Seoul,
Kuopio Uni Hospital Kuopio,
Kyungpook National University Chilgok Hospital Daegu,
LKH-Univ. Klinikum Graz Graz,
La Hematology Oncology Medical Group Glendale, California
Lakeridge Health Oshawa Oshawa, Ontario
MVR Cancer Centre and Research Institute Kozhikode, Kerala
Maharaj Nakorn Chiang Mai Hospital;Depart of Radiology Muang Chiang MAI Delivery Branch 3,
Marin Cancer Care Inc Greenbrae, California
Maryland Oncology Hematology Annapolis, Maryland
Mater Hospital North Sydney, New South Wales
Mater Misericordiae Limited South Brisbane,
Max Super Speciality Hospital New Delhi, National Capital Territory of Delhi
Mazowiecki Szpital Wojewódzki im. ?w. Jana Paw?a II Siedlce,
McGill University Health Centre - Glen Site Montreal, Quebec
MedStar Washington Hosp Center Washington D.C., District of Columbia
Medi-k Guatemala City,
Medical University Innsbruck Innsbruck,
Medical University of South Carolina Charleston, South Carolina
Medikal Park Samsun Samsun,
Medizinische Universität Wien Vienna,
Mersin City Education and Research Hospital Mersin,
Mission Cancer + Blood - IMMC Des Moines, Iowa
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad Warsaw,
Narodowy Instytut Onkologii Odzia? w Gliwicach Gliwice,
National Cancer Centre Singapore,
National Cancer Institute Putrajaya,
National Taiwan Uni Hospital Taipei,
National University Hospital Singapore,
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg,
Nepean Hospital Kingswood, New South Wales
New England Cancer Specialists Westbrook, Maine
No. 900 Hospital (Fuzhou General Hospital) Fuzhou,
Nograd Varmegyei Szent Lazar Korhaz Salgótarján,
North York General Hospital Toronto, Ontario
Northern Beaches Hospital Frenchs Forest, New South Wales
Northwest Medical Specialties Tacoma, Washington
Obras Sociais Irma Dulce - Osid Salvador, Estado de Bahia
Onco Go, S.A. Guatemala City,
Oncology Hematology Care Cincinnati, Ohio
Oncology Hematology West - Grand Island Grand Island, Nebraska
Oncology Hematology West - Legacy Omaha, Nebraska
Oncomedica Guatemala City,
Oncomedica S.A. Montería,
Oncosalud Sac Lima,
Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda Ijuí, Rio Grande do Sul
Oncovida Santiago, Santiago Metropolitan
Oo. Gesundheits- und Spitals-AG/LKH Steyr Steyr,
Opolskie Centrum Onkologii Opole,
Ordensklinikum Linz Barmherzige Schwestern Linz,
Orszagos Onkologiai Intezet Budapest,
Ospedale Di Macerata Macerata, The Marches
Palmerston North Hospital Palmerston North,
Pamela Youde Nethersole Eastern Hospital Chai Wan,
PanAmerican Clinical Research, Querétaro Queréaro, Querétaro
PanOncology Trials San Juan,
Panamerican Clinical Research S.A de C.V. Guadalajara, Jalisco
Policlinico S.Orsola-Malpighi Bologna, Emilia-Romagna
Policlinico Universitario Agostino Gemelli Rome, Lazio
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR Freiburg im Breisgau,
Presidio Ospedaliero di Summa-Perrino Brindisi, Apulia
Princess Margaret Cancer Center Toronto,
Proclinical Pharma San José,
Productos y Servicios Oncologicos Acacias SA de CV Mexico City, Mexico CITY (federal District)
Przychodnia Lekarska KOMED, Roman Karaszewski Konin,
Queen Mary Hospital Hong Kong,
Queens Hospital Cancer Center Jamaica, New York
RCCS - Centro di Riferimento Aviano (PN), Friuli Venezia Giulia
RENATI INNOVATION S.A.P.I. de C.V Guadalajara, Jalisco
Rabin Medical Center Petah Tikva,
Rajavithi Hospital Bangkok,
Regional Cancer Centre Trivandrum, Kerala
Rocky Mountain Cancer Centers Denver, Colorado
Rotkreuzklinikum München München,
Royal Victoria Regional Health Centre Barrie, Ontario
SCRI Oncology Partners Nashville, Tennessee
Sahyadri Speciality Hospital Pune, Maharashtra
Sakarya Training and Research Hospital Sakarya,
Samsung Medical Center Seoul,
Sanatorio Allende Córdoba,
Sanatorio Parque S.A. Rosario,
Santa Casa de Misericordia de Porto Alegre Porto Alegre,
Saskatoon Cancer Centre Saskatoon, Saskatchewan
Seoul National University Bundang Hospital Seongnam-si,
Seoul National University Hospital Seoul,
Severance Hospital, Yonsei University Health System Seoul,
Shandong Cancer Hospital Jinan, Shandong
Shanxi Province Cancer Hospital Taiyuan, Shanxi
Sheba MC Ramat Gan,
Sichuan Provincial People's Hospital Chengdu,
Sir H. N. Reliance Foundation Hospital and Research Centre Mumbai,
Sociedad de Oncología y hematología del Cesar Ltda Valledupar,
Songklanagarind Hospital Songkhla,
Sourasky Medical Center Tel Aviv,
South West Healthcare Warrnambool, Victoria
Southern Cancer Center Daphne, Alabama
Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie Bamberg,
Spitalul Clinic Filantropia Bucharest,
Springfield Clinic Springfield, Illinois
St. Elisabeth Krankenhaus Köln GmbH Cologne,
Steve Biko Academic Hospital Pretoria,
Sunact Cancer Institute Thane, Maharashtra
Sunshine Hospital St Albans, Victoria
Sutter Auburn Faith Hospital Auburn, California
Sutter Health Medical Center Sacramento, California
Sutter Medical Group, Roseville Clinic Roseville, California
Szpital Morski im. PCK Gdynia,
Szpital Wojewódzki im. Miko?aja Kopernika Koszalin,
Taizhou Hospital of Zhejiang Province Taizhou, Zhejiang
Tampere University Hospital Tampere,
Texas Oncology - DFW Dallas, Texas
Texas Oncology Cancer Center Austin, Texas
The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu
The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan
The First Affiliated Hospital to Henan University of Science and Technology Luoyang,
The First Affiliated Hospital, Chongqing Medical University Chongqing,
The First People's Hospital of Yunnan Province Kunming,
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente Torrance, California
The Second Affiliated Hospital of Xi'an Jiao Tong University Xi'an,
The Second Affiliated Hospital of Zhejiang University College Hangzhou,
The Tumor Hospital of Xinjiang Medical University Ürümqi,
Thunder Bay Regional Health Sciences Centre Thunder Bay, Ontario
Tianjin Cancer Hospital Tianjin, Tianjin Municipality
USC Norris Cancer Center Newport Beach, California
USC Norris Comprehensive Cancer Center Los Angeles, California
UZ Gent Ghent,
UZ Leuven Gasthuisberg Leuven,
Ulsan University Hosiptal Ulsan,
Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei
University Hospital of Larissa Larissa,
University Hospital of Patras Medical Oncology Pátrai,
University of Nairobi - Institute of Tropical and Infectious Diseases Nairobi,
University of the Sunshine Coast Buderim,
Università Campus Bio-Medico di Roma Rome, Lazio
Universitätsklinikum Erlangen Erlangen,
Universitätsklinikum des Saarlandes Homburg,
Vencer Oncoclínica - Centro de Pesquisa do Piauí Teresina, Piauí
Veterans General Hospital Taipei,
Veterans General Hospital - Taichung Taichung,
Virginia Cancer Specialists, PC Fairfax, Virginia
Virginia Commonwealth University - Massey Cancer Center Richmond, Virginia
WellSpan Oncology Research York, Pennsylvania
West Cancer Center Germantown, Tennessee
West China Hospital of Sichuan University Chengdu,
West Virginia University Hospitals Inc Morgantown, West Virginia
Whangarei Hospital Whangarei,
Winship Cancer Institute of Emory University Atlanta, Georgia
Xi'an International Medical Center Hospital Xi'an,
ZAS Sint Augustinus Wilrijk Wilrijk,
Zachodniopomorskie Centrum Onkologii Szczecin,
Zhejiang Cancer Hospital Hangzhou, Zhejiang
Zhongshan Hospital Fudan University Shanghai,
the First Hospital of Jilin University Changchun, Jilin

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com - Clinical.Trials@bms.com

NCT06356129
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria \- Histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including: i) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified \[including germinal center B-cell (GCB) and activated B-cell (ABC) types\] ii) High-grade B-cell lymphoma, with MYC and BCL2 rearrangements (HGBL-MYC/BCL2 double-hit lymphomas) iii) High-grade B-cell lymphoma, not otherwise specified iv) T-cell/histiocyte/rich large B-cell lymphoma (THRLBCL) v) Epstein-Barr virus + DLBCL * International Prognostic Index (IPI) score 1 or 2 with lactate dehydrogenase (LDH) \> 1.3 x upper limit of normal (ULN) and/or bulky disease defined as single lesion of ≥ 7 cm OR IPI ≥ 3. * Measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (\> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification. * Must have Ann Arbor Stage II-IV disease. Exclusion Criteria * Any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study. * Any other subtype of lymphoma. Cases of primary mediastinal (thymic) large B-cell lymphoma (PMBCL), primary cutaneous DLBCL-leg type, Grade 3b FL, indolent lymphoma transformed to large B-cell lymphoma (LBCL), Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, primary effusion lymphoma, and Burkitt lymphoma. * Documented or suspected central nervous system (CNS) involvement by lymphoma. * Other protocol-defined Inclusion/Exclusion criteria apply.
DRUG: Golcadomide, DRUG: Placebo, DRUG: Rituximab, DRUG: Cyclophosphamide, DRUG: Doxorubicin, DRUG: Vincristine, DRUG: Prednisone
Large B-cell Lymphoma
Lymphoma, Large B-Cell, Lymphoma, BMS-986369, CC-99282, DLBCL
I'm interested
Share via email
Show 344 locations

Study Locations

Hide all locations
Location Contacts
A. C. Camargo Cancer Center São Paulo, São Paulo
Affidea Fundeni Bucharest,
Aidport Skórzewo, Greater Poland Voivodeship
Alaska Oncology and Hematology Anchorage, Alaska
All India Institute of Medical Sciences New Delhi, National Capital Territory of Delhi
Allina Health Cancer Institute - Abbott Northwestern Hospital Minneapolis, Minnesota
Ankara University Health Practice and Research Hospitals Ankara,
Aster Medcity Kochi, Kerala
Astera Cancer Care East Brunswick, New Jersey
Atlantic Health System Morristown Medical Center Morristown, New Jersey
Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO Palermo, Sicily
Brooke Army Medical Center Fort Sam Houston, Texas
CHN - Complexo Hospitalar de Niterói Niterói, Rio de Janeiro
Cancer Care Specialists Reno, Nevada
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa Porto Alegre, Rio Grande do Sul
Centro de Investigacion Clinica Chapultepec Morelia, Michoacán
Centro de Investigacion Clinica de Oaxaca Oaxaca City, Oaxaca
Centrum Onkologii Ziemi Lubelskiej Lublin, Lublin Voivodeship
Chang Gung Medical Foundation-LinKou Branch Taoyuan District,
Chang Gung Memorial Hospital at Kaohsiung Kaohsiung City,
Chang Gung Memorial Hospital- Chiayi Chiayi City, Chiayi
Chi Mei Medical Center Tainan, Tainan
China Medical University Hospital Taichung,
Chongqing University Cancer Hospital Chongqing, Chongqing Municipality
Cleveland Clinic Florida Weston, Florida
Clínica Supera Chapecó, Santa Catarina
Debreceni Egyetem Klinikai Kozpont Debrecen, Hajdú-Bihar
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi Ankara,
Ege Universitesi Hastanesi Izmir,
Emory University School of Medicine- Grady Campus Atlanta, Georgia
Faculty of Medicine Siriraj Hospital Bangkok, Bangkok
Fakultni nemocnice Hradec Kralove Hradec Králové, Hradec Králové
Fakultni nemocnice Kralovske Vinohrady Prague, Praha 10
Fakultni nemocnice Olomouc Olomouc, Olomoucký kraj
Fakultni nemocnice Plzen Pilsen, Plzeň Region
Fakultní nemocnice Brno Bohunice Brno, Brno-město
Florida Cancer Specialists - East West Palm Beach, Florida
Florida Cancer Specialists - North St. Petersburg, Florida
Florida Cancer Specialists - South Fort Myers, Florida
Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality
Fujian Cancer Hospital Fuzhou, Fujian
Fundacion Ctic Centro de Tratamiento E Investigacion Sobre Cancer Luis Carlos Sarmiento Angulo Bogotá, Bogota D.C.
Fundação Faculdade Regional de Medicina de São José do Rio Preto São José do Rio Preto, São Paulo
Fundação Pio XII - Hospital de Câncer de Barretos Barretos, São Paulo
Fundeni Clinical Institute Bucharest, București
Gazi University Health Research and Application Center Gazi Hospital Ankara,
Guangxi Medical University Affiliated Tumor Hospital Nanning, Guangxi
Harbin Medical University Cancer Hospital Harbin, Heilongjiang
Health Pharma Professional Research S.A. de C.V: Mexico City, DIF
Hematology-Oncology Associates of Central New York, PC East Syracuse, New York
Henan Cancer Hospital Zhengzhou, Henan
Hospital 9 De Julho São Paulo,
Hospital Alemão Oswaldo Cruz São Paulo, São Paulo
Hospital Amaral Carvalho Jaú, São Paulo
Hospital Brasilia Lago Sul, Federal District
Hospital Erasto Gaertner Curitiba, Paraná
Hospital São Lucas de Copacabana Rio de Janeiro,
Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Monterrey, Nuevo León
Hospital das Clinicas FMUSP São Paulo,
Hunan Cancer Hospital Changsha, Hunan
Icahn School of Medicine at Mount Sinai New York, New York
Instituto D'Or de Pesquisa e Ensino (IDOR) São Paulo,
Instituto Joinvilense De Hematologia e Oncologia Joinville, Santa Catarina
Instituto Nacional De Cancerologia Bogota, Cundinamarca
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico City, DIF
Institutul Oncologic Cluj Cluj-Napoca,
Institutul Regional de Oncologie Iași,
Jiangxi Provincial Cancer Hospital Nanchang, Jiangxi
KLES Dr. Prabhakar Kore Hospital & M.R.C Belagavi, Karnataka
Karadeniz Teknik Universitesi Tip Fakultesi Trabzon,
Koo Foundation Sun Yat-Sen Cancer Center Taipei,
Liga Norte Riograndense Contra O Cancer Natal, Rio Grande do Norte
Local Institution - 0004 Sherbrooke, Quebec
Local Institution - 0009 Pittsburgh, Pennsylvania
Local Institution - 0066 Massillon, Ohio
Local Institution - 0068 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0069 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0070 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0071 L'Hospitalet Del Llobregat, Barcelona [Barcelona]
Local Institution - 0072 Madrid,
Local Institution - 0073 Montreal, Quebec
Local Institution - 0074 Montpellier, Languedoc-Roussillon
Local Institution - 0076 Villejuif, Val-de-Marne
Local Institution - 0077 Paris,
Local Institution - 0079 Tours, Indre-et-Loire
Local Institution - 0081 Lille, Nord
Local Institution - 0083 Nice, Alpes-Maritimes
Local Institution - 0084 Strasbourg, Alsace
Local Institution - 0087 Marseille, Bouches-du-Rhône
Local Institution - 0089 Pierre-Bénite, Rhône
Local Institution - 0090 Bordeaux, Aquitaine
Local Institution - 0091 Victoria, British Columbia
Local Institution - 0092 Málaga, Málaga
Local Institution - 0093 Salamanca,
Local Institution - 0095 Cáceres,
Local Institution - 0096 Majadahonda, Madrid, Comunidad de
Local Institution - 0098 Porto,
Local Institution - 0100 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0106 Santiago, Santiago Metropolitan
Local Institution - 0107 Santiago, Santiago Metropolitan
Local Institution - 0108 Santiago, Santiago Metropolitan
Local Institution - 0109 Chile, Santiago Metropolitan
Local Institution - 0110 Santiago, Santiago Metropolitan
Local Institution - 0111 Córdoba,
Local Institution - 0112 Buenos Aires,
Local Institution - 0113 Buenos Aires, Buenos Aires F.D.
Local Institution - 0114 Busan, Pusan-Kwangyǒkshi
Local Institution - 0115 Busan, Pusan-Kwangyǒkshi
Local Institution - 0116 Deagu, Taegu-Kwangyǒkshi
Local Institution - 0117 Seongnam, Kyǒnggi-do
Local Institution - 0118 Seoul,
Local Institution - 0119 Buenos Aires,
Local Institution - 0123 Huixquilucan,
Local Institution - 0126 Mexico City, Mexico City
Local Institution - 0128 Mexico City, Mexico City
Local Institution - 0131 Busan, Pusan-Kwangyǒkshi
Local Institution - 0136 Buenos Aires,
Local Institution - 0143 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0149 Goyang-si, Kyǒnggi-do
Local Institution - 0153 Montreal, Quebec
Local Institution - 0155 Ürümqi, Xinjiang
Local Institution - 0164 Viña del Mar, Región de Valparaíso
Local Institution - 0166 Sakai, Osaka
Local Institution - 0167 Yamagata,
Local Institution - 0168 Kashiwa, Chiba
Local Institution - 0170 Isehara, Kanagawa
Local Institution - 0171 Kumamoto,
Local Institution - 0172 Santa Cruz de Tenerife, Canary Islands
Local Institution - 0174 Chapel Hill, North Carolina
Local Institution - 0182 Chicago, Illinois
Local Institution - 0190 Buffalo, New York
Local Institution - 0200 Créteil, Val-de-Marne
Local Institution - 0202 Lille, Hauts-de-France
Local Institution - 0204 Bratislava,
Local Institution - 0215 Kyoto,
Local Institution - 0223 La Tronche, Isère
Local Institution - 0233 Suwon, Kyǒnggi-do
Local Institution - 0244 Bayonne,
Local Institution - 0268 Itabashiku, Tokyo
Local Institution - 0269 Hidaka, Saitama
Local Institution - 0270 Kanazawa, Ishikawa-ken
Local Institution - 0271 Ōgaki, Gifu
Local Institution - 0272 Hiroshima,
Local Institution - 0273 Amagasaki, Hyōgo
Local Institution - 0276 Anjo, Aichi-ken
Local Institution - 0277 Uppsala, Uppsala Län [se-03]
Local Institution - 0278 Linköping, Östergötlands Län [se-05]
Local Institution - 0279 Lund, Skåne Län [se-12]
Local Institution - 0280 Helsinki,
Local Institution - 0281 Oulu, North Ostrobothnia
Local Institution - 0282 Turku, Southwest Finland
Local Institution - 0283 Kuopio, Northern Savonia
Local Institution - 0284 Odense, Region Syddanmark
Local Institution - 0285 Aarhus, Central Jutland
Local Institution - 0286 Lisbon,
Local Institution - 0288 Nagaizumi-cho,Sunto-gun, Shizuoka
Local Institution - 0289 Tianjin, Tianjin Municipality
Local Institution - 0292 Dijon, Côte-d'Or
Local Institution - 0306 Poitiers, Vienne
Local Institution - 0313 Fukuoka,
Local Institution - 0314 Donostia / San Sebastian, Gipuzkoa
Local Institution - 0315 Caen,
Local Institution - 0319 Fukuoka,
Local Institution - 0320 Sendai, Miyagi
Local Institution - 0321 Saint Priest En Jarez, Pays de la Loire Region
Local Institution - 0322 Osaka,
Local Institution - 0323 Saint-Pierre, La Réunion
Local Institution - 0324 Pessac, Aquitaine
Local Institution - 0325 Nantes, Pays de la Loire Region
Local Institution - 0327 Sapporo, Hokkaido
Local Institution - 0328 Himeji, Hyōgo
Local Institution - 0329 Okayama,
Local Institution - 0330 Katowice, Silesian Voivodeship
Local Institution - 0331 Chūō, Yamanashi
Local Institution - 0332 Brest, Finistère
Local Institution - 0333 Yokohama, Kanagawa
Local Institution - 0335 Saint-Cloud, Hauts-de-Seine
Local Institution - 0342 San Francisco, California
Local Institution - 0343 Morioka, Iwate
Local Institution - 0347 Osaka,
Local Institution - 0348 Fukuoka,
Local Institution - 0350 Bunkyo-ku, Tokyo
Local Institution - 0355 Banská Bystrica, Banská Bystrica Region
Local Institution - 0356 Birtinya, Queensland
Local Institution - 0357 Gosford, New South Wales
Local Institution - 0358 Westmead, New South Wales
Local Institution - 0359 St Albans, Victoria
Local Institution - 0360 Southport, Queensland
Local Institution - 0361 Sydney, New South Wales
Local Institution - 0362 Heidelberg, Victoria
Local Institution - 0363 Tiwi, Northern Territory
Local Institution - 0364 Warrnambool, Victoria
Local Institution - 0365 Frankston, Victoria
Local Institution - 0366 Hamilton, Waikato Region
Local Institution - 0367 Dunedin, Otago
Local Institution - 0368 Sapporo, Hokkaido
Local Institution - 0369 New York, New York
Local Institution - 0370 Essen,
Local Institution - 0371 Nagoya, Aichi-ken
Local Institution - 0375 Bucharest, București
Local Institution - 0383 Augsburg, Bavaria
Local Institution - 0384 Koblenz, Rhineland-Palatinate
Local Institution - 0385 Wels, Upper Austria
Local Institution - 0386 Vienna,
Local Institution - 0387 Linz,
Local Institution - 0389 Barakaldo, Bizkaia
Local Institution - 0390 Zagreb, City of Zagreb
Local Institution - 0391 Oslo,
Local Institution - 0392 Sofia,
Local Institution - 0395 Ioannina, Ípeiros
Local Institution - 0396 Athens, Attikí
Local Institution - 0397 Chaïdári, Attikí
Local Institution - 0398 Alexandroupoli, Anatolikí Makedonía Kai Thráki
Local Institution - 0399 Athens, Attikí
Local Institution - 0409 El Palmar, Murcia, Murcia, Región de
Local Institution - 0412 A Coruña, A Coruña [La Coruña]
Local Institution - 0415 Margate, Florida
Local Institution - 0416 Riyadh,
Local Institution - 0421 Buenos Aires, Buenos Aires F.D.
Local Institution - 0422 Ankara,
Local Institution - 0427 Singapore, Central Singapore
Local Institution - 0429 Srinagar, Jammu and Kashmir
Local Institution - 0431 Kuching, Sarawak
Local Institution - 0432 George Town, Pulau Pinang
Local Institution - 0434 Bangkok, Bangkok
Local Institution - 0436 Edgewood, Kentucky
Local Institution - 0437 Kansas City, Missouri
Local Institution - 0438 Jeddah,
Local Institution - 0439 Dammam, Eastern Province
Local Institution - 0440 Osijek,
Local Institution - 0441 Deagu, Taegu-Kwangyǒkshi
Local Institution - 0442 Daegu, Taegu-Kwangyǒkshi
Local Institution - 0444 Hermosillo, Sonora
Local Institution - 0445 Riyadh, Riyadh Region
Local Institution - 0448 Guadalajara, Jalisco
Local Institution - 0449 Ampang, Selangor
Local Institution - 0450 Tulsa, Oklahoma
Local Institution - 0453 Lembah Pantai, Kuala Lumpur
Local Institution - 0455 Seongnam,
Local Institution - 0456 Seongnam, Kyǒnggi-do
Local Institution - 0459 Santiago, Santiago Metropolitan
Local Institution - 0462 Auckland,
Local Institution - 0463 Hermosillo, Sonora
Local Institution - 0465 Tacoma, Washington
Local Institution - 0475 Eiheiji-cho,Yoshida-gun, Fukui
Local Institution - 0480 Hackensack, New Jersey
Local Institution - 0484 New York, New York
Local Institution - 0486 Besançon, Doubs
Local Institution - 0487 Solna, Stockholms Län [se-01]
Local Institution - 0488 Madrid,
Local Institution - 0489 Seville,
Local Institution - 0490 Madrid,
Local Institution - 0491 Badalona, Barcelona [Barcelona]
Local Institution - 0492 Edmonton, Alberta
Local Institution - 0493 Rome, Lazio
Local Institution - 0495 Ravenna, Emilia-Romagna
Local Institution - 0496 Novara,
Local Institution - 0499 Groningen,
Local Institution - 0500 Leiden, South Holland
Local Institution - 0503 Cottbus,
Local Institution - 0504 Halle, Saxony-Anhalt
Local Institution - 0505 Erlangen, Bavaria
Local Institution - 0506 Lübeck, Schleswig-Holstein
Local Institution - 0507 Langen, Hesse
Local Institution - 0508 Berlin,
Local Institution - 0510 Dresden,
Local Institution - 0511 Ulm, Baden-Wurttemberg
Local Institution - 0512 Bayreuth, Bavaria
Local Institution - 0513 Hanover, Lower Saxony
Local Institution - 0516 Houston, Texas
Maharaj Nakorn Chiang Mai Hospital Chiang Mai,
Markusovszky Egyetemi Oktatokorhaz Szombathely, Vas County
Mary Bird Perkins Cancer Center Baton Rouge Baton Rouge, Louisiana
Mayo Clinic in Arizona - Phoenix Phoenix, Arizona
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester, Minnesota Rochester, Minnesota
Memorial Hermann Hospital - Texas Medical Center Houston, Texas
Mission Cancer + Blood Waukee, Iowa
Moffitt Cancer Center Tampa, Florida
Mount Sinai Cancer Center Miami Beach, Florida
Narayana Superspecialty Hospital Howrah, West Bengal
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie Warsaw, Masovian Voivodeship
National Taiwan University Hospital Taipei,
Núcleo de Oncologia e Hematologia do Ceará Fortaleza, Ceará
Ondokuz Mayıs Universitesi Samsun,
Orchard Healthcare Research Inc. Skokie, Illinois
Oregon Health and Science University Portland, Oregon
Orszagos Onkologiai Intezet Budapest,
Pan American Center for Oncology Trials - Ciudadela San Juan,
Peking University Third Hospital Beijing, Beijing Municipality
Pratia MCM Kraków Krakow, Lesser Poland Voivodeship
Qilu Hospital of Shandong University Jinan, Shandong
Rajiv Gandhi Cancer Institute And Research Centre New Delhi, National Capital Territory of Delhi
Ramathibodi Hospital Bangkok, Bangkok
Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai, Shanghai Municipality
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Sacred Heart Medical Oncology Group Pensacola, Florida
Sc Onco Card Srl Brasov,
Semmelweis Egyetem Budapest,
Shandong Cancer Hospital Jinan, Shandong
Shanxi Bethune Hospital Taiyuan, Shanxi
Shengjing Hospital of China Medical University Shenyang, Liaoning
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein São Paulo,
Somogy Varmegyei Kaposi Mor Oktato Korhaz Kaposvár, Somogy County
Southern Medical University Nanfang Hospital Guangzhou, Guangdong
Spital Clinic Judetean de Urgenta Tg.Mures Tg.Mures, Mureș County
Spitalul Clinic Coltea Bucharest,
Spitalul Clinic Coltea Bucharest,
Spitalul Clinic Județean de Urgență Sibiu Sibiu,
Spitalul Universitar de Urgenta Bucuresti Bucharest,
Sun Yat-sen University Cancer Center Guangzhou, Guangdong
Szabolcs Szatmár Bereg Vármegyei Oktatókórház Nyíregyháza, Szabolcs-Szatmár-Bereg
Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Taichung Veterans General Hospital Taichung,
Taipei Veterans General Hospital Taipei,
Tata Medical Center New Town, West Bengal
Tata Memorial Hospital Mumbai, Maharashtra
The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality
The First Affiliated Hospital of NanChang University Nanchang, Jiangxi
The First Affiliated Hospital of Soochow University Suzhou, Jiangsu
The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang
The First Affiliated Hospital of Xiamen University Xiamen, Fujian
The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang
The First Hospital of China Medical University Shenyang, Liaoning
The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang
The University of Kansas Cancer Center - Westwood Westwood, Kansas
Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin Municipality
Tongji Hospital Tongji Medical,Science & Technology Wuhan, Hubei
UMHAT 'Sveti Ivan Rilsky' Sofia,
USA Mitchell Cancer Institute Mobile, Alabama
Unidad Médica Onco-Hematológica Puebla City,
Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei
Universidade Federal de Goias Goiânia, Goiás
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD Plovdiv,
University of Michigan Ann Arbor, Michigan
University of Texas MD Anderson Cancer Center Houston, Texas
VM Medical Park Mersin Hastanesi Mersin,
Virginia Commonwealth University (VCU) Medical Center Richmond, Virginia
Vseobecna Fakultni Nemocnice v Praze Prague,
WellSpan Oncology Research York, Pennsylvania
West China Hospital, Sichuan University Chengdu, Sichuan
Winship Cancer Institute, Emory University Atlanta, Georgia
Xinjiang Medical University Cancer Hospital - Urumqi Ürümqi, Xinjiang
the First Hospital of Jilin University Changchun, Jilin

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

ctrrecruit@vcu.edu

NCT05602194
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* \>= 15 and \< 40 years at time of diagnosis * Newly diagnosed B-ALL, T-ALL, lymphoblastic lymphoma (LLy), or mixed-phenotype acute leukemia/lymphoma (MPAL) * Note: Philadelphia chromosome (PH)+ and PH-like acute leukemia are eligible (use of tyrosine kinase inhibitors \[TKI\] or CRLF2- targeted concomitant medication must be documented, if used) * Conjugated bilirubin =\< 1.5 x upper limit of normal (ULN) for age, regardless of baseline bilirubin (within 7 days prior to enrollment), and * Serum glutamate pyruvate transaminase (SGPT) (ALT) =\< 225 U/L (=\< 5x ULN) (within 7 days prior to enrollment), and * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L and serum glutamic oxaloacetic transaminase (SGOT) (AST) to 50 U/L regardless of baseline * SGOT (AST) =\< 250 U/L (=\< 5x ULN) (within 7 days prior to enrollment) * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L and SGOT (AST) to 50 U/L regardless of baseline * For patients receiving ursodiol prior to enrollment, laboratory values must meet above criteria off ursodiol for 7 days * PEDIATRIC PATIENTS (AGE 15-17 years): * A 24-hour urine creatinine clearance \>= 30 mL/min/1.73 m\^2 (within 7 days prior to enrollment) OR * A glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m\^2. GFR must be performed using one of the following methods (within 7 days prior to enrollment): * 1\. Estimated GFR (eGFR) \>= 30 mL/min/1.73 m\^2. * An online calculator is available through the National Kidney Foundation at https://www.kidney.org/professionals/kdoqi/gfr\_calculatorped * 2\. Measured GFR \>= 30 mL/min/1.73 m\^2 (any age). If measured GFR is used, it must be performed using direct measurement with a nuclear blood sampling method or small molecule clearance method (iothalamate or other molecule per institutional standard). * ADULT PATIENTS (AGE 18 YEARS OR OLDER): Creatinine clearance \>= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection (within 7 days prior to enrollment). Estimated creatinine clearance is based on actual body weight * An online calculator is available through the National Kidney Foundation at https://www.kidney.org/professionals/kdoqi/gfr\_calculatorcoc * Berlin-Frankfurt-Munich (BFM), Children's Oncology Group (COG), or C10403-based Induction regimen and must be inclusive of \>= 1 dose of pegaspargase or calaspargase pegol, and * First dose of asparaginase must be planned within the first week of induction therapy, and * Dose of pegaspargase or calaspargase pegol must be \>= 1,000 IU/ m\^2 (dose-capping permitted per primary regimen) * Note: Co-enrollment on a therapeutic consortia trial is not required * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
* Down syndrome * Known inherited or autoimmune liver disease impacting conjugated bilirubin (e.g., Alagille syndrome, primary sclerosing cholangitis, other) * Known biopsy (or imaging) proven severe liver fibrosis (Batts-Ludwig \>= stage 3) * Unable to tolerate oral formulation of study drug at enrollment * Patients who received chemotherapy or treatment for a prior malignancy are not eligible * The following are permitted: steroid prophase, hydroxyurea, or other cytoreduction prior to initiation of Induction chemotherapy (must be documented) and chemotherapy for current diagnosis (i.e. initiation of Induction therapy within enrollment window). Chemotherapy prior to enrollment for treatment of a non-malignancy (e.g., steroid or methotrexate for autoimmune disease) is also permitted and must be documented * Female patients who are pregnant since fetal toxicities and teratogenic effects in humans are unknown for study drug. A pregnancy test is required for female patients of childbearing potential * Lactating females who plan to breastfeed their infants * Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
PROCEDURE: Biospecimen Collection, DRUG: Calaspargase Pegol, DIETARY_SUPPLEMENT: Levocarnitine, DRUG: Pegaspargase, OTHER: Quality-of-Life Assessment
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9,22)(q34.1,q11.2), BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
I'm interested
Share via email
Show 223 locations

Study Locations

Hide all locations
Location Contacts
AdventHealth Orlando Orlando, Florida Site Public Contact - (FH.Cancer.Research@flhosp.org)
Advocate Children's Hospital-Oak Lawn Oak Lawn, Illinois
Advocate Children's Hospital-Park Ridge Park Ridge, Illinois Site Public Contact - (helpdesk@childrensoncologygroup.org)
Albany Medical Center Albany, New York
Alfred I duPont Hospital for Children Wilmington, Delaware Site Public Contact - (Allison.bruce@nemours.org)
Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Ann M Wierman MD LTD Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Arkansas Children's Hospital Little Rock, Arkansas
Ascension Saint Vincent Indianapolis Hospital Indianapolis, Indiana Site Public Contact - (research@stvincent.org)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BI-LO Charities Children's Cancer Center Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Banner University Medical Center - Tucson Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Beacon Kalamazoo Kalamazoo, Michigan
Beacon Kalamazoo Cancer Center Kalamazoo, Michigan
Blank Children's Hospital Des Moines, Iowa Site Public Contact - (samantha.mallory@unitypoint.org)
Bronson Battle Creek Battle Creek, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
C S Mott Children's Hospital Ann Arbor, Michigan
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan Site Public Contact - (connie.szczepanek@crcwm.org)
Carilion Children's Roanoke, Virginia Site Public Contact - (wpmccarty@carilionclinic.org)
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Carson Tahoe Regional Medical Center Carson City, Nevada Site Public Contact - (research@sncrf.org)
Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia Site Public Contact - (Olivia.Floyd@choa.org)
Children's Hospital London, Ontario
Children's Hospital Colorado Aurora, Colorado Site Public Contact - (josh.b.gordon@nsmtp.kp.org)
Children's Hospital Los Angeles Los Angeles, California
Children's Hospital Medical Center Of Akron Akron, Ohio
Children's Hospital New Orleans New Orleans, Louisiana
Children's Hospital and Medical Center of Omaha Omaha, Nebraska
Children's Hospital at Montefiore The Bronx, New York Site Public Contact - (aaraiza@montefiore.org)
Children's Hospital of Alabama Birmingham, Alabama Site Public Contact - (oncologyresearch@peds.uab.edu)
Children's Hospital of Michigan Detroit, Michigan Site Public Contact - (helpdesk@childrensoncologygroup.org)
Children's Hospital of Philadelphia Philadelphia, Pennsylvania Site Public Contact - (CancerTrials@email.chop.edu)
Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania Site Public Contact - (jean.tersak@chp.edu)
Children's Hospital of San Antonio San Antonio, Texas Site Public Contact - (bridget.medina@christushealth.org)
Children's Hospital of Wisconsin Milwaukee, Wisconsin Site Public Contact - (MACCCTO@mcw.edu)
Children's Hospital of the King's Daughters Norfolk, Virginia Site Public Contact - (CCBDCresearch@chkd.org)
Children's Mercy Hospitals and Clinics Kansas City, Missouri Site Public Contact - (COGResearchGroup@cmh.edu)
Children's National Medical Center Washington D.C., District of Columbia Site Public Contact - (OncCRC_OnCall@childrensnational.org)
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio Site Public Contact - (cancer@cchmc.org)
City of Hope Comprehensive Cancer Center Duarte, California Site Public Contact - (becomingapatient@coh.org)
Cleveland Clinic Foundation Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Central Valley Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Northwest Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Town Center Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Horizon Ridge Henderson, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Southeast Henderson Henderson, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Summerlin Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Cook Children's Medical Center Fort Worth, Texas Site Public Contact - (CookChildrensResearch@cookchildrens.org)
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Covenant Children's Hospital Lubbock, Texas Site Public Contact - (mbisbee@providence.org)
Dayton Children's Hospital Dayton, Ohio
Dell Children's Medical Center of Central Texas Austin, Texas Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org)
Driscoll Children's Hospital Corpus Christi, Texas Site Public Contact - (Crystal.DeLosSantos@dchstx.org)
East Tennessee Childrens Hospital Knoxville, Tennessee
El Paso Children's Hospital El Paso, Texas Site Public Contact - (ranjan.bista@ttuhsc.edu)
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Golisano Children's Hospital of Southwest Florida Fort Myers, Florida Site Public Contact - (molly.arnstrom@leehealth.org)
Hackensack University Medical Center Hackensack, New Jersey
Hope Cancer Care of Nevada Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Hope Cancer Care of Nevada-Pahrump Pahrump, Nevada Site Public Contact - (research@sncrf.org)
Hospital for Sick Children Toronto, Ontario
IWK Health Centre Halifax, Nova Scotia Site Public Contact - (Research@iwk.nshealth.ca)
Inova Fairfax Hospital Falls Church, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
Jersey Shore Medical Center Neptune City, New Jersey
Johns Hopkins All Children's Hospital St. Petersburg, Florida Site Public Contact - (Ashley.Repp@jhmi.edu)
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Site Public Contact - (jhcccro@jhmi.edu)
Kaiser Permanente Downey Medical Center Downey, California
Kaiser Permanente Los Angeles Medical Center Los Angeles, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Anaheim Anaheim, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Bellflower Bellflower, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Fontana Fontana, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-San Diego Mission San Diego, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-San Diego Zion San Diego, California Site Public Contact - (clinical.trials@kp.org)
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Kingman Regional Medical Center Kingman, Arizona Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Cathedral Rock Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Green Valley Henderson, Nevada Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Pebble Henderson, Nevada Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Pecos Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Smoke Ranch Las Vegas, Nevada Site Public Contact - (research@smcrf.org)
Las Vegas Urology - Sunset Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Loma Linda University Medical Center Loma Linda, California
Lucile Packard Children's Hospital Stanford University Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
Madigan Army Medical Center Tacoma, Washington Site Public Contact - (melissa.a.forouhar.mil@health.mil)
Maine Children's Cancer Program Scarborough, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mary Bridge Children's Hospital and Health Center Tacoma, Washington Site Public Contact - (research@multicare.org)
Mayo Clinic in Rochester Rochester, Minnesota
Medical City Dallas Hospital Dallas, Texas
Memorial Health University Medical Center Savannah, Georgia Site Public Contact - (Lorraine.OHara@hcahealthcare.com)
Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida Site Public Contact - (OHR@mhs.net)
Mercy Hospital Saint Louis St Louis, Missouri
Methodist Children's Hospital of South Texas San Antonio, Texas Site Public Contact - (Vinod.GidvaniDiaz@hcahealthcare.com)
Miami Cancer Institute Miami, Florida
Michigan State University East Lansing, Michigan
Miller Children's and Women's Hospital Long Beach Long Beach, California
Montefiore Medical Center - Moses Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Einstein Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Weiler Hospital The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
NYP/Weill Cornell Medical Center New York, New York
NYU Langone Hospital - Long Island Mineola, New York Site Public Contact - (cancertrials@nyulangone.org)
Natalie Warren Bryant Cancer Center at Saint Francis Tulsa, Oklahoma
Nationwide Children's Hospital Columbus, Ohio Site Public Contact - (Melinda.Triplet@nationwidechildrens.org)
Nemours Children's Clinic - Pensacola Pensacola, Florida Site Public Contact - (helpdesk@childrensoncologygroup.org)
Nemours Children's Clinic-Jacksonville Jacksonville, Florida Site Public Contact - (Allison.bruce@nemours.org)
Nemours Children's Hospital Orlando, Florida Site Public Contact - (Allison.bruce@nemours.org)
New York Medical College Valhalla, New York
Newark Beth Israel Medical Center Newark, New Jersey Site Public Contact - (Christine.Kosmides@rwjbh.org)
Nicklaus Children's Hospital Miami, Florida
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima, Washington Site Public Contact - (Memorial-ClinicalTrials@yvmh.org)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
Norton Children's Hospital Louisville, Kentucky Site Public Contact - (CancerResource@nortonhealthcare.org)
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Oncology Las Vegas - Henderson Henderson, Nevada Site Public Contact - (research@sncrf.org)
Oncology Las Vegas - Tenaya Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at MountainView Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
PCR Oncology Arroyo Grande, California Site Public Contact - (research@sncrf.org)
Penn State Children's Hospital Hershey, Pennsylvania
Phoenix Childrens Hospital Phoenix, Arizona
Presbyterian Hospital Albuquerque, New Mexico Site Public Contact - (wburman@phs.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Greenville Memorial Hospital Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio Site Public Contact - (PCIOncResearch@promedica.org)
Providence Alaska Medical Center Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington Site Public Contact - (HopeBeginsHere@providence.org)
Radiation Oncology Associates Reno, Nevada Site Public Contact - (research@sncrf.org)
Radiation Oncology Centers of Nevada Central Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Radiation Oncology Centers of Nevada Southeast Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Rainbow Babies and Childrens Hospital Cleveland, Ohio
Renown Regional Medical Center Reno, Nevada Site Public Contact - (research@sncrf.org)
Riley Hospital for Children Indianapolis, Indiana
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center Denver, Colorado Site Public Contact - (PSGResearchSharedMailbox@HCAHealthcare.com)
Sacred Heart Hospital Pensacola, Florida
Saint Francis Cancer Center Greenville, South Carolina Site Public Contact - (Heather_Rich@bshsi.org)
Saint Francis Hospital Federal Way, Washington Site Public Contact - (Heather_Rich@bshsi.org)
Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida Site Public Contact - (jennifer.manns@baycare.org)
Saint Joseph's Regional Medical Center Paterson, New Jersey Site Public Contact - (HallL@sjhmc.org)
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Mary's Regional Medical Center Reno, Nevada Site Public Contact - (research@sncrf.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Seattle Children's Hospital Seattle, Washington
Sinai Hospital of Baltimore Baltimore, Maryland
Southern Illinois University School of Medicine Springfield, Illinois
Stanford Cancer Institute Palo Alto Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
Stony Brook University Medical Center Stony Brook, New York
Summerlin Hospital Medical Center Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Sunrise Hospital and Medical Center Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Sutter Medical Center Sacramento Sacramento, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Tampa General Hospital Tampa, Florida Site Public Contact - (syapchanyk@tgh.org)
The Children's Hospital at TriStar Centennial Nashville, Tennessee
The Steven and Alexandra Cohen Children's Medical Center of New York New Hyde Park, New York
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Muskegon Hospital Muskegon, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
UCSF Benioff Children's Hospital Oakland Oakland, California Site Public Contact - (PedOncRschOAK@ucsf.edu)
UCSF Medical Center-Mission Bay San Francisco, California Site Public Contact - (cancertrials@ucsf.edu)
UF Health Cancer Institute - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
UMC Cancer Center / UMC Health System Lubbock, Texas
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
University Medical Center of Southern Nevada Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Site Public Contact - (slusserb@med.umich.edu)
University of Michigan Health - West Wyoming, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
University of Mississippi Medical Center Jackson, Mississippi
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Texas Health Science Center at San Antonio San Antonio, Texas Site Public Contact - (phoresearchoffice@uthscsa.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
Urology Specialists of Nevada - Central Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Green Valley Henderson, Nevada Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Northwest Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Southwest Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Children's Hospital Madera, California Site Public Contact - (Research@valleychildrens.org)
Valley Medical Center Renton, Washington Site Public Contact - (research@valleymed.org)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Wake Forest University Health Sciences Winston-Salem, North Carolina
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus (STRIDE)

Ona Whelove - clinicaltrials@cerevasc.com

NCT06498960
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Each subject must meet the following criteria:
• Patients ≥60 years old on the day of study informed consent
• Patient or legally authorized representative is able and willing to provide written informed consent
• History or evidence of gait impairment with a duration ≥3 months
• Clinical presentation consistent with NPH including two or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with all of the following:
• Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans' Index \>0.3) and the absence of severe hippocampal atrophy,
• Pre-procedure spinal tap test or lumbar drain with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%,
• CSF opening pressure ≥8 cmH2O,
• Baseline cognitive evaluation assessed by Montreal Cognitive Assessment (MoCA) test score ≥12
• Patient is willing and able to attend all scheduled visits and comply with study procedures.
• Confirmation of anatomy suitable for the eShunt procedure, as determined by evaluation of pre-procedure imaging (CT and MRI) and approved by an independent anatomical screening committee.
Exclusion Criteria:
Each subject may not:
• Be unable to walk 10 meters (33 feet) with or without an assistive device
• Be diagnosed with obstructive hydrocephalus
• Have an active systemic infection or infection detected in CSF
• Have had prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
• Demonstrate hypersensitivity or contraindication to heparin or radiographic contrast agents against which the subject cannot be adequately pre-medicated, desensitized or where no alternative is available
• Have occlusion or stenosis of the internal jugular vein which would prohibit access to the IPS
• Present with venous distension in the neck on physical exam
• Have medical conditions associated with prolonged elevation of jugular venous pressure, including jugular vein stenosis or stricture, right sided heart failure, cirrhosis of the liver, arteriovenous fistulas in the arm for dialysis purposes, or an arterial venous fistula or malformation in the neck or brain
• Have history of bleeding diatheses, coagulopathy or refuse to consent for blood transfusion in cases of emergency
• Have had an ischemic stroke or transient ischemic attack within 180 days of eShunt procedure
• Have documented evidence of a deep vein thrombosis superior to the popliteal vein
• Have intrinsic blood clotting disorder
• Have medical conditions requiring anticoagulation which is unable to be managed to allow for surgical procedure
• Have presence of a posterior fossa tumor or mass
• Have a life expectancy \<1 year
• Be currently participating in another interventional (drug, device, etc.) research project that may confound the results of this study.
• Have established diagnosis of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, or Lewy body dementia
• Be diagnosed with schizophrenia or any psychiatric diagnosis (including depression) that may complicate outcome evaluation
• Need an intracranial neurosurgical procedure within 180 days of study index procedure
• Be unwilling or unable to comply with follow-up requirements
• Have mRS of 0, 5, or 6
DEVICE: CereVasc eShunt System, DEVICE: VP Shunt
Normal Pressure Hydrocephalus
I'm interested
Share via email
Show 28 locations

Study Locations

Hide all locations
Location Contacts
Advocate Lutheran General Hospital Park Ridge, Illinois Gina Littlejohn, BSN, RN, CCRC - (Gina.Littlejohn@aah.org)
Albany Medical Center Albany, New York Julia Zajaceskowski - (zajacej@amc.edu)
Baptist Medical Center - Jacksonville Jacksonville, Florida Jefferson Atillo, RN, BSN - (jefferson.atillo@bmcjax.com)
Beth Israel Deaconess Medical Center Boston, Massachusetts Mark Rotondo, MS - (mrotondo@bidmc.harvard.edu)
Brigham and Women's Hospital Boston, Massachusetts Odysseas Nikas - (onikas@bwh.harvard.edu)
Cleveland Clinic Cleveland, Ohio Joyce Barmen - (BARMENJ2@ccf.org)
Clinica La Sagrada Familia Buenos Aires, Carlos Toranzo - (ctoranzo@lylyk.com.ar)
Cooper Neurological Institute Camden, New Jersey Sean Behnke - (Behnke-sean@cooperhealth.edu)
Henry Ford Health Detroit, Michigan Rehnuma Newaz - (rnewaz1@hfhs.org)
Icahn School of Medicine at Mount Sinai New York, New York Kevin Buttet - (kevin.buttet@mountsinai.org)
Indiana University Indianapolis, Indiana Caliel Hines - (calhines@iu.edu)
Lenox Hill Hospital New York, New York Sara Massimo - (smassimo@northwell.edu)
Massachusetts General Hospital Boston, Massachusetts Shayna Hollander - (sdhollander@mgh.harvard.edu)
Montefiore Medical Center The Bronx, New York Lyanna Gomez, MD - (lygomez@montefiore.org)
NYU Langone Health New York, New York Michelle Sclafani - (michelle.sclafani@nyulangone.org)
Northwell Health New Hyde Park, New York Ajith Vellat - (avellat1@northwell.edu)
Northwestern University Chicago, Illinois Pouya Nazari - (pouya.nazari@northwestern.edu)
Rhode Island Hospital Providence, Rhode Island Wendy Smith, BS, RTRCV, CCRP - (wsmith@brownhealth.org)
St. Michael's Hospital Toronto, Ontario Eileen Liu - (Eileen.liu@unityhealth.to)
Thomas Jefferson University Philadelphia, Pennsylvania Sha'Mere Herder - (shamere.herder@jefferson.edu)
University at Buffalo Neurosurgery Buffalo, New York Ellen Carl - (ecarl@ubns.com)
University of Kansas Medical Center Kansas City, Kansas Max Hardenbrook - (mhardenbrook@kumc.edu)
University of Kentucky Research Foundation Lexington, Kentucky Rachel Norris - (rachel.norris@uky.edu)
University of Rochester Medical Center Rochester, New York Tilor Hallquist - (Tilor_Hallquist@URMC.Rochester.edu)
University of South Florida Tampa, Florida Shalini Nampally - (snampally@tgh.org)
University of Southern California Newport Beach, California Kelly Hu - (kelly.hu@med.usc.edu)
Virginia Commonwealth University Richmond, Virginia Amy Erickson - (amy.e.stout@vcuhealth.org)
Yale University New Haven, Connecticut Lindsey Fraczkiewicz - (lindsey.fraczkiewicz@yale.edu)

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) (Shamrock)

Sabine Coppieters, MD - clinicaltrials@argenx.com

NCT06503731
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* The participant is within the ages of 18 and 80 years old * The participant had a kidney transplant (living or deceased donor) at least 6 months before the study * The participant has received a diagnosis of active or chronic active antibody-mediated rejection (AMR) with detectable donor-specific antibodies at time of the study * A participant may be allowed into the study if they receive the following medications:
• Received mycophenolate mofetil for at least 20 weeks before the study
• Has remained on a stable dose of mycophenolate mofetil and tacrolimus for at least 4 weeks before being allowed to participate in the study
• Has remained on tacrolimus doses between 5 to 10 ng/mL at least 4 weeks before being allowed to participate in the study
• Steroid dose was between 0 to 10 mg per day of prednisone (or dose equivalent) for at least 4 weeks before being allowed to participate in the study
Exclusion Criteria:
* Confirmed T-cell or mixed rejection at time of the study * Recent change in immunosuppressive therapy agents * Any other medical condition that, in the investigator's opinion, would interfere with the results of the study or put the participant at undue risk * Pregnant or lactating state or intention to become pregnant during the study The complete list of criteria can be found in the protocol
COMBINATION_PRODUCT: Efgartigimod PH20 SC - prefilled syringe, OTHER: Placebo PH20 SC - prefilled syringe
Antibody-mediated Rejection
Active AMR, Chronic active AMR, Late AMR
I'm interested
Share via email
Show 22 locations

Study Locations

Hide all locations
Location Contacts
Allgemeines Krankenhaus der Stadt Wien (AKH Wien) - Medizinischer Universitätscampus Vienna, Georg A. Boehmig, MD - (clinicaltrials@argenx.com)
Cedars-Sinai Medical Center Los Angeles, California Stanley Jordan, MD - (clinicaltrials@argenx.com)
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Pellegrin Bordeaux, Lionel Couzi, MD - (clinicaltrials@argenx.com)
Centre Hospitalier Universitaire (CHU) de Grenoble Alpes - Hôpital Michallon La Tronche, Paolo Malvezzi, MD - (clinicaltrials@argenx.com)
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil Toulouse, Nassim Kamar, MD - (clinicaltrials@argenx.com)
Charite - Universitatsmedizin Berlin Berlin, Eva Schrezenmeier, MD - (clinicaltrials@argenx.com)
Duke University Hospital Durham, North Carolina Goni Katz-Greenberg, MD - (clinicaltrials@argenx.com)
Hospital Del Mar Barcelona, Catalonia Marta Crespo, MD - (clinicaltrials@argenx.com)
Hospital Universitario Miguel Servet Zaragoza, Alex Gutierrez-Dalmau, MD - (clinicaltrials@argenx.com)
Hospital Universitario Vall d'Hebron Barcelona, Francesc Moreso, MD - (clinicaltrials@argenx.com)
Hospital Universitario de Bellvitge L'Hospitalet de Llobregat, Edoardo Melilli, MD - (clinicaltrials@argenx.com)
Institut klinicke a experimentalni mediciny (IKEM) Prague, Ondrej Viklický, MD - (clinicaltrials@argenx.com)
London Health Sciences Centre London, Lakshman Gunaratnam, MD - (clinicaltrials@argenx.com)
The Ohio State University Wexner Medical Center Columbus, Ohio Todd Pesavento, MD - (clinicaltrials@argenx.com)
Universitaetsklinikum Carl Gustav Carus Dresden Dresden, Christian Hugo, MD - (clinicaltrials@argenx.com)
Universitair Ziekenhuis (UZ) Gent Ghent, Steven Van Laecke, MD - (clinicaltrials@argenx.com)
Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg Leuven, Dirk Kuypers, MD - (clinicaltrials@argenx.com)
Universitatsklinikum Hamburg-Eppendorf Hamburg, Florian Grahammer, MD - (clinicaltrials@argenx.com)
University of Alabama at Birmingham (UAB) Hospital Birmingham, Alabama Navya Eleti, MD - (clinicaltrials@argenx.com)
University of Nebraska Medical Center Omaha, Nebraska Eric Langewisch, MD - (clinicaltrials@argenx.com)
University of Washington Medical Center Seattle, Washington Nicolae Leca, MD - (clinicaltrials@argenx.com)
Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center Richmond, Virginia Gaurav Gupta, MD - (clinicaltrials@argenx.com)

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

LumaBridge CRO - contact@lumabridge.com

NCT06028074
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
General * Written informed consent * ECOG performance status 0-1. * Laboratory assessment 28 days prior to enrollment for assessment of acceptable cardiac, renal and hepatic functions * Recommended Double methods of contraception 90-days post treatment Cancer Specific * Histologically or cytologically confirmed locally advanced/unresectable or metastatic solid tumor * Received FDA approved treatment of PD-1 inhibitor or PD-L1 inhibitor for advance malignant tumors and have progressed/relapsed, are refractory, or intolerant * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 * Had prior therapy with PD-1/PD-L1 inhibitors. Other checkpoint inhibitors (ie, CTLA4, LAG3) are permitted if they did not lead to treatment discontinuation * No other lines of therapy that are available
Exclusion Criteria:
General * Enrolled in any other interventional clinical trial, starting within 4 weeks of the first dose of GIM-122 and throughout the duration of the study, or is receiving other therapy directed at their malignancy * Women who are pregnant or breastfeeding * History of cardiac issues, pulmonary embolism, active and clinically significant bacterial, fungal, or viral infection ≤ 6 months prior to dosing * Contraindications to the imaging assessments or other study procedures that subjects will undergo or any medical or social condition that, in the opinion of the investigator, might place a subject at an increased risk, affect compliance, or confound safety or other clinical study data interpretation Cancer Specific * Current second malignancy at other sites * Leptomeningeal disease * Spinal cord compression * Symptomatic or new or enlarging central nervous system (CNS) metastases Treatment-specific Exclusion Criteria * Ongoing toxicity \> Grade 1 from prior therapy according to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 * Has undergone a major surgery \< 1 month prior to administration of GIM-122 * Has received radiation therapy within 2 weeks prior to administration of GIM-122 * Has undergone or is anticipated to undergo organ transplantation including allogeneic or autologous stem cell transplantation at any time * Has received systemic anti-cancer therapy within 2 weeks and cytotoxic agents that have a major delayed toxicity within 4 weeks, of the first dose of GIM-122 * Prior treatment with other immune modulating agents within \< 4 weeks prior to the first dose of GIM-122. * Has a diagnosis of immunodeficiency, either primary or acquired * Has received treatment with systemic steroids or any form of immunosuppressive therapy within 14 days prior to administration of GIM-122 * Has active or prior history of autoimmune disease, including ulcerative colitis and Crohn's disease, or any condition that requires systemic steroids. * Has a known severe intolerance to or hypersensitivity reactions to monoclonal antibodies, Fc-bearing proteins, or IV immunoglobulin preparations; prior history of human anti-human antibody response; known allergy to any of the study medications, or excipients in the various formulations of any agent. * Has received live vaccines within 30 days of study initiation (inactivated vaccines are allowed; seasonal vaccines should be up to date \> 30 days prior to administration of GIM-122).
DRUG: GIM122
Advanced Solid Malignancies
solid tumor, advanced malignancies, GIM-122
I'm interested
Share via email
Show 11 locations

Study Locations

Hide all locations
Location Contacts
Florida Cancer Specialists West Palm Beach, Florida
NEXT Oncology Dallas Irving, Texas
Norton Cancer Institute Louisville, Kentucky Juanita Dwingelo, MS, PhD, ACRP-CP - (juanita.vondwingelo@nortonhealthcare.org)
Rutgers Cancer Institute of Nj New Brunswick, New Jersey Taryn Bollaro - (tb509@cinj.rutgers.edu)
Tennessee Oncology, PLLC Nashville, Tennessee Amber Hilyard - (ahilyard@tnonc.com)
Texas Oncology - Baylor Sammons Cancer Center Dallas, Texas
The Angeles Clinic and Research Institute Los Angeles, California
UCLA Hematology/Oncology Los Angeles, California Thu Ly - (tply@mednet.ucla.edu)
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California Markee Micu - (markee.micu@ucsf.edu)
USC/Norris Comprehensive Cancer Center Los Angeles, California Thomas Won - (thomas.won@med.usc.edu)
Virginia Commonwealth University Richmond, Virginia Faith McFadden - (mcfaddenfr@vcu.edu)

EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation (EXCLAMATORY)

Pamela Grizzard - pamela.grizzard@vcuhealth.org

NCT06212791
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Age ≥18 years * Diagnosis of paroxysmal AF * Left ventricular ejection fraction ≥50% * Scheduled for catheter ablation * Able to speak, hear, and read English * Willing and able to provide informed consent
Exclusion Criteria:
* Persistent or permanent AF * Prior ablation (catheter based or surgical) for AF * Significant sinus node dysfunction * Implanted pacemaker or defibrillator * Contraindication to or inability to complete cardiovascular magnetic resonance study * Contraindication to or inability to complete exercise testing * Chronic kidney disease with estimated glomerular filtration rate \<30 mL/min/1.73m2 * Severe left ventricular hypertrophy * Unrelated cardiomyopathy that is expected to limit exercise capacity, including but not limited to: * Hypertrophic cardiomyopathy * Cardiac amyloidosis * Constrictive pericarditis * Pulmonary arterial hypertension * Prior cardiac surgery * Active pregnancy
BEHAVIORAL: Self- Report Evaluation-Duke Activity Status Index, BEHAVIORAL: Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire, DIAGNOSTIC_TEST: Cardiopulmonary exercise test (CPET), DIAGNOSTIC_TEST: Transthoracic echocardiogram, DIAGNOSTIC_TEST: Ambulatory cardiac rhythm assessment, DIAGNOSTIC_TEST: Cardiovascular magnetic resonance (CMR)
Paroxysmal Atrial Fibrillation
Catheter ablation, Exercise capacity
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Pamela Grizzard - (pamela.grizzard@vcuhealth.org) Melissa Sears - (melissa.sears@vcuhealth.org)

Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients

Patrice Wiecek - wiecekpj@vcu.edu

NCT06043531
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Aged \> 18 years * Speak and understand English * Have received and LT
Exclusion Criteria:
* Acute cellular or chronic rejection within 3 months * Post-LT liver or non-liver related malignancy * Active viral hepatitis (B or C) or autoimmune hepatitis * Untreated biliary strictures or vascular complications (e.g. hepatic artery thrombosis) * Poorly controlled diabetes (HbA1c \>8.5%) * Relapse of alcohol use after LT * Follow a vegetarian or vegan diet * Current pregnancy * Unable to provide informed consent
OTHER: Experimental: EVOO
Liver Transplant
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Danielle Kirkman - (dlkirkman@vcu.edu) Patrice Wiecek - (wiecekpj@vcu.edu)

Effect of Clear Aligner Attachment Size on Extrusion of Maxillary Lateral Incisors

Alexis Catalano - catalanoam2@vcu.edu

NCT06814262
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients treated with either Comprehensive Invisalign or Invisalign Teen treatment * The maxillary arch has less than 6 mm of crowding or spacing * Maxillary lateral incisors have a minimum of 0.3 mm of extrusion prescribed in the Tooth Movement Table on the Invisalign ClinCheck for the first set of aligners * Maxillary lateral incisors within a normal range of bucco-lingual inclination * Patients 12 years of age or older and either the patient or legal guardian are able to give consent * Patients confirm good compliance throughout the study period
Exclusion Criteria:
* Patients do not complete all aligners in the first phase as prescribed * Poor compliance recorded for aligner wear * Restorations placed or oral surgery completed prior to final scan * Midcourse intervention to improve tracking such as a bootstrap * Maxillary lateral incisors not tracking and noted by minimum of 1 mm of aligner material incisally displaced when aligner fully seated * Treatment plans include surgery or extractions * Maxillary lateral incisors with pathology and restorations * Missing teeth other than third molars * Patients with anterior crossbite
DEVICE: Corresponding treatment order in the prescription with Align Technology, DEVICE: Superimposition of final and initial positions of lateral incisors: Predicted model, DEVICE: Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x3mm aligners, DEVICE: Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x4mm aligners, DEVICE: Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x5mm aligners
Orthodontic Appliance Complication
Extrusion of Maxillary Lateral Incisors, Clear Aligner Attachment
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Alexis Catalano - (catalanoam2@vcu.edu) Steven Lindauer - (sjlindau@vcu.edu)

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia (LOTUS)

Ashley Mack, MS - URCC_22063@urmc.rochester.edu

NCT06073431
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Have a primary diagnosis of unresectable or stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer * Note: Patients do not need to have cachexia to be eligible * Plan to start first-line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, interventional clinical trial) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks. * NOTE: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant treatment and have since recurred are still eligible if such treatment ended \> 6 months prior to enrollment. Patients receiving concurrent radiation with systemic therapy or received local therapy alone (surgery, radiation therapy \[RT\]) prior to first line therapy remain eligible. Patients receiving maintenance treatment after first line therapy are not eligible * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Be able to understand, speak and read English * Be 18 years of age or older
Exclusion Criteria:
* Have contraindications to physical function assessments (30-second arm curl, Timed-Up-And-Go test, or 30-second chair-stand test) per the treating provider or their designee * Have any planned major surgeries within the next 3 months * Have received chemotherapy or surgery for separate primary cancer within the past 3 years other than early local staged non-melanoma skin cancer * Be pregnant
PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, OTHER: Electronic Health Record Review, OTHER: Medical Device Usage and Evaluation, OTHER: Physical Performance Testing, PROCEDURE: Positron Emission Tomography, OTHER: Survey Administration
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
I'm interested
Share via email
Show 225 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Outpatient Center - Oak Lawn Oak Lawn, Illinois Site Public Contact - (ncorp@aah.org)
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
AnMed Health Cancer Center Anderson, South Carolina Site Public Contact - (rhonda.ballew@anmedhealth.org)
Armes Family Cancer Center Findlay, Ohio
Ascension All Saints Hospital Racine, Wisconsin Site Public Contact - (AWRI.Inquiry@Ascension.org)
Ascension Calumet Hospital Chilton, Wisconsin Site Public Contact - (AWRI.inquiry@ascension.org)
Ascension Columbia Saint Mary's Hospital - Milwaukee Milwaukee, Wisconsin Site Public Contact - (AWRI.Inquiry@Ascension.org)
Ascension Columbia Saint Mary's Hospital Ozaukee Mequon, Wisconsin Site Public Contact - (AWRI.Inquiry@Ascension.org)
Ascension Medical Group Southeast Wisconsin - Mayfair Road Wauwatosa, Wisconsin Site Public Contact - (AWRI.Inquiry@Ascension.org)
Ascension Mercy Hospital Oshkosh, Wisconsin Site Public Contact - (AWRI.inquiry@ascension.org)
Ascension Saint Elizabeth Hospital Appleton, Wisconsin Site Public Contact - (AWRI.inquiry@ascension.org)
Ascension Saint Francis - Reiman Cancer Center Franklin, Wisconsin Site Public Contact - (AWRI.Inquiry@Ascension.org)
Ascension Southeast Wisconsin Hospital - Elmbrook Campus Brookfield, Wisconsin Site Public Contact - (AWRI.Inquiry@Ascension.org)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Center - Greenfield Greenfield, Wisconsin Site Public Contact - (ncorp@aah.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Beebe Health Campus Rehoboth Beach, Delaware Site Public Contact - (research@beebehealthcare.org)
Beebe South Coastal Health Campus Millville, Delaware Site Public Contact - (research@beebehealthcare.org)
Blanchard Valley Hospital Findlay, Ohio
Boulder Community Foothills Hospital Boulder, Colorado
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Center of Western Wisconsin New Richmond, Wisconsin Site Public Contact - (mmcorc@healthpartners.com)
Carle BroMenn Medical Center Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Cancer Institute Normal Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Carson Tahoe Regional Medical Center Carson City, Nevada Site Public Contact - (research@sncrf.org)
Centralia Oncology Clinic Centralia, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Christiana Care - Union Hospital Elkton, Maryland Site Public Contact - (frank.crum@christianacare.org)
Christiana Care Health System-Christiana Hospital Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Christiana Care Health System-Wilmington Hospital Wilmington, Delaware Site Public Contact - (lbarone@christianacare.org)
Colorado Blood Cancer Institute Denver, Colorado
Comprehensive Cancer Centers of Nevada - Central Valley Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Northwest Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Town Center Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Southeast Henderson Henderson, Nevada Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Summerlin Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dayton Physician LLC - Englewood Dayton, Ohio
Dayton Physicians LLC - Troy Troy, Ohio
Dayton Physicians LLC-Atrium Franklin, Ohio
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dickinson County Healthcare System Iron Mountain, Michigan Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Lakes Medical Center Wyoming, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Northland Medical Center Princeton, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Gibbs Cancer Center-Gaffney Gaffney, South Carolina Site Public Contact - (kmertz-rivera@gibbscc.org)
Gibbs Cancer Center-Pelham Greer, South Carolina Site Public Contact - (kmertz-rivera@gibbscc.org)
Greater Dayton Cancer Center Kettering, Ohio
HSHS Sacred Heart Hospital Eau Claire, Wisconsin
HSHS Saint Elizabeth's Hospital O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Hawaii Cancer Care - Westridge ‘Aiea, Hawaii Site Public Contact - (info@hawaiicancercare.com)
Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii Site Public Contact - (i.webster@hawaiicancercare.com)
Helen F Graham Cancer Center Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Hennepin County Medical Center Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Highland Hospital Rochester, New York
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Indu and Raj Soin Medical Center Beavercreek, Ohio
John B Amos Cancer Center Columbus, Georgia Site Public Contact - (cdean@iacthealth.com)
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Kettering Medical Center Kettering, Ohio
Lake Regional Hospital Osage Beach, Missouri Site Public Contact - (clinicaltrials@lakeregional.com)
Lakeview Hospital Stillwater, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Lenox Hill Hospital New York, New York
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Savannah, Georgia Site Public Contact - (underberga@sjchs.org)
Manhattan Eye Ear and Throat Hospital New York, New York
Marietta Memorial Hospital Marietta, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Marshfield Medical Center - Minocqua Minocqua, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
MedStar Georgetown University Hospital Washington D.C., District of Columbia
Medical Oncology Hematology Consultants PA Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Memorial Health University Medical Center Savannah, Georgia Site Public Contact - (Lorraine.OHara@hcahealthcare.com)
Memorial Hospital of Carbondale Carbondale, Illinois Site Public Contact - (clinical.research@sih.net)
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Methodist Medical Center of Illinois Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Minnesota Oncology - Burnsville Burnsville, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monticello Cancer Center Monticello, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
New Ulm Medical Center New Ulm, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
North Memorial Medical Health Center Robbinsdale, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Northeast Georgia Medical Center Braselton Braselton, Georgia Site Public Contact - (cancerpatient.navigator@nghs.com)
Northeast Georgia Medical Center-Gainesville Gainesville, Georgia Site Public Contact - (cancerpatient.navigator@nghs.com)
Northside Hospital Atlanta, Georgia Site Public Contact - (ClinicalTrials@northside.com)
Northside Hospital - Duluth Duluth, Georgia Site Public Contact - (Clinical.trials@northside.com)
Northside Hospital - Gwinnett Lawrenceville, Georgia Site Public Contact - (Clinical.trials@northside.com)
Northwell Health/Center for Advanced Medicine Lake Success, New York
Noyes Memorial Hospital/Myers Cancer Center Dansville, New York Site Public Contact - (WCICTOresearch@urmc.rochester.edu)
OSF Saint Anthony's Health Center Alton, Illinois
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Oncology Hematology Care Inc-Kenwood Cincinnati, Ohio
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at MountainView Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Pali Momi Medical Center ‘Aiea, Hawaii
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
PeaceHealth Saint John Medical Center Longview, Washington Site Public Contact - (kmakin-bond@peacehealth.org)
PeaceHealth Saint Joseph Medical Center Bellingham, Washington
PeaceHealth Southwest Medical Center Vancouver, Washington Site Public Contact - (kmakin-bond@peacehealth.org)
Pluta Cancer Center Rochester, New York Site Public Contact - (ctsucontact@westat.com)
Prisma Health Cancer Institute - Butternut Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Faris Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Queen's Cancer Cenrer - POB I Honolulu, Hawaii
Queen's Cancer Center - Kuakini Honolulu, Hawaii
Queen's Cancer Center - Pearlridge ‘Aiea, Hawaii
Queen's Medical Center Honolulu, Hawaii
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Reid Health Richmond, Indiana
Renown Regional Medical Center Reno, Nevada Site Public Contact - (research@sncrf.org)
Rice Memorial Hospital Willmar, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Ridgeview Medical Center Waconia, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Rocky Mountain Cancer Centers - Centennial Centennial, Colorado
Rocky Mountain Cancer Centers - Swedish Englewood, Colorado
Rocky Mountain Cancer Centers-Aurora Aurora, Colorado
Rocky Mountain Cancer Centers-Boulder Boulder, Colorado
Rocky Mountain Cancer Centers-Lakewood Lakewood, Colorado
Rocky Mountain Cancer Centers-Littleton Littleton, Colorado
Rocky Mountain Cancer Centers-Midtown Denver, Colorado
Rocky Mountain Cancer Centers-Rose Denver, Colorado
Rocky Mountain Cancer Centers-Sky Ridge Lone Tree, Colorado
Rocky Mountain Cancer Centers-Thornton Thornton, Colorado
SIH Cancer Institute Carterville, Illinois Site Public Contact - (clinical.research@sih.net)
SMC Center for Hematology Oncology Union Union, South Carolina Site Public Contact - (kmertz-rivera@gibbscc.org)
Saint Elizabeth Boardman Hospital Boardman, Ohio
Saint Elizabeth Youngstown Hospital Youngstown, Ohio
Saint Francis Regional Medical Center Shakopee, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint John's Hospital - Healtheast Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Warren Hospital Warren, Ohio
Saint Joseph's/Candler - Bluffton Campus Bluffton, South Carolina Site Public Contact - (underberga@sjchs.org)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Shenandoah Oncology PC Winchester, Virginia Site Public Contact - (William.Houck@usoncology.com)
South Carolina Cancer Specialists PC Hilton Head Island, South Carolina Site Public Contact - (underberga@sjchs.org)
South Georgia Medical Center/Pearlman Cancer Center Valdosta, Georgia Site Public Contact - (maryann.heddon@sgmc.org)
Southern Illinois University School of Medicine Springfield, Illinois
Spartanburg Medical Center Spartanburg, South Carolina Site Public Contact - (kmertz-rivera@gibbscc.org)
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Straub Clinic and Hospital Honolulu, Hawaii
Strecker Cancer Center-Belpre Belpre, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Summerlin Hospital Medical Center Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
The Longstreet Clinic - Gainesville Gainesville, Georgia
The Melanoma and Skin Cancer Institute Englewood, Colorado
The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii Site Public Contact - (rohta@queens.org)
The Women's Imaging Center Denver, Colorado
ThedaCare Regional Cancer Center Appleton, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
Tift Regional Medical Center Tifton, Georgia
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University of Rochester Rochester, New York
Urology Specialists of Nevada - Green Valley Henderson, Nevada Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Northwest Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Southwest Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
VCU Community Memorial Health Center South Hill, Virginia Site Public Contact - (nemer.elmouallem@vcuhealth.org)
Valley Medical Center Renton, Washington Site Public Contact - (research@valleymed.org)
Valley Radiation Oncology Peru, Illinois
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Wayne Hospital Greenville, Ohio
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Wilmot Cancer Institute Radiation Oncology at Greece Rochester, New York
Wilmot Cancer Institute at Webster Webster, New York Site Public Contact - (WCICTOresearch@urmc.rochester.edu)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Toll Free Number - Trialsites@msd.com

NCT03486873
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Treated on the parent pembrolizumab studies established by the Sponsor as MK-3475-587 ready. * Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinib from parent studies or in a follow-up phase. Additional eligibility criteria for participants who enter Second Course Phase once they are enrolled on MK-3475-587: * Has not received any anticancer systemic treatment since the last dose of pembrolizumab or a pembrolizumab-based combination in First Course Phase. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Demonstrates adequate organ function. * Have resolution of any toxic effect(s) of First Course Phase trial treatment with pembrolizumab or a pembrolizumab-based combination to Grade 1 or less (except alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of \>30 Gray (Gy), they must have recovered from the toxicity and/or complications of the intervention. * A female participant is eligible to enroll if she is not pregnant, not breastfeeding, and ≥1 of the following conditions applies: A woman of childbearing potential (WOCBP) who agrees to use contraception during the study treatment period and for ≥120 days (corresponding to time needed to eliminate any study combination treatment(s) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity. Additional eligibility criteria for participants who enter dosing with Lenvatinib: * Adequately controlled blood pressure (BP) to \<150/90 mmHg, with or without antihypertensive medications. * For male agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective contraceptive method while receiving study drug and for 7 days after the last dose of lenvatinib. * Is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (WOCBP), is a WOCBP and uses highly effective contraception (low user dependency method OR a user dependent hormonal method in combination with a barrier method) or is a WOCBP who is abstinent from heterosexual intercourse.
Exclusion Criteria:
-There are no exclusion criteria to participate in MK-3475-587. Participants are excluded from entering Second Course trial treatment once they are enrolled on MK-3475-587 if any of the following criteria applies: * Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients. * Has received a live vaccine within 30 days prior to the first dose of Second Course Phase trial treatment. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the Cycle 1 Day 1 of Second Course Phase. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with curative intent, melanoma (non-ulcerated, thin primary), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy. * Has known active central nervous system metastases and/or carcinomatous meningitis. * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. Note: Participants that experienced pneumonitis during First Course that did not meet the criteria for permanent discontinuation are eligible. * Non-small cell lung cancer (NSCLC) participants only: Has interstitial lung disease. * Has an active infection requiring systemic therapy. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known history of or is positive for hepatitis B or hepatitis C. For parent studies where inclusion of participants with hepatitis was permitted, MK-3475-587 will follow the parent study eligibility criteria for hepatitis. * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Second Course Phase eligibility Visit through 120 days after the last dose of study treatment. * Has severe cardiovascular disease, i.e., arrhythmias, requiring chronic treatment, congestive heart failure (New York Heart Association Class III or IV) or symptomatic ischemic heart disease. * Has hepatic decompensation (Child-Pugh score \>6 \[class B and C\]). * Has uncontrolled thyroid dysfunction. * Has uncontrolled diabetes mellitus. * Has had an allogeneic tissue/solid organ transplant. * Has a known history of active tuberculosis (TB; Bacillus tuberculosis). Additional exclusion criteria for participants who enter dosing with Lenvatinib: * Has had major surgery within 3 weeks prior to first dose of study intervention(s). * Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula. * Has urine protein ≥1 g/24 hours. * Has LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO). * Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation. * Prolongation of QT intervals corrected for heart rate using Fridericia's (cube root) correction (QTcF) interval to \>480 ms. * Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability. * Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib. * Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug. * Has a history of any contraindication or has a severe hypersensitivity to any components of lenvatinib.
DRUG: Pembrolizumab, DRUG: Standard of Care (SOC), DRUG: Lenvatinib, DRUG: Olaparib, DRUG: MK-4280, BIOLOGICAL: MK-4280A
Solid Tumors, Hematologic Malignancies
PD1, PD-1, PDL1, PD-L1
I'm interested
Share via email
Show 752 locations

Study Locations

Hide all locations
Location Contacts
A. C. Camargo Cancer Center ( Site 1002) São Paulo,
AO Santa Maria della Misericordia-Oncology Department ( Site 1971) Perugia, Umbria
AZ Maria Middelares ( Site 2908) Ghent, Oost-Vlaanderen
AZ Sint-Maarten ( Site 2904) Mechelen, Antwerpen
Aberdeen Royal Infirmary-Department of Oncology ( Site 0521) Aberdeen, Aberdeen City
Acibadem Adana Hospital-Pediatric Hematology-Oncology ( Site 1312) Adana,
Acibadem Altunizade Hospital-Oncology ( Site 1317) Üsküdar /Istanbul, Istanbul
Acibadem Universitesi Atakent Hastanesi ( Site 1319) Istanbul,
Acıbadem Maslak Hastanesi-Medical Oncology ( Site 1321) Istanbul,
Ad-Vance Medical Research-Research ( Site 1151) Ponce,
Adana Sehir Egitim ve Arastirma Hastanesi ( Site 1324) Adana,
Addenbrookes Hospital ( Site 0522) Cambridge, Cambridgeshire
Administradora Country S.A. ( Site 2701) Bogotá, Bogota D.C.
Aichi Cancer Center ( Site 3101) Nagoya, Aichi-ken
Ajou University Hospital ( Site 0969) Suwon, Kyonggi-do
Akdeniz Universitesi Hastanesi-Medical Onkology ( Site 1318) Antalya,
Almazov National Medical Research Centre ( Site 1233) Saint Petersburg, Sankt-Peterburg
Altai Regional Clinical Oncology Center ( Site 1229) Barnaul, Altayskiy Kray
Ambroise Pare Hopital ( Site 2503) Boulogne, Hauts-de-Seine
Amsterdam UMC, locatie VUmc ( Site 1555) Amsterdam, North Holland
Andreas Syggros Hospital ( Site 1853) Athens, Attica
Anhui Provincial Hospital-Cancer Chemotherapy Department ( Site 3480) Hefei, Anhui
Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 3487) Hefei, Anhui
Ankara City Hospital-Medical Oncology ( Site 1311) Ankara,
Ankara University Health Practice and Research Hospitals ( Site 1331) Ankara,
Ankara University Hospital Cebeci ( Site 1306) Ankara,
Antoni van Leeuwenhoek Ziekenhuis ( Site 1551) Amsterdam, North Holland
Arizona Cancer Center at UMC North ( Site 0018) Tucson, Arizona
Army Medical Center of People's Liberation Army-Oncology Department ( Site 3477) Chongqing, Chongqing Municipality
Arthur J.E. Child Comprehensive Cancer Centre ( Site 2815) Calgary, Alberta
Asan Medical Center ( Site 0952) Songpagu, Seoul
Asklepion Medical Center ( Site 3667) Khodosovka, Kyivska Oblast
Atatürk Üniversitesi ( Site 1333) Erzurum,
Auckland City Hospital ( Site 1503) Auckland,
Augusta University ( Site 0077) Augusta, Georgia
Austin Health-Austin Hospital ( Site 3004) Heidelberg, Victoria
Avix Investigación Clinica, S.C.-Oncology ( Site 1104) Monterrey, Nuevo León
Azienda Ospedaliera San Camillo Forlanini ( Site 1958) Roma,
Azienda Ospedaliera San Gerardo ( Site 1980) Monza, Lombardy
Azienda Ospedaliera Santa Maria ( Site 1962) Terni,
Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 1972) Brescia,
Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica ( Site 1964) Parma,
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ( Site 1974) Torino,
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII-UOC Oncologia ( Site 1967) Bergamo,
BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 1030) São Paulo,
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 1419) Kecskemét, Bács-Kiskun county
Ballarat Oncology & Haematology Services ( Site 3022) Wendouree, Victoria
Baptist MD Anderson Cancer Center ( Site 0083) Jacksonville, Florida
Barts Health NHS Trust ( Site 0512) London, London, City of
Bashkir State Medical University ( Site 1221) Ufa, Baskortostan, Respublika
Baskent Universitesi Ankara Hastanesi ( Site 1303) Ankara,
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1307) Adana,
Beijing Cancer Hospital ( Site 3451) Beijing, Beijing Municipality
Beijing Cancer Hospital ( Site 3499) Beijing, Beijing Municipality
Beijing Cancer Hospital ( Site 3500) Beijing, Beijing Municipality
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 3454) Beijing, Beijing Municipality
Belfast City Hospital ( Site 0508) Belfast, Northern Ireland
Belgorod Oncology Dispensary ( Site 1213) Belgorod, Belgorod Oblast
Bezmialem Vakf Üniversitesi-Oncology ( Site 1308) Istanbul,
Bialostockie Centrum Onkologii ( Site 1610) Bialystok, Podlaskie Voivodeship
Biocenter ( Site 2763) Concepción, Región del Biobío
Blod och Tumorssjukdomar. Akademiska sjukhuset ( Site 0801) Uppsala, Uppsala County
Blue Ridge Cancer Care ( Site 0067) Roanoke, Virginia
Bnai Zion Medical Center ( Site 2060) Haifa,
Bon Secours St. Francis Medical Center-Oncology Research ( Site 0075) Midlothian, Virginia
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház ( Site 1409) Miskolc, Borsod-Abauj Zemplen county
Bradfordhill-Clinical Area ( Site 2756) Santiago, Region M. de Santiago
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház-Megyei Onkológiai Centrum ( Site 1405) Gyula, Bekes County
C.H.U. Pontchaillou ( Site 2511) Pierre-Bénite, Rhone
C.H.U. de Tours - Hopital Bretonneau ( Site 2515) Tours, Indre-et-Loire
CELAN,S.A ( Site 3405) Guatemala City,
CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 1034) Florianópolis, Santa Catarina
CEPON ( Site 1012) Florianópolis, Santa Catarina
CH Lyon Sud Hospices Civils de Lyon ( Site 2521) Pierre-Bénite, Auvergne-Rhône-Alpes
CHA Bundang Medical Center CHA University ( Site 0957) Seongnam-si, Kyonggi-do
CHRU Brest - Hopital Cavale Blanche ( Site 2504) Brest, Finistere
CHRU Lille Hospital Claude Huriez ( Site 2506) Lille, Nord
CHU Bordeaux Haut-Leveque ( Site 2534) Pessac, Aquitaine
CHU Hopital Saint Antoine ( Site 2517) Paris,
CHU Jean Minjoz ( Site 2520) Besançon, Doubs
CHU La Timone ( Site 2508) Marseille, Bouches-du-Rhone
CHU Montpellier. ( Site 2556) Montpellier, Herault
CHU Toulouse - Hopital Rangueil ( Site 2518) Toulouse, Haute-Garonne
CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 2526) Toulouse, Haute-Garonne
CHU-Jean Minjoz ( Site 2550) Besançon, Doubs
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 0876) Santiago de Compostela, La Coruna
CIDO SpA ( Site 2765) Temuco, Región de la Araucanía
CIMCA ( Site 3900) San José,
COMMUNAL NONPROFIT ENTERPRISE "CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 3671) Cherkasy, Cherkasy Oblast
CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA-Pesquisa Clínica ( Site 1024) Fortaleza, Ceará
Cabinet Medical Oncomed ( Site 3554) Timișoara, Timiș County
California Cancer Associates for Research & Excellence ( Site 0016) Fresno, California
Calvary Mater Newcastle ( Site 3005) Waratah, New South Wales
Cancer Institute Hospital of JFCR ( Site 3108) Tokyo,
Cancer Institute Hospital of JFCR ( Site 3146) Koto, Tokyo
Cancer Institute Hospital of JFCR ( Site 3164) Koto, Tokyo
Cancer Institute of New Jersey ( Site 0025) New Brunswick, New Jersey
CancerCare Manitoba ( Site 2814) Winnipeg, Manitoba
Canterbury Regional Cancer & Blood Service ( Site 1500) Christchurch, Canterbury
Cape Town Oncology Trials ( Site 2007) Cape Town, Western Cape
Capital & Coast District Health Board - Wellington Hospital ( Site 1501) Wellington,
Cardiomed SRL Cluj-Napoca ( Site 3555) Cluj-Napoca, Cluj
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 2525) Rennes, Ille-et-Vilaine
Centre Francois Baclesse ( Site 2558) Caen, Calvados
Centre Georges François Leclerc-Centre de recherche clinique ( Site 2536) Dijon, Cote-d Or
Centre Henri Becquerel ( Site 2547) Rouen, Seine-Maritime
Centre Hopitalar Leon-Berard ( Site 2519) Lyon, Auvergne
Centre Hopitalier Intercommunal Creteil ( Site 2514) Créteil, Val-de-Marne
Centre Hospitalier Annecy Genevois ( Site 2554) Epagny Metz Tessy, Haute-Savoie
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2539) Nice, Alpes-Maritimes
Centre Hospitalier Universitaire de Poitiers-Dermatologie ( Site 2544) Poitiers, Vienne
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 2807) Montreal, Quebec
Centre Hospitalier du Mans-Pneumologie ( Site 2527) Le Mans, Sarthe
Centre Intégré de Santé et de Services Sociaux (CISSS) de La-Centre intégré de cancérologie de Lava ( Site 2810) Laval, Quebec
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre-Oncology ( Site 2809) Greenfield Park, Quebec
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 2542) Clermont-Ferrand, Puy-de-Dome
Centre Oscar Lambret ( Site 2551) Lille, Hauts-de-France
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 2816) Trois-Rivières, Quebec
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 2805) Québec, Quebec
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 2812) Sherbrooke, Quebec
Centro Hospitalar de Sao Joao - Hospital de Sao Joao ( Site 1752) Porto,
Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0869) Madrid,
Centro Medico Privado CEMAIC ( Site 1371) Córdoba,
Centro Medico San Roque-Oncology ( Site 1352) San Miguel de Tucumán,
Centro Oncologico Norte. ( Site 1370) Santiago del Estero,
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 1368) Buenos Aires., Buenos Aires
Centro de Investigaciones ( Site 2755) Viña del Mar, Región de Valparaíso
Centro de Oncología e Investigación de Buenos Aires ( Site 1357) Berazategui, Buenos Aires
Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 1016) Fortaleza, Ceará
Centro de Urologa Avanzada del Noreste ( Site 1110) San Pedro Garza García, Nuevo León
Centrul de Oncologie "Sfântul Nectarie" ( Site 3552) Craiova, Dolj
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1612) Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Chaim Sheba Medical Center ( Site 2055) Ramat Gan,
Chaim Sheba Medical Center. ( Site 2052) Ramat Gan,
Champalimaud Foundation ( Site 1751) Lisbon, Lisbon District
Chang Gung Medical Foundation-Linkou Branch ( Site 3206) Taoyuan District,
Changhua Christian Hospital ( Site 3210) Changhua,
Chelyabinsk Regional Clinical Oncology Dispensary ( Site 1253) Chelyabinsk, Chelyabinsk Oblast
Chiba Cancer Center ( Site 3117) Chiba,
China Medical University Hospital ( Site 3204) Taichung,
Chinese Academy of medical science, Peking Union Medical College Hospital(Dongdan) ( Site 3466) Beijing, Beijing Municipality
Chonnam National University Hwasun Hospital-Hemato-Oncology ( Site 0959) Hwasun, Jeonranamdo
Chris OBrien Lifehouse ( Site 3003) Camperdown, New South Wales
Chulalongkorn University ( Site 2363) Bangkok, Bangkok
Chungbuk National University Hospital ( Site 0961) Cheongju-si, North Chungcheong
Chungnam national university hospital-Department of Internal Medicine ( Site 0958) Daejeon, Taejon-Kwangyokshi
City Clinical Oncology Center ( Site 1237) Saint Petersburg, Sankt-Peterburg
Clinica Universitaria de Navarra ( Site 0855) Madrid,
Clinica Viedma ( Site 1353) Viedma, Río Negro Province
Clinica Viver ( Site 1021) Santa Maria, Rio Grande do Sul
Clinica de la Costa S.A.S. ( Site 2705) Barranquilla, Atlántico
Clinical Research Center of specialized types medical care-Oncology ( Site 1205) Saint Petersburg, Sankt-Peterburg
Clinique de L'Europe ( Site 2548) Amiens, Somme
Cliniques Universitaires de Bruxelles - CUB - Hopital Erasme ( Site 2905) Brussels, Bruxelles-Capitale, Region de
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 2911) Brussels, Bruxelles-Capitale, Region de
Clínica Imbanaco S.A.S ( Site 2708) Cali, Valle del Cauca Department
Clínica Inmunocel ( Site 2762) Santiago, Region M. de Santiago
Clínica de Pesquisa e Centro de Estudos em Ginecologia Oncológica e Mamária LTDA ( Site 1017) São Paulo, São Paulo
Communal Non-Commercial Enterprise "Prykarpatski Clinical Oncological Center" of Ivano-Frankivsk Reg ( Site 3663) Ivano-Frankivsk, Ivano-Frankivsk Oblast
Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 3662) Vinnytsia, Vinnytsia Oblast
Complejo Hospitalario de Jaén-Servicio de Oncología Médica ( Site 0879) Jaén,
Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054) Bakersfield, California
Comprehensive Cancer Centers of Nevada ( Site 0043) Las Vegas, Nevada
Cross Cancer Institute ( Site 2804) Edmonton, Alberta
Cuidados Oncologicos. ( Site 1118) Querétaro,
Dana-Farber Cancer Institute ( Site 0006) Boston, Massachusetts
Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 1415) Debrecen,
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 1412) Debrecen,
Derma Internacional SA ( Site 1372) CABA, Buenos Aires
Dokkyo Medical University Saitama Medical Center ( Site 3152) Koshigaya, Saitama
Dokuz Eylul Universitesi Hastanesi ( Site 1323) Izmir,
Duke Cancer Center ( Site 0028) Durham, North Carolina
Ege Universitesi Tip Fakultesi Hastanesi ( Site 1300) Izmir,
Ehime University Hospital ( Site 3158) Tōon, Ehime
Elbe Klinikum Buxtehude ( Site 2400) Buxtehude, Lower Saxony
Emory School of Medicine ( Site 0013) Atlanta, Georgia
Erasmus MC ( Site 1553) Rotterdam, South Holland
EuroCityClinic ( Site 1230) Saint Petersburg, Sankt-Peterburg
European Interbalkan Medical Center ( Site 1855) Thessaloniki,
FDI Clinical Research ( Site 1152) San Juan,
FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 1208) Moscow, Moscow
FSBI-FRCC of Special Types Med. Care and Technologies FMBA of Russia ( Site 1234) Moscow, Moscow
Facharztzentrum Eppendorf ( Site 2415) Hamburg,
Faculty of Medicine - Khon Kaen University ( Site 2366) Muang, Changwat Khon Kaen
Faculty of Medicine Siriraj Hospital ( Site 2365) Bangkok, Bangkok
Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 0702) Prague, Praha 4
Fakultni nemocnice Olomouc ( Site 0701) Olomouc,
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0704) Olomouc, Olomoucký kraj
Fakultni nemocnice v Motole ( Site 0700) Prague,
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0705) Prague, Praha 5
Farkasgyepui Tudogyogyintezet-Pulmonologia ( Site 1414) Farkasgyepű, Veszprém megye
Fejér Megyei Szent György Egyetemi Oktató Kórház-l.Pulmonologia ( Site 1407) Székesfehérvár, Fejér
Fiona Stanley Hospital ( Site 3029) Murdock, Western Australia
First Moscow State Medical University n.a. I.M.Sechenov ( Site 1245) Moscow, Moscow
First Pavlov State Medical University of Saint Petersburg ( Site 1232) Saint Petersburg, Sankt-Peterburg
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1977) Milan, Lombardy
Fondazione IRCCS Policlinico San Matteo ( Site 1982) Pavia,
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1975) Rome, Lazio
Fox Chase Cancer Center ( Site 0042) Philadelphia, Pennsylvania
Fred Hutchinson Cancer Center ( Site 0024) Seattle, Washington
Fudan University Shanghai Cancer Center ( Site 3467) Shanghai, Shanghai Municipality
Fujian Provincial Cancer Hospital ( Site 3461) Fuzhou, Fujian
Fundacion Arturo Lopez Perez FALP ( Site 2750) Santiago, Region M. de Santiago
Fundacion Colombiana de Cancerología Clinica Vida ( Site 2707) Medellín, Antioquia
Fundacion Estudios Clinicos ( Site 1369) Rosario, Santa Fe Province
Fundacion Favaloro ( Site 1367) CABA, Buenos Aires
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 1358) La Rioja,
Fundación Valle del Lili ( Site 2700) Cali, Valle del Cauca Department
Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1003) São José do Rio Preto, São Paulo
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1010) Barretos, São Paulo
GBUZ LOKB ( Site 1218) Saint-Petersburg, Leningradskaya Oblast'
GBUZ LOKB-Oncology department #1 ( Site 1222) Saint-Petersburg, Leningradskaya Oblast'
GBUZ SK Pyatigorsk Interdistrict Oncology dispensary ( Site 1223) Pyatigorsk, Stavropol Kray
GVI Oncology ( Site 2008) George, Western Cape
Gachon University Gil Medical Center ( Site 0967) Inceon, Incheon
Gallipoli Medical Research Ltd ( Site 3011) Brisbane, Queensland
Gangnam Severance Hospital, Yonsei University Health System ( Site 0966) Gangnam-gu, Seoul
Gazi University Health Research and Application Center Gazi Hospital ( Site 1325) Ankara,
General Hospital of Athens "Laiko"-Hematology Department ( Site 1851) Athens, Attica
Georgetown University Medical Center ( Site 0023) Washington D.C., District of Columbia
Gifu University Hospital ( Site 3161) Gifu,
Gleneagles Penang ( Site 0625) George Town, Pulau Pinang
Gold Coast University Hospital ( Site 3028) Southport, Queensland
Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 2545) Paris,
Groupe hospitalier Paris saint Joseph-Service de Pneumologie-Allergologie -Oncologie Thoracique ( Site 2533) Paris, Île-de-France Region
Grupo Medico Angeles ( Site 3402) Guatemala City,
Guangdong Provincial People's Hospital-Cancer Center ( Site 3462) Guangzhou, Guangdong
H. Marques de Valdecilla ( Site 0865) Santander, Cantabria
H.R.U Malaga - Hospital General ( Site 0884) Málaga, Malaga
H.U. Vall de Hebron ( Site 0850) Barcelona,
HENRI MONDOR HOSPITAL ( Site 2561) Créteil, Val-de-Marne
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 0872) Seville,
Hacettepe Universitesi-oncology hospital ( Site 1304) Ankara,
Hadassah Ein Kerem Medical Center ( Site 2051) Jerusalem,
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2801) Hamilton, Ontario
Hangzhou Cancer Hospital-Medical Oncology ( Site 3468) Hangzhou, Zhejiang
Hanoi Oncology Hospital ( Site 3780) Hanoi, Hanoi
Harbin Medical University Cancer Hospital ( Site 3506) Harbin, Heilongjiang
Harbin Medical University Cancer Hospital-Harbin Medical University Cancer Hospital ( Site 3475) Harbin, Heilongjiang
Helios Klinikum Emil von Behring Berlin-Zehlendorf-Lungenklinik Heckeshorn ( Site 2418) Berlin,
Helse Bergen Haukeland universitetssykehus ( Site 1451) Bergen, Vestfold
Henan Cancer Hospital ( Site 3488) Zhengzhou, Henan
Hiroshima City Hiroshima Citizens Hospital ( Site 3119) Hiroshima,
Hiroshima University Hospital ( Site 3154) Hiroshima,
Hokkaido University Hospital ( Site 3165) Sapporo, Hokkaido
Holy Cross Hospital, Michael & Dianne Bienes Comp Cancer Ctr ( Site 0022) Fort Lauderdale, Florida
Hopital Cochin ( Site 2509) Paris,
Hopital Nord ( Site 2516) Marseille, Bouches-du-Rhone
Hopital Saint Louis ( Site 2510) Paris,
Hopital Trousseau ( Site 2512) Chambray-lès-Tours, Indre-et-Loire
Hospital Aleman-Oncology ( Site 1351) Buenos Aires,
Hospital Amaral Carvalho ( Site 1023) Jaú, São Paulo
Hospital Arnau de Vilanova ( Site 0866) Valencia, Valenciana, Comunitat
Hospital Cayetano Heredia-Oncology ( Site 0675) Lima,
Hospital Clinic de Barcelona ( Site 0852) Barcelona, Catalonia
Hospital Clinico San Carlos ( Site 0857) Madrid,
Hospital Clinico Universitario Lozano Blesa ( Site 0859) Zaragoza,
Hospital Clinico de Valencia ( Site 0858) Valencia, Valenciana, Comunitat
Hospital Erasto Gaertner ( Site 1036) Curitiba, Paraná
Hospital General Universitario 12 de Octubre ( Site 0856) Madrid,
Hospital General Universitario de Alicante-Oncologia ( Site 0881) Alicante,
Hospital General Universitario de Valencia ( Site 0854) Valencia, Valenciana, Comunitat
Hospital Metropolitano - Sede Lindora ( Site 3901) Santa Ana, Provincia de San José
Hospital Nossa Senhora da Conceição ( Site 1011) Porto Alegre, Rio Grande do Sul
Hospital Paulistano ( Site 1033) São Paulo,
Hospital Privado Universitario de Córdoba ( Site 1354) Córdoba,
Hospital Provincial del Centenario ( Site 1359) Rosario, Santa Fe Province
Hospital Son Llatzer ( Site 0886) Palma de Mallorca, Balearic Islands
Hospital São Carlos-Oncocentro Ce ( Site 1029) Fortaleza, Ceará
Hospital São Lucas da PUCRS-Centro de Pesquisa em Oncologia ( Site 1006) Porto Alegre, Rio Grande do Sul
Hospital Tacchini ( Site 1040) Bento Gonçalves, Rio Grande do Sul
Hospital Tengku Ampuan Afzan ( Site 0627) Kuantan, Pahang
Hospital Universitari Sant Joan de Reus-Oncology ( Site 0874) Reus, Tarragona
Hospital Universitari Son Espases-Oncologia ( Site 0883) Palma, Balearic Islands
Hospital Universitari i Politecnic La Fe ( Site 0875) Valencia, Valencia
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 1113) Monterrey, Nuevo León
Hospital Universitario Central de Asturias-Medical Oncology ( Site 0870) Oviedo, Principality of Asturias
Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0871) Madrid,
Hospital Universitario Gregorio Maranon ( Site 0864) Madrid,
Hospital Universitario Insular de Gran Canaria ( Site 0867) Las Palmas de Gran Canaria, Las Palmas
Hospital Universitario La Paz ( Site 0853) Madrid,
Hospital Universitario Puerta de Hierro-Majadahonda ( Site 0861) Majadahonda, Madrid
Hospital Universitario Quiron Madrid ( Site 0868) Pozuelo de Alarcón, Madrid
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0877) Madrid, Madrid, Comunidad de
Hospital Universitario Reina Sofia ( Site 0885) Córdoba,
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 0880) Seville,
Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 0882) Seville,
Hospital Universitario Virgen de la Victoria ( Site 0878) Málaga, Andalusia
Hospital Universitario de Donostia ( Site 0890) San Sebastian- Donostia, Basque Country
Hospital de Clinicas de Porto Alegre ( Site 1000) Porto Alegre, Rio Grande do Sul
Hospital de Clínicas de Passo Fundo ( Site 1025) Passo Fundo, Rio Grande do Sul
Hospital de la Santa Creu i Sant Pau-Oncología Médica ( Site 0862) Barcelona, Catalonia
Humanitas Gavazzeni ( Site 1954) Bergamo,
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1968) Rozzano, Milano
Hunan Cancer Hospital ( Site 3485) Changsha, Hunan
Hunan Cancer Hospital ( Site 3501) Changsha, Hunan
Hyogo Cancer Center ( Site 3131) Akashi, Hyōgo
Hyogo Medical University Hospital ( Site 3100) Nishinomiya, Hyōgo
Hôpital Avicenne-Dermatologie ( Site 2538) Bobigny, Seine-Saint-Denis
Hôpital Beaujon ( Site 2524) Clichy, Île-de-France Region
Hôpital Foch ( Site 2543) Suresnes, Hauts-de-Seine
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes-lung oncology ( Site 2546) Saint-Herblain, Loire-Atlantique
Hôpital Privé Clairval ( Site 2549) Marseille, Bouches-du-Rhone
Hôpital Tenon ( Site 2530) Paris,
Hôpital Universitaire Paul Brousse ( Site 2541) Villejuif, Val-de-Marne
Hôpitaux Universitaires de Genève (HUG) ( Site 0753) Geneva, Canton of Geneva
I.E.U. Medical Point Hastanesi-Oncology ( Site 1310) Izmir,
IC La Serena Research ( Site 2766) La Serena, Coquimbo Region
IDIM - Instituto de Investigaciones Metabólicas ( Site 1362) Ciudad de Buenos Aires, Buenos Aires
IMAT S.A.S ( Site 2703) Montería, Departamento de Córdoba
INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1102) Mexico City, Mexico City
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 0681) Lima,
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0678) Lima,
IRCCS A.O.U. San Martino - IST ( Site 1961) Genova,
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1978) Bologna, Emilia-Romagna
IRCCS CRO Aviano, Hematology/Oncology ( Site 1957) Aviano, Pordenone
Ibaraki Prefectural Central Hospital ( Site 3180) Kasama, Ibaraki
Inonu Universitesi ( Site 1309) Malatya,
Institut Bergonie ( Site 2502) Bordeaux, Gironde
Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0851) Badalona, Catalonia
Institut Gustave Roussy ( Site 2513) Villejuif, Île-de-France Region
Institut Jules Bordet ( Site 2903) Anderlecht, Bruxelles-Capitale, Region de
Institut Sainte Catherine ( Site 2557) Avignon, Vaucluse
Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE ( Site 2560) Toulouse, Haute-Garonne
Institut de Cancérologie de Lorraine Alexis Vautrin ( Site 2532) Vandœuvre-lès-Nancy, Lorraine
Institut de Cancérologie de l'Ouest-Oncologie Médicale ( Site 2522) Saint-Herblain, Loire-Atlantique
Institute of Science Tokyo Hospital ( Site 3149) Bunkyō, Tokyo
Instituto Alexander Fleming ( Site 1364) Ciudad Autónoma de Buenos Aires, Buenos Aires
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0860) L'Hospitalet de Llobregat, Barcelona
Instituto Médico Río Cuarto ( Site 1375) Río Cuarto, Córdoba Province
Instituto Nacional De Cancerologia-Oncología Clínica ( Site 2706) Bogota, Cundinamarca
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 1020) Rio de Janeiro,
Instituto Nacional del Cancer-CR Investigación ( Site 2753) Santiago, Region M. de Santiago
Instituto Português de Oncologia do Porto Francisco Gentil, EPE-Oncologia Médica ( Site 1753) Porto,
Instituto San Marcos ( Site 1366) San Juan,
Instituto Valenciano de Oncologia - IVO ( Site 0863) Valencia, Valenciana, Comunitat
Instituto de Cancerología-Oncology ( Site 2702) Medellín, Antioquia
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1363) Mar del Plata, Buenos Aires
Instituto de Oncologia Saint Gallen ( Site 1039) Ssanta Cruz Do Sul, Rio Grande do Sul
Instituto de Oncologia de Rosario ( Site 1350) Rosario, Santa Fe Province
Instituto de de Educação, pesquisa e Gestão em Saúde ( Site 1014) Rio de Janeiro,
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 1001) São Paulo,
Institutul Oncologic "Prof. Dr. Ioan Chiricuta" ( Site 3551) Cluj-Napoca,
Instytut Centrum Zdrowia Matki Polki-Klinika Onkologii ( Site 1609) Lodz, Łódź Voivodeship
Investigación Oncofarmacéutica-Investigación clínica ( Site 1114) La Paz, Baja California Sur
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 1035) Porto Alegree, Rio Grande do Sul
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1302) Istanbul,
Istanbul University Capa Campus ( Site 1314) Istanbul,
Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 1963) Rome, Lazio
Istituto Europeo di Oncologia ( Site 1952) Milan,
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1955) Napoli,
Istituto Oncologico Veneto IRCCS ( Site 1976) Padua, Veneto
Istituto di Candiolo - IRCCS ( Site 1960) Candiolo, Torino
Iwate Medical University Hospital ( Site 3157) Shiwa-gun, Iwate
James Graham Brown Cancer Center ( Site 0058) Louisville, Kentucky
James Lind Centro de Investigacion del Cancer ( Site 2757) Temuco, Región de la Araucanía
Jewish General Hospital ( Site 2800) Montreal, Quebec
Jiangsu Cancer Hospital-Medical Oncotherapy ( Site 3469) Nanjing, Jiangsu
Jichi Medical University Hospital ( Site 3141) Shimotsuke, Tochigi
Jilin Province Tumor Hospital ( Site 3484) Changchun, Jilin
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0038) Hackensack, New Jersey
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 1401) Szolnok, Jász-Nagykun-Szolnok
K Hospital - National Cancer Hospital ( Site 3783) Hanoi, Hanoi
Kagawa University Hospital ( Site 3171) Kita, Kagawa-ken
Kaiser Permanente Moanalua Medical Center ( Site 0063) Honolulu, Hawaii
Kanagawa Cancer Center ( Site 3137) Yokohama, Kanagawa
Kanazawa University Hospital ( Site 3140) Kanazawa, Ishikawa-ken
Kansai Medical University Hospital ( Site 3126) Hirakata, Osaka
Kaohsiung Chang Gung Memorial Hospital ( Site 3203) Kaohsiung City,
Karmanos Cancer Institute ( Site 0047) Detroit, Michigan
Karolinska Universitetssjukhuset Solna ( Site 0802) Stockholm, Stockholm County
Keimyung University Dongsan Hospital CRC room 1 ( Site 0960) Daegu, Taegu-Kwangyokshi
Keio University Hospital ( Site 3127) Tokyo,
Kepler Universitätsklinikum ( Site 2955) Linz, Upper Austria
Kindai University Hospital ( Site 3102) Sakai, Osaka
Kindai University Hospital ( Site 3135) Sakai, Osaka
Kindai University Hospital ( Site 3166) Sakai, Osaka
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2808) Kingston, Ontario
Kitasato University Hospital ( Site 3142) Sagamihara, Kanagawa
Klaipeda University Hospital-Oncology chemotherapy ( Site 3302) Klaipėda, Klaipedos Miestas
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2954) Vienna,
Kobe City Medical Center General Hospital ( Site 3144) Kobe, Hyōgo
Kocaeli Üniversitesi ( Site 1313) Kocaeli,
Kochi Health Sciences Center ( Site 3145) Kochi,
Koo Foundation Sun Yat-Sen Cancer Center-Gynecology, Obstetrics, and women's health ( Site 3207) Taipei,
Korea University Anam Hospital ( Site 0956) Seoul,
Korea University Guro Hospital ( Site 0963) Seoul,
Krankenhaus Nordwest ( Site 2409) Frankfurt am Main, Hesse
Kumamoto University Hospital ( Site 3179) Kumamoto,
Kurashiki Central Hospital ( Site 3132) Kurashiki, Okayama-ken
Kurume University Hospital ( Site 3105) Kurume, Fukuoka
Kyorin University Hospital ( Site 3103) Mitaka, Tokyo
Kyorin University Hospital ( Site 3147) Mitaka-shi, Tokyo
Kyoto University Hospital ( Site 3181) Kyoto,
Kyungpook National University Chilgok Hospital ( Site 0964) Deagu, Taegu-Kwangyokshi
Kyushu University Hospital ( Site 3143) Fukuoka,
Kyushu University Hospital ( Site 3185) Fukuoka,
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2005) Pretoria, Gauteng
LLC Clinic Verum Expert ( Site 3669) Kyiv, Kyivska Oblast
Lacks - Oncologia E Hematologia ( Site 1026) Pelotas, Rio Grande do Sul
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032) New York, New York
Levine Cancer Institute ( Site 0034) Charlotte, North Carolina
Liepjas reionl slimnca ( Site 3851) Liepāja,
LinYi Cancer Hospital ( Site 3511) Linyi, Shandong
Liv Hospital Ankara ( Site 1330) Ankara,
Liverpool Hospital-Medical Oncology ( Site 3021) Liverpool, New South Wales
London Regional Cancer Program - LHSC ( Site 2806) London, Ontario
Lung Center of the Philippines ( Site 1705) Quezon City, National Capital Region
LungenClinic Grosshansdorf GmbH ( Site 2412) Großhansdorf, Schleswig-Holstein
Luxmed Onkologia sp. z o. o. ( Site 1621) Warsaw, Masovian Voivodeship
ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 3668) Dnipro, Dnipropetrovsk Oblast
MEDI-K ( Site 3403) Guatemala City,
MEMORIAL HEALTHCARE INTERNATIONAL S.R.L ( Site 3553) Bucharest, București
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional-Chemotherapy department ( Site 3657) Kryvyi Rih, Dnipropetrovsk Oblast
MNPE Regional Center of Oncology ( Site 3665) Kharkiv, Kharkivs’ka Oblast’
Mackay Memorial Hospital ( Site 3205) Taipei,
Macquarie University ( Site 3010) Macquarie University, New South Wales
Makati Medical Center ( Site 1702) Makati City, National Capital Region
Markusovszky Egyetemi Oktatokorhaz-Onkológiai Osztály ( Site 1410) Szombathely, Vas County
Marmara Universitesi Pendik Egitim Arastirma Hastanesi-Medical Oncology ( Site 1305) Istanbul,
Maryland Oncology Hematology (MOH) ( Site 8000) Columbia, Maryland
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0703) Brno, Brno-mesto
Massachusetts General Hospital ( Site 0041) Boston, Massachusetts
Mater Hospital Sydney ( Site 3007) North Sydney, New South Wales
Mater Misercordiae University Hospital ( Site 1800) Dublin, Leinster
Mater Misericordiae Limited-Medical Oncology ( Site 3019) Brisbane, Queensland
Mayo Clinic in Rochester, Minnesota ( Site 0002) Rochester, Minnesota
McGill University Health Centre ( Site 2818) Montreal, Quebec
Med-Polonia Sp. z o. o. ( Site 1605) Poznan, Greater Poland Voivodeship
MedStar Franklin Square Medical Center ( Site 0046) Baltimore, Maryland
Medical Care and Research SA de CV ( Site 1103) Mérida, Yucatán
Medical University of Graz ( Site 2952) Graz, Styria
Medipol Mega Universite Hastanesi ( Site 1326) Istanbul,
Medizinische Hochschule Hannover ( Site 2402) Hanover, Lower Saxony
Medizinische Universitaet Innsbruck ( Site 2951) Innsbruck, Tyrol
Medizinische Universität Wien ( Site 2953) Vienna,
Melanoma Institute Australia ( Site 3001) Wollstonecraft, New South Wales
Memorial Antalya Hospital-Oncology ( Site 1315) Antalya,
Memorial Sloan Kettering Cancer Center ( Site 0012) New York, New York
Mercy Health-Paducah Cancer Center ( Site 0084) Paducah, Kentucky
Mid Essex Hospitals Service Trust. Broomfield Hospital ( Site 0503) Broomfield, Essex
Miyagi Cancer Center ( Site 3122) Natori-shi, Miyagi
Moffitt Cancer Center ( Site 0011) Tampa, Florida
Monash Health ( Site 3015) Clayton, Victoria
Mount Sinai Hospital ( Site 2811) Toronto, Ontario
Mount Sinai Medical Center Comprehensive Cancer Center ( Site 0031) Miami Beach, Florida
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council ( Site 3650) Dnipro, Dnipropetrovsk Oblast
Municipal institution of Lviv regional council Lviv Oncology-Chemotherapy ( Site 3653) Lviv, Lviv Oblast
Municipal non-profit enterprise "Kyiv City Clinical Oncology Center" of executive body of Kyiv City ( Site 3651) Kyiv, Kyivska Oblast
Municipal non-profit enterprise "Zaporizhzhia regional clinical hospital" of Zaporizhzhia regional c ( Site 3664) Zaporizhzhia, Zaporizhzhia Oblast
Mátrai Gyógyintézet ( Site 1417) Gyöngyös, Heves County
N.N. Blokhin NMRCO ( Site 1209) Moscow, Moscow
N.N.Petrov Research Institute of Oncology-Department of Preclinical and Clinical Research ( Site 1211) Saint Petersburg, Sankt-Peterburg
Nagoya University Hospital ( Site 3151) Nagoya, Aichi-ken
Nara Medical University Hospital ( Site 3110) Kashihara, Nara
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1620) Gliwice, Silesian Voivodeship
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 1608) Krakow, Lesser Poland Voivodeship
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1604) Warsaw, Masovian Voivodeship
National Cancer Center ( Site 0955) Goyang-si, Kyonggi-do
National Cancer Center Hospital ( Site 3130) Tokyo,
National Cancer Center Hospital East ( Site 3121) Kashiwa, Chiba
National Cancer Centre Singapore ( Site 2200) Singapore, Central Singapore
National Cancer Institute-Department of Minimally Invasive and Endoscopic Surgery, Interventional R ( Site 3658) Kyiv, Kyivska Oblast
National Cheng Kung University Hospital ( Site 3201) Tainan,
National Defense Medical College Hospital ( Site 3177) Tokorozawa, Saitama
National Hospital Organization Himeji Medical Center ( Site 3111) Himeji, Hyōgo
National Hospital Organization Hokkaido Cancer Center ( Site 3160) Sapporo, Hokkaido
National Hospital Organization Kyushu Cancer Center ( Site 3169) Fukuoka,
National Hospital Organization Kyushu Medical Center ( Site 3136) Fukuoka,
National Hospital Organization Nagoya Medical Center ( Site 3109) Nagoya, Aichi-ken
National Hospital Organization Osaka National Hospital ( Site 3162) Osaka,
National Hospital Organization Shikoku Cancer Center ( Site 3116) Matsuyama, Ehime
National Hospital Organization Yamaguchi Ube Medical Center ( Site 3123) Ube, Yamaguchi
National Lung Hospital ( Site 3781) Hanoi, Hanoi
National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1210) Saint Petersburg, Sankt-Peterburg
National Taiwan University Hospital ( Site 3200) Taipei,
National Taiwan University Hospital - Hsinchu branch ( Site 3208) Hsinchu,
National University Hospital-Haematology -Oncology Research Group ( Site 2201) Singapore, South West
New Cross Hospital-Department of Oncology ( Site 0517) Wolverhampton,
Niigata Cancer Center Hospital ( Site 3173) Niigata, Niigata
Niigata University Medical & Dental Hospital ( Site 3174) Niigata,
Nippon Medical School Hospital ( Site 3139) Tokyo,
Nippon Medical School Musashi Kosugi Hospital ( Site 3178) Kawasaki, Kanagawa
Norrlands Universitetssjukhus ( Site 0800) Umeå, Västerbotten County
Northern Jiangsu People's Hospital-General Surgery Department ( Site 3474) Yangzhou, Jiangsu
Northwest Georgia Oncology Centers PC ( Site 0061) Marietta, Georgia
Nottingham University Hospitals NHS Trust ( Site 0510) Nottingham, Nottinghamshire
Nouvel Hôpital Civil (NHC) ( Site 2529) Strasbourg, Alsace
ONCOCENTRO APYS-ACEREY ( Site 2758) Viña del Mar, Región de Valparaíso
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 1008) Ijuí, Rio Grande do Sul
Oaxaca Site Management Organization ( Site 1106) Oaxaca City, Oaxaca
Obstetrics & Gynecology Hospital of Fudan University ( Site 3494) Shanghai, Shanghai Municipality
Odense Universitetshospital ( Site 0650) Odense, Region Syddanmark
Odessa Regional Oncology Center ( Site 3655) Odesa, Odesa Oblast
Ogarev Mordovia State University ( Site 1206) Saransk, Mordoviya, Respublika
Okayama University Hospital ( Site 3107) Okayama,
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0082) Tulsa, Oklahoma
Oncare Viaducto Napoles ( Site 1107) Mexico City,
Oncological Dispensary #2 of Ministry of Health of Krasnodar region ( Site 1244) Sochi, Krasnodarskiy Kray
Oncologos del Occidente ( Site 2709) Pereira, Risaralda Department
Oncomedica ( Site 3401) Guatemala City,
Oncovida ( Site 2759) Santiago, Region M. de Santiago
Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Kosza-Klinika Onkologii z Odcinkiem Dziennym ( Site 1616) Opole, Opole Voivodeship
Orange Hospital-Clinical Trials Unit ( Site 3027) Orange, New South Wales
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 2957) Linz, Upper Austria
Orlandi Oncologia-Oncology ( Site 2752) Santiago, Region M. de Santiago
Orszagos Koranyi Pulmonologiai Intezet ( Site 1403) Budapest,
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1411) Budapest, Pest County
Osaka City General Hospital ( Site 3125) Osaka,
Osaka General Medical Center ( Site 3184) Osaka,
Osaka Habikino Medical Center ( Site 3138) Habikino, Osaka
Osaka Medical and Pharmaceutical University Hospital ( Site 3167) Takatsuki, Osaka
Osaka Medical and Pharmaceutical University Hospital ( Site 3187) Takatsuki, Osaka
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 3129) Osaka,
Osaka Rosai Hospital ( Site 3148) Sakai, Osaka
Oslo Universitetssykehus Radiumhospitalet ( Site 1450) Oslo,
Oslo universitetssykehus, Radiumhospitalet ( Site 1452) Oslo,
Ospedale Cannizzaro ( Site 1981) Catania, Sicily
Ospedale San Luigi Gonzaga ( Site 1956) Orbassano, Torino
Ospedale San Raffaele. ( Site 1979) Milan,
P. A. Hertsen Moscow Oncology Research Center ( Site 1214) Moscow, Moscow
P. A. Hertsen Moscow Oncology Research Center ( Site 1247) Moscow, Moscow
Palmerston North Hospital, MidCentral DHB ( Site 1504) Palmerston North, Manawatu-Wanganui
Pantai Hospital Kuala Lumpur ( Site 0628) Kuala Lumpur,
Parc de Salut Mar - Hospital del Mar-Oncologia ( Site 0873) Barcelona,
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3008) Melbourne, Victoria
Policlinico Universitario Agostino Gemelli ( Site 1965) Roma,
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 2751) Santiago, Region M. de Santiago
Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3020) Port Macquarie, New South Wales
Powiatowe Centrum Zdrowia w Brzezinach Sp. z o. o. Oddział Dziennej Chemioterapii ( Site 1611) Brzeziny, Łódź Voivodeship
Princess Alexandra Hospital ( Site 3002) Woolloongabba, Queensland
Princess Margaret Cancer Centre ( Site 2803) Toronto, Ontario
Princess Margaret Hospital ( Site 1903) Hong Kong,
Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 3656) Kropyvnytskyi, Kirovohrad Oblast
Providence Medical Foundation ( Site 0087) Fullerton, California
Providence Portland Medical Center ( Site 0051) Portland, Oregon
Providence Saint John's Health Center ( Site 0059) Santa Monica, California
Przychodnia Lekarska KOMED ( Site 1603) Konin, Greater Poland Voivodeship
Queen Mary Hospital ( Site 1902) Hksar,
Queen Mary Hospital-Department of Medicine (Respiratory) ( Site 1900) Hksar,
RIGA EAST UNIVERSITY HOSPITAL ,Oncology Centre of Latvia-Out-patient and Day patient facility of Ch ( Site 3850) Riga,
Rabin Medical Center ( Site 2059) Petah Tikva,
Radboud University Medical Center ( Site 1554) Nijmegen, Gelderland
Ramathibodi Hospital. ( Site 2364) Bangkok, Bangkok
Rambam Health Care Campus-Oncology Division ( Site 2053) Haifa,
Regional Budgetary Healthcare Institution 'Ivanovo Regional Oncology Dispensary'-Urology ( Site 1219) Ivanovo, Ivanovo Oblast
Republican Clinical Oncology Dispensary ( Site 1228) Kazan', Tatarstan, Respublika
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1204) Ufa, Baskortostan, Respublika
Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 1203) Kazan', Tatarstan, Respublika
Royal Adelaide Hospital ( Site 3014) Adelaide, South Australia
Royal Brisbane and Women's Hospital ( Site 3009) Herston, Queensland
Royal Free Hospital ( Site 0507) London, London, City of
Royal Marsden Hospital ( Site 0505) London, London, City of
Royal North Shore Hospital-Medical Oncology Clinical Trials ( Site 3025) St Leonards, New South Wales
Royal Preston Hospital ( Site 0518) Preston, Lancashire
Royal Prince Alfred Hospital-A.W. Morrow Gastroenterology and Liver Centre ( Site 3016) Camperdown, New South Wales
Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1201) Moscow, Moscow
Russian Scientific Center of Roentgenoradiology ( Site 1215) Moscow, Moscow
Russian Scientific Research Institute of Hematology and Blood Transfusion-Hematology ( Site 1224) Saint Petersburg, Sankt-Peterburg
SAIH of the Tyumen region, Multidisciplinary Clinical Medical Center "Medical town" ( Site 1220) Tyumen, Tyumen Oblast
SO"Grigoriev Inst for Med Radiolgy and Oncology of NAMS of Ukraine" ( Site 3666) Kharlkiv, Kharkivs’ka Oblast’
SRH Wald-Klinikum Gera GmbH ( Site 2403) Gera, Thuringia
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal Medicine ( Site 3452) Guangzhou, Guangdong
Sahlgrenska Universitetssjukhuset-Department of Oncology CTU Clinical Trial Unit ( Site 0803) Gothenburg, Västra Götaland County
Saint Francis Health System ( Site 0089) Greenville, South Carolina
Saitama Medical University International Medical Center ( Site 3118) Hidaka, Saitama
Saitama Prefectural Cancer Center ( Site 3112) Kitaadachi-gun, Saitama
Sakarya University School of Medicine ( Site 1332) Sakarya,
Samsun Medical Park Hastanesi ( Site 1328) Samsun,
Samsung Medical Center ( Site 0950) Seoul,
Samsung Medical Center ( Site 0970) Seoul,
Samsung Medical Center ( Site 0971) Seoul,
Sanatorio Parque ( Site 1355) Rosario, Santa Fe Province
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 2004) Sandton, Gauteng
Sanford Cancer Center ( Site 0066) Sioux Falls, South Dakota
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0065) Fargo, North Dakota
Sapporo Kosei General Hospital ( Site 3172) Sapporo, Hokkaido
Sapporo Medical University Hospital ( Site 3113) Sapporo, Hokkaido
Sarah Cannon Research UK ( Site 0504) London, London, City of
Semmelweis University-Belgyógyászati és Hematológiai Klinika ( Site 1406) Budapest,
Sendai Kousei Hospital ( Site 3115) Sendai, Miyagi
Seoul National University Bundang Hospital ( Site 0951) Seongnam-si, Kyonggi-do
Seoul National University Hospital ( Site 0953) Seoul,
Severance Hospital ( Site 0954) Seoul,
Severance Hospital, Yonsei University Health System ( Site 0962) Seoul,
Shaare Zedek Medical Center ( Site 2068) Jerusalem,
Shamir Medical Center Assaf Harofeh ( Site 2058) Ẕerifin,
Shandong Cancer Hospital ( Site 3517) Jinan, Shandong
Shanghai Pulmonary Hospital ( Site 3470) Shanghai, Shanghai Municipality
Sheba Medical Center ( Site 2062) Ramat Gan,
Sheba Medical Center ( Site 2065) Ramat Gan,
Shizuoka Cancer Center ( Site 3128) Nakatogari, Shizuoka
Sichuan Cancer hospital. ( Site 3515) Chengdu, Sichuan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0056) Baltimore, Maryland
Sir Charles Gairdner Hospital ( Site 3006) Nedlands, Western Australia
Sir Run Run Shaw Hospital ( Site 3505) Hangzhou, Zhejiang
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 2704) Valledupar, Cesar Department
Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1402) Kaposvár,
Songklanagarind Hospital ( Site 2367) Hat Yai, Changwat Songkhla
Sotiria Regional Chest Diseases Hospital of Athens ( Site 1850) Athens, Attica
Sourasky Medical Center ( Site 2054) Tel Aviv,
South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001) San Antonio, Texas
Southern medical university Nangfang Hospital ( Site 3490) Guanghzou, Guangdong
Spitalul Județean Sfântul Ioan cel Nou Suceava-Oncology ( Site 3550) Suceava,
St James University Hospital ( Site 0509) Leeds,
St John of God Subiaco Hospital ( Site 3013) Subiaco, Western Australia
St Vincent's Hospital-Oncology Clinical Trials ( Site 3018) Melbourne, Victoria
St. James s Hospital ( Site 1801) Dublin,
St. Luke s Medical Center ( Site 1700) Quezon City, National Capital Region
St. Luke's University Health Network ( Site 0017) Bethlehem, Pennsylvania
St. Marianna University Hospital ( Site 3182) Kawasaki, Kanagawa
St. Marys Hospital Center ( Site 2820) Montreal, Quebec
St. Petersburg Clinical Hospital of Russian Academy Of Sciences ( Site 1235) Saint Petersburg, Sankt-Peterburg
St.Luke's International Hospital ( Site 3120) Tokyo,
Stanford Cancer Center ( Site 0086) Palo Alto, California
Sumy regional clinical oncological dispensary-Oncothoracic department ( Site 3661) Sumy, Sumska Oblast
Sun Yat-sen University Cancer Center-melanoma ( Site 3482) Guangzhou, Guangdong
Sunnybrook Research Institute ( Site 2802) Toronto, Ontario
Sunshine Coast University Private Hospital-Coastal Cancer Care ( Site 3032) Sunshine Coast, Queensland
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu Medycznego im. K. Marcinkowskiego w Pozna ( Site 1601) Poznan, Greater Poland Voivodeship
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1625) Gdynia, Pomeranian Voivodeship
Szpital Rejonowy im. dr. J. Rostka w Raciborzu ( Site 1624) Racibórz, Silesian Voivodeship
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1618) Krakow, Lesser Poland Voivodeship
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 1614) Koszalin, West Pomeranian Voivodeship
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1316) Istanbul,
Taipei Medical University Hospital ( Site 3211) Taipei,
Taipei Veterans General Hospital ( Site 3202) Taipei,
Tallaght University Hospital ( Site 1803) Dublin,
Tampere University Hospital [Tampere Finland] ( Site 0600) Tampere, Pirkanmaa
Tangdu Hospital of Fourth Military Medical University of Chi-department of radiotherapy ( Site 3455) Xi'an, Shaanxi
Tartu University Hospital-Radiotherapy and oncology ( Site 3800) Tartu, Tartu
Tasman Oncology Research Pty Ltd ( Site 3012) Southport, Queensland
Teikyo University Hospital ( Site 3104) Tokyo,
Texas Oncology - Central/South Texas ( Site 8001) Austin, Texas
Texas Oncology-Baylor Sammons Cancer Center ( Site 0062) Dallas, Texas
The Affiliated Cancer Hospital of Guizhou Medical University ( Site 3498) Guiyang, Guizhou
The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 3502) Ürümqi, Xinjiang
The Angeles Clinic and Research Institute ( Site 0005) Los Angeles, California
The Beatson West of Scotland Cancer Centre ( Site 0506) Glasgow, Glasgow City
The Catholic University Of Korea St. Vincent's Hospital ( Site 0968) Suwon, Kyonggi-do
The Christie ( Site 0516) Manchester, England
The Fifth Medical Center Of The Chinese PLA General Hospital (South) ( Site 3465) Beijing, Beijing Municipality
The First Affiliated Hospital of Guangzhou Medical University-thoracic surgery department ( Site 3460) Guangzhou, Guangdong
The First Affiliated Hospital of Nanchang University ( Site 3513) Nanchang, Jiangxi
The First Affiliated Hospital of Xi an Jiaotong University ( Site 3489) XiAn, Shanxi
The First Affiliated Hospital of Xiamen University ( Site 3514) Xiamen, Fujian
The First Affiliated Hospital, Sun Yat-sen University-pneumology department ( Site 3459) Guangzhou, Guangdong
The First Hospital of Jilin University-Oncology ( Site 3464) Changchun, Jilin
The Jikei University Hospital ( Site 3156) Tokyo,
The National Medico-Surgical Center N.I. Pirogov ( Site 1225) Moscow, Moscow
The Oncology Centre ( Site 2000) Durban, KwaZulu-Natal
The Ottawa Hospital - General Campus ( Site 2813) Ottawa, Ontario
The Queen Elizabeth Hospital ( Site 3026) Woodville, South Australia
The Royal Marsden NHS Foundation Trust. ( Site 0513) Sutton,
The Second People's Hospital of Yibin ( Site 3516) Yibin, Sichuan
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 3491) Guangzhou, Guangdong
The Townsville Hospital ( Site 3017) Townsville, Queensland
The University of Chicago ( Site 0020) Chicago, Illinois
The University of Osaka Hospital ( Site 3168) Suita, Osaka
Tianjin Medical University Cancer Institute and Hospital ( Site 3456) Tianjin, Tianjin Municipality
Tohoku University Hospital ( Site 3175) Sendai, Miyagi
Tokyo Medical University Hospital ( Site 3170) Shinjuku-ku, Tokyo
Tokyo Metropolitan Komagome Hospital ( Site 3133) Tokyo,
Tomsk Scientific Research Institute of Oncology ( Site 1227) Tomsk, Tomsk Oblast
Tongji Hospital Tongji Medical,Science & Technology-oncology ( Site 3476) Wuhan, Hubei
Toranomon Hospital ( Site 3134) Minato-ku, Tokyo
Toranomon Hospital ( Site 3153) Minato-ku, Tokyo
Toyama Prefectural Central Hospital ( Site 3183) Toyama,
Trakya Universitesi Tip Fakultesi ( Site 1301) Edirne,
Transcarpathian Regional Clinical Oncology Center-Chemotherapy dept. ( Site 3652) Uzhhorod, Zakarpattia Oblast
Turku University Hospital ( Site 0601) Turku, Southwest Finland
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0009) Los Angeles, California
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004) San Francisco, California
UNIVERSIDAD CATÓLICA DEL MAULE ( Site 2768) Talca, Maule Region
UPMC Hillman Cancer Center ( Site 0008) Pittsburgh, Pennsylvania
UPR Comprehensive Cancer Center ( Site 1150) San Juan,
UZ Brussel ( Site 2900) Brussels, Bruxelles-Capitale, Region de
UZ Leuven ( Site 2901) Leuven, Vlaams-Brabant
UZ Leuven - Campus Gasthuisberg ( Site 2906) Leuven, Vlaams-Brabant
UZ Leuven Gasthuisberg, Gynaecologie-Verloskunde ( Site 2907) Leuven, Vlaams-Brabant
Udmurtian Republican Clinical Oncology Center ( Site 1212) Izhevsk, Udmurtiya Republic
Umraniye Training and Research Hospital ( Site 1329) Istanbul,
Unidade Local de Saude de Santa Maria - Hospital Pulido Valente ( Site 1750) Lisbon,
Uniklinikum Salzburg ( Site 2956) Salzburg,
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3492) Wuhan, Hubei
Universitaetsklinik Muenchen ( Site 2406) Munich, Bavaria
Universitaetsklinikum Essen ( Site 2404) Essen, North Rhine-Westphalia
Universitaetsklinikum Tuebingen ( Site 2405) Tübingen, Baden-Wurttemberg
Universitaetsklinikum des Saarlandes-Klinik für Innere Medizin V-Pneumologie, Allergologie, Beatmun ( Site 2411) Homburg, Saarland
Universitaetsspital Zuerich ( Site 0750) Zürich-Flughafen, Canton of Zurich
Universitair Medisch Centrum Groningen ( Site 1550) Groningen,
Universitatsklinikum Carl Gustav Carus ( Site 2407) Dresden, Saxony
University College London Hospital-Cancer Clinical Trials Unit ( Site 0520) London, London, City of
University Hospital Basel ( Site 0752) Basel, Canton of Basel-City
University Hospital Coventry & Warwickshire ( Site 0524) Coventry,
University Hospitals ( Site 0044) Cleveland, Ohio
University Malaya Medical Centre ( Site 0626) Kuala Lumpur,
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0076) Orange, California
University of Colorado Cancer Center ( Site 0021) Aurora, Colorado
University of Iowa Hospital and Clinics ( Site 0026) Iowa City, Iowa
University of North Carolina at Chapel Hill ( Site 0040) Chapel Hill, North Carolina
University of Pennsylvania ( Site 0010) Philadelphia, Pennsylvania
University of Texas MD Anderson Cancer Center ( Site 0007) Houston, Texas
University of Tsukuba Hospital ( Site 3176) Tsukuba, Ibaraki
University of Virginia Health System ( Site 0035) Charlottesville, Virginia
University of the Ryukyus Hospital ( Site 3155) Ginowan, Okinawa
Universitätsklinikum Erlangen ( Site 2408) Erlangen, Bavaria
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi ( Site 2909) Namur,
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 1607) Poznan, Greater Poland Voivodeship
Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site 1622) Gdansk, Pomeranian Voivodeship
Uzhhorod City Multidisciplinary Clinical Hospital ( Site 3672) Uzhhorod, Zakarpattia Oblast
Uzsoki Utcai Kórház-Onkoradiológiai Osztály ( Site 1413) Budapest,
VCU Health Adult Outpatient Pavillion ( Site 0080) Richmond, Virginia
Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060) Nashville, Tennessee
Vanderbilt Ingram Cancer Center ( Site 0015) Nashville, Tennessee
Vejle Sygehus ( Site 0653) Vejle, Region Syddanmark
Vilniaus Universiteto Ligonine Santaros Klinikos ( Site 3300) Vilnius,
Vilnius University Hospital Santaros Clinics Affiliate - National Cancer Center ( Site 3301) Vilnius,
Volga District Medical Center Federal Medical and Biological Agency ( Site 1242) Nizhny Novgorod, Nizhny Novgorod Oblast
WCR Office ( Site 2002) Johannesburg, Gauteng
Waikato Hospital ( Site 1502) Hamilton, Waikato Region
Wakayama Medical University Hospital ( Site 3124) Wakayama,
WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074) Cary, North Carolina
West Cancer Center and Research Institute ( Site 0055) Germantown, Tennessee
West China Hospital Sichuan University-respiratory ( Site 3473) Chengdu, Sichuan
Western General Hospital ( Site 0502) Edinburgh, Edinburgh, City of
Western Health-Sunshine & Footscray Hospitals ( Site 3023) St Albans, Victoria
Westmead Hospital ( Site 3000) Westmead, New South Wales
Weston Park Hospital ( Site 0519) Sheffield, England
White Plains Hospital-Center for Cancer Care ( Site 0069) White Plains, New York
Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 1619) Poznan, Greater Poland Voivodeship
Wilgers Oncology Centre ( Site 2006) Pretoria, Gauteng
Wojskowy Instytut Medyczny-Klinika Onkologii ( Site 1606) Warsaw, Masovian Voivodeship
Women s Hospital School of Medicine Zhejiang University ( Site 3493) Hangzhou, Zhejiang
Women's Cancer Care ( Site 0088) Covington, Louisiana
Xiangya Hospital Central South University ( Site 3508) Changsha, Hunan
Xiangya Hospital Central South University-Gynecology ( Site 3497) Changsha, Hunan
Xiangya Hospital Central South University-Respiratory ( Site 3479) Changsha, Hunan
Xinjiang Medical University Cancer Hospital - Urumqi-galactophore department ( Site 3486) Ürümqi, Xinjiang
Yale Cancer Center ( Site 0014) New Haven, Connecticut
Yamaguchi University Hospital ( Site 3114) Ube, Yamaguchi
Yancheng First People s Hospital ( Site 3504) Yancheng, Jiangsu
Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1243) Yaroslavl, Yaroslavl Oblast
Yokohama City University Hospital ( Site 3163) Yokohama, Kanagawa
Yokosuka Kyosai Hospital ( Site 3150) Yokosuka, Kanagawa
ZIV Medical Center-Hematology Institute ( Site 2061) Safed,
Zala Megyei Szent Rafael Korhaz ( Site 1400) Zalaegerszeg,
Zhejiang Cancer Hospital ( Site 3481) Hangzhou, Zhejiang
Zhejiang Cancer Hospital ( Site 3495) Hangzhou, Zhejiang
Zhongshan Hospital of Fudan University ( Site 3503) Shanghai, Shanghai Municipality
Zhytomyr Regional Oncology Center ( Site 3670) Zhytomyr, Zhytomyr Oblast
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 1969) Siena,

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

ctrrecruit@vcu.edu

NCT06126276
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N5 based on the presence of an actionable mutation as defined in EAY191 * Patients must have a HER2 amplified solid tumor except breast cancer. Patient's cancer must have HER2 amplification as defined with ≥ 7 copies by next generation sequencing (NGS) testing * Patients must have recurrent or persistent disease * No known evidence of RB1 loss or deletion including copy number loss or deleterious mutation * Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191) * Patients must have measurable disease based on RECIST 1.1. A second measurable lesion outside of the biopsiable lesion is required * Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression for 3 months or more and patient is not on steroids and is asymptomatic * No known leptomeningeal disease * Patients may have received up to 5 prior lines of systemic therapy * Prior therapy with trastuzumab or pertuzumab, either alone or in combination, antibody drug conjugates (ADC) such as DS8201a or T-DM1 is allowed * Prior therapy with tyrosine kinase inhibitors (TKI) such as neratinib or tucatinib is not allowed * No prior therapy with CDK4/6 inhibition * No cancer directed therapy within 3 weeks prior to registration. For oral therapy, the washout can be reduced to greater than or equal to 5 half lives of the drug. No HER2 targeting ADCs within 30 days prior to registration * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 * Not pregnant and not nursing * Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3 * Platelets ≥ 100,000 cells/mm\^3 * Hemoglobin ≥ 9 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin (Hgb) ≥ 9 g/dl is acceptable) * Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula * Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional upper limit of normal (ULN) * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * No active infection requiring parenteral antibiotics * No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube * No current evidence of malabsorption or chronic diarrhea or any other significant gastro-intestinal disease (e.g gastrectomy, ileal bypass, Crohn's disease, gastroparesis), associated with moderate to severe diarrhea (grade 2 or more) or inability to tolerate oral therapy * No lung disease causing dyspnea at rest * No interstitial lung disease with ongoing signs and symptoms at the time of registration * No history of allergic reaction to the study agents, compound of similar chemical or biologic composition of the study agents or any of their excipients
PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, PROCEDURE: Echocardiography Test, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Multigated Acquisition Scan, DRUG: Neratinib Maleate, DRUG: Palbociclib
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
I'm interested
Share via email
Show 175 locations

Study Locations

Hide all locations
Location Contacts
Alaska Women's Cancer Care Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Asplundh Cancer Pavilion Willow Grove, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Ballad Health Cancer Care - Bristol Bristol, Virginia Site Public Contact - (charles.mays@balladhealth.org)
Ballad Health Cancer Care - Kingsport Kingsport, Tennessee Site Public Contact - (charles.mays@balladhealth.org)
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Bristol Regional Medical Center Bristol, Tennessee Site Public Contact - (charles.mays@balladhealth.org)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Carle BroMenn Medical Center Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Cancer Institute Normal Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Cedars Sinai Medical Center Los Angeles, California
Columbus Oncology and Hematology Associates Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Columbus Oncology and Hematology Associates Inc Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Corewell Health Beaumont Troy Hospital Troy, Michigan
Corewell Health Dearborn Hospital Dearborn, Michigan
Corewell Health Farmington Hills Hospital Farmington Hills, Michigan
Corewell Health William Beaumont University Hospital Royal Oak, Michigan
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dayton Physician LLC - Englewood Dayton, Ohio
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Delaware Health Center-Grady Cancer Center Delaware, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Doctors Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Dublin Methodist Hospital Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Duke University Medical Center Durham, North Carolina
Duke Women's Cancer Care Raleigh Raleigh, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Genesee Hematology Oncology PC Flint, Michigan
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Grady Memorial Hospital Delaware, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Grant Medical Center Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
Harold Alfond Center for Cancer Care Augusta, Maine
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Inova Fairfax Hospital Falls Church, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
Inova Schar Cancer Institute Fairfax, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
Jersey City Medical Center Jersey City, New Jersey Site Public Contact - (Roster@nrgoncology.org)
John H Stroger Jr Hospital of Cook County Chicago, Illinois
Kettering Medical Center Kettering, Ohio
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Lafayette Family Cancer Center-EMMC Brewer, Maine
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MaineHealth Maine Medical Center- Scarborough Scarborough, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Marshfield Medical Center - Minocqua Minocqua, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic in Rochester Rochester, Minnesota
Mercyhealth Cancer Institute - Rockford Rockford, Illinois Site Public Contact - (oncologyclinicaltrials@mhemail.org)
Miami Valley Cancer Care and Infusion Greenville, Ohio
Miami Valley Hospital Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Monmouth Medical Center Southern Campus Lakewood, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
National Institutes of Health Clinical Center Bethesda, Maryland
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan Site Public Contact - (WI_research_admin@hshs.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
OhioHealth Mansfield Hospital Mansfield, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Marion General Hospital Marion, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth O'Bleness Hospital Athens, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Pickerington Methodist Hospital Pickerington, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Westerville Medical Campus/Westerville Cancer Center Westerville, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Premier Blood and Cancer Center Dayton, Ohio
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Regional Cancer Center at Johnson City Medical Center Johnson City, Tennessee Site Public Contact - (charles.mays@balladhealth.org)
Riverside Methodist Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
SIH Cancer Institute Carterville, Illinois Site Public Contact - (clinical.research@sih.net)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint John's Hospital - Healtheast Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Hospital East Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sanford Bismarck Medical Center Bismarck, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Joe Lueken Cancer Center Bemidji, Minnesota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Roger Maris Cancer Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Southeastern Medical Oncology Center-Clinton Clinton, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Goldsboro Goldsboro, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Jacksonville Jacksonville, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southern Illinois University School of Medicine Springfield, Illinois
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
State University of New York Upstate Medical University Syracuse, New York
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The Angeles Clinic and Research Institute - West Los Angeles Office Los Angeles, California Site Public Contact - (ctsucontact@westat.com)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
UC San Diego Health System - Encinitas Encinitas, California
UC San Diego Medical Center - Hillcrest San Diego, California Site Public Contact - (rhabbaba@health.ucsd.edu)
UC San Diego Moores Cancer Center La Jolla, California Site Public Contact - (cancercto@ucsd.edu)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Coral Springs Coral Springs, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
UPMC Altoona Altoona, Pennsylvania Site Public Contact - (Roster@nrgoncology.org)
UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania Site Public Contact - (ClinicalResearchServices@upmc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania Site Public Contact - (ClinicalResearchServices@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Western Maryland Cumberland, Maryland
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania
UPMC-Passavant Hospital Pittsburgh, Pennsylvania
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Site Public Contact - (gingerreeves@uabmc.edu)
University of Illinois Chicago, Illinois
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of South Alabama Mitchell Cancer Institute Mobile, Alabama Site Public Contact - (pfrancisco@usouthal.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
Upper Valley Medical Center Troy, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Walter Reed National Military Medical Center Bethesda, Maryland
Wellmont Holston Valley Hospital and Medical Center Kingsport, Tennessee Site Public Contact - (charles.mays@balladhealth.org)
West Virginia University Healthcare Morgantown, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Woodland Cancer Care Center Michigan City, Indiana

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

ctrrecruit@vcu.edu

NCT06589804
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Histologically confirmed diagnosis head and neck squamous cell carcinomas (HNSCC). * Previously untreated for recurrent and/or metastatic disease incurable by local therapies. * Primary tumor location of oral cavity, oropharynx, larynx, or hypopharynx. * Note: Other primary tumor sites of HNSCC, including nasopharynx primary tumor are not eligible. Unknown primary tumors may be eligible and can be enrolled at the discretion of the treatment team with approval by the study chair. * Measurable disease. * Must have platinum-refractory disease defined as disease progression during or ≤ 29 weeks after completion of definitive therapy (chemoradiation therapy) or adjuvant (post-operative) therapy. * Patient must have a combined positive score PD-L1 positive (CPS \>/= 1) tumor. * Any radiation therapy must be completed \>= 10 days prior to registration. * Patients should not have received any prior treatment in the recurrent or metastatic setting. * Prior therapy with neoadjuvant or induction anti PD-1/PD-L1 monoclonal antibody or cetuximab in the curative setting is allowed if last treatment dose was \>= 26 weeks prior to registration without evidence of disease progression during that treatment period. * Patient has not received a live vaccine within 30 days prior to registration. * Patient does not have a history of any contraindication or has a severe hypersensitivity to any component of pembrolizumab or cetuximab (≥ grade 3). * Patient has not received chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to registration. * Patient with oropharyngeal cancer only must have negative results from testing of human papillomavirus (HPV) status defined as p16 immunohistochemistry (IHC) and/or HPV in situ hybridization (ISH). * Note: A Clinical Laboratory Improvement Act (CLIA) certified circulating tumor HPV deoxyribonucleic acid (ctHPVDNA) assay can be used if tissue sample is not available. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Absolute neutrophil count (ANC) ≥ 1,500/mm\^3. * Platelet count ≥ 100,000/mm\^3. * Hemoglobin (Hgb) ≥ 9 g/dL (if \< 9 g/dL, then transfusions are acceptable to increase hemoglobin above 9 g/dL). * Creatinine ≤ 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault formula for participant with creatinine levels \> 1.5 x institutional ULN. * Total bilirubin ≤ 1.5 x ULN OR direct bilirubin \< ULN for participant with total bilirubin \> 1.5 x institutional ULN. * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \[SGPT\]) ≤ 3.0 x ULN unless liver metastases are present in which case \< 5.0 x ULN. * Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. * Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 7 days prior to registration is required. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included. * For treated/stable brain metastases: Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. * Patients does not have a history of active myocarditis. * Patients does not have a history of any form of pneumonitis or diffuse idiopathic or immune mediated interstitial pulmonary disease. * Patient does not have a history of solid organ transplantation.
PROCEDURE: Biospecimen Collection, BIOLOGICAL: Cetuximab, PROCEDURE: Computed Tomography, PROCEDURE: Magnetic Resonance Imaging, BIOLOGICAL: Pembrolizumab, PROCEDURE: Positron Emission Tomography
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
I'm interested
Share via email
Show 166 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate High Tech Medical Park Palos Heights, Illinois Site Public Contact - (ncorp@aah.org)
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Outpatient Center - Oak Lawn Oak Lawn, Illinois Site Public Contact - (ncorp@aah.org)
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
Avera Cancer Institute Sioux Falls, South Dakota Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute - Mitchell Mitchell, South Dakota Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute at Pierre Pierre, South Dakota Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute at Yankton Yankton, South Dakota Site Public Contact - (OncRegulatory@avera.org)
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado Site Public Contact - (protocols@AllianceNCTN.org)
Cancer Centers of Southwest Oklahoma Research Lawton, Oklahoma
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
FirstHealth of the Carolinas-Moore Regional Hospital Pinehurst, North Carolina Site Public Contact - (jcwilliams@firsthealth.org)
Fremont - Rideout Cancer Center Marysville, California
Genesee Hematology Oncology PC Flint, Michigan
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Glens Falls Hospital Glens Falls, New York
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
HaysMed Hays, Kansas
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Jefferson Cherry Hill Hospital Cherry Hill, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Jefferson Torresdale Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Lake Regional Hospital Osage Beach, Missouri Site Public Contact - (clinicaltrials@lakeregional.com)
Lawrence Memorial Hospital Lawrence, Kansas Site Public Contact - (Stephanie.Norris@LMH.ORG)
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Lutheran Hospital - Cancer Centers of Colorado Golden, Colorado Site Public Contact - (peaksresearch@imail.org)
Margaret R Pardee Memorial Hospital Hendersonville, North Carolina Site Public Contact - (pardeecancerresearch@unchealth.unc.edu)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mary Greeley Medical Center Ames, Iowa
McFarland Clinic - Ames Ames, Iowa Site Public Contact - (ksoder@mcfarlandclinic.com)
McFarland Clinic - Boone Boone, Iowa
McFarland Clinic - Jefferson Jefferson, Iowa
McFarland Clinic - Marshalltown Marshalltown, Iowa
McFarland Clinic - Trinity Cancer Center Fort Dodge, Iowa
Medical Center of the Rockies Loveland, Colorado
Medical University of South Carolina Charleston, South Carolina Site Public Contact - (hcc-clinical-trials@musc.edu)
Memorial Hospital East Shiloh, Illinois Site Public Contact - (dschwab@wustl.edu)
Memorial Hospital North Colorado Springs, Colorado
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Nassau Uniondale, New York
Memorial Sloan Kettering Westchester Harrison, New York
Mercy Hospital Coon Rapids, Minnesota
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mount Sinai Medical Center Miami Beach, Florida
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Pocono Medical Center East Stroudsburg, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Poudre Valley Hospital Fort Collins, Colorado
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProHealth Waukesha Memorial Hospital Waukesha, Wisconsin
ProMedica Flower Hospital Sylvania, Ohio Site Public Contact - (PCIOncResearch@promedica.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
SUNY Upstate Medical Center-Community Campus Syracuse, New York
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint John's Hospital - Healtheast Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Salina Regional Health Center Salina, Kansas Site Public Contact - (mleepers@srhc.com)
Sanford Bismarck Medical Center Bismarck, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Joe Lueken Cancer Center Bemidji, Minnesota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Roger Maris Cancer Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Southern Illinois University School of Medicine Springfield, Illinois
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
State University of New York Upstate Medical University Syracuse, New York
The University of Kansas Cancer Center - Olathe Olathe, Kansas Site Public Contact - (OlatheCCResearch@kumc.edu)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UCHealth Greeley Hospital Greeley, Colorado Site Public Contact - (protocols@AllianceNCTN.org)
UCHealth Memorial Hospital Central Colorado Springs, Colorado
UChicago Medicine Northwest Indiana Crown Point, Indiana Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
UW Health Carbone Cancer Center Rockford Rockford, Illinois Site Public Contact - (lkline@uwhealth.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University Health Truman Medical Center Kansas City, Missouri
University of Arkansas for Medical Sciences Little Rock, Arkansas
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Chicago Medicine-Orland Park Orland Park, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - Briarcliff Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center-Overland Park Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
Upstate Cancer Center at Verona Verona, New York Site Public Contact - (McDowelE@upstate.edu)
VA Palo Alto Health Care System Palo Alto, California
VCU Massey Cancer Center at Stony Point Richmond, Virginia Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
West Virginia University Charleston Division Charleston, West Virginia

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

ctrrecruit@vcu.edu

NCT05828069
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* 180 days- \< 22 years (at time of study enrollment) * Patient must have a body surface area of ≥ 0.3 m\^2 * Patients with progressive, relapsed, or recurrent LCH with measurable disease at study entry * Patients must have had histologic verification of LCH (from either original diagnosis or relapse/progression) at the time of study entry * Tissue confirmation of relapse is recommended but not required. * Pathology report must be submitted for central confirmation of diagnosis within 7 days of enrollment. * Formalin-fixed paraffin-embedded (FFPE) blocks or unstained slides (initial diagnosis and/or subsequent biopsies) will be required for retrospective central confirmation of diagnosis and molecular studies * Patients with mixed histiocytic disorders (e.g. LCH with juvenile xanthogranuloma) may be included * Patients must have measurable disease * Patients must have progressive or refractory disease or experience relapse after at least one previous systemic treatment strategy * Pathogenic somatic mutation detected in genes encoding tyrosine kinase receptors (CSFR1, ERBB3 or ALK), RAS or RAF (may be from original or subsequent biopsy or peripheral blood/bone marrow aspirate). Clinical mutation reports may include quantitative polymerase chain reaction (PCR) (e.g. BRAFV600E) and/or Sanger or next generation sequencing. Immunohistochemistry (e.g. VE1 antibody for BRAFV600E) alone is not sufficient * Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet, which may be taken by mouth or other enteral route such as nasogastric, jejunostomy, or gastric tube * Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50% for patients =\< 16 years of age * Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age * Myelosuppressive chemotherapy: Patients must not have received within 14 days of entry onto this study * Investigational agent or any other anticancer therapy not defined above: Patients must not have received any investigational agent or any other anticancer therapy (including MAPK pathway inhibitor) for at least 14 days prior to planned start of tovorafenib (DAY101) * Radiation therapy (RT): Patient must not have received RT within 2 weeks after the last dose fraction of RT * Patients must have fully recovered from any prior surgery * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, targeted inhibitor, and/or radiotherapy with toxicities reduced to grade 1 or less (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) * Steroids: =\< 0.5 mg/kg/day of prednisone equivalent (maximum 20 mg/day) averaged during the month prior to study enrollment is permissible * Strong inducers or inhibitors of CYP2C8 are prohibited for 14 days before the first dose of tovorafenib (DAY101) and from planned administration for the duration of study participation * Medications that are breast cancer resistant protein (BCRP) substrates that have a narrow therapeutic index are prohibited for 14 days before the first dose of tovorafenib (DAY101) and for the duration of study participation * Peripheral absolute neutrophil count (ANC) \>= 750/uL unless secondary to bone marrow involvement, in such cases bone marrow involvement must be documented (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment) * Platelet count \>= 75,000/uL (unsupported/without transfusion within the past 7 days) (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment) * Patients with marrow disease must have platelet count of \>= 75,000/uL (transfusion support allowed) and must not be refractory to platelet transfusions. Bone marrow involvement must be documented * Hemoglobin \>= 8 g/dL (unsupported/without transfusion within the past 7 days). Patients with marrow disease must have hemoglobin \>= 8 g/dL (transfusion support allowed). Bone marrow involvement must be documented * Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g., Neulasta \[registered trademark\]) or 7 days for short-acting growth factor * A serum creatinine based on age/sex as follows (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment) * Age: 6 months to \< 1 year; Maximum Serum Creatinine (mg/dL):= 0.5 mg/dl (male and female) * Age: 1 to \< 2 years; Maximum Serum Creatinine (mg/dL): = 0.6 mg/dl (male and female) * Age: 2 to \< 6 years; Maximum Serum Creatinine (mg/dL): = 0.8 mg/dl (male and female) * Age: 6 to \< 10 years; Maximum Serum Creatinine (mg/dL): = 1.0 mg/dl (male and female) * Age: 10 to \< 13 years; Maximum Serum Creatinine (mg/dL): = 1.2 mg/dl (male and female) * Age: 13 to \< 16 years; Maximum Serum Creatinine (mg/dL): = 1.5 mg/dl (male) and 1.4 mg/dl (female) * Age: \>= 16 years; Maximum Serum Creatinine (mg/dL): = 1.7 mg/dl (male) and 1.4 mg/dl (female) * OR- a 24 hour urine creatinine clearance \>= 50 mL/min/1.73 m\^2 * OR- a glomerular filtration rate (GFR) \>= 50 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) * Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility * Bilirubin (sum of conjugated + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment) * Alanine aminotransferase (ALT) =\< 3 x ULN for age (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment) * Serum albumin \>= 2 g/dl must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment) * For patients with liver disease caused by their histiocytic disorder (as evaluated on radiographic imaging or biopsy): patients may be enrolled with abnormal bilirubin, aspartate aminotransferase (AST), ALT and albumin with documentation of histiocytic liver disease * Fractional shortening (FS) of \>= 25% or ejection fraction of \>= 50%, as determined by echocardiography or multigated acquisition scan (MUGA) within 28 days prior to study enrollment. Depending on institutional standard, either FS or left ventricular ejection fraction (LVEF) is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above (must be obtained within 28 days prior to enrollment and start of protocol therapy) (repeat if necessary) * No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% if there is clinical indication for determination; unless it is due to underlying pulmonary LCH * Central Nervous System Function Defined As: * Patients with seizure disorder may be enrolled if well controlled * Central nervous system (CNS) toxicity =\< Grade 2 * Human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial unless antiretroviral therapy interacts with the metabolism of tovorafenib (DAY101) and cannot safely be changed to antivirals that do not interact with study medication * All patients and/or their parent(s) or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.
Exclusion Criteria:
* LCH arising along with other hematologic malignancy (e.g. mixed LCH with acute lymphoblastic leukemia) or any history of non-histiocytic malignancy * Disease scenarios as below will be excluded * Skin-limited disease * Gastrointestinal (GI) tract involvement only (those that have disease that can be determined by endoscopic biopsies only) * LCH-associated neurodegeneration (LCH-ND) without parenchymal lesions or other systemic lesions * Patients with activating mutations in MAP2K1 are not eligible for this study due to drug target specificity. Mutation status will be submitted to study team within 7 days of enrollment * Refractory nausea and vomiting, malabsorption, or external biliary shunt that would preclude adequate absorption of tovorafenib (DAY101) * Uncontrolled systemic bacterial, viral, or fungal infection * Major surgical procedure or significant traumatic injury within 14 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device or minor surgery is permitted within fourteen (14) days of study enrollment (provided that the wound has healed) * History of significant bowel resection that would preclude adequate absorption or other significant malabsorptive disease * Ophthalmologic considerations: Patients with known significant ophthalmologic conditions or known risk factors for retinal vein occlusion (RVO) or central serous retinopathy (CSR) are not eligible * History of solid organ or hematopoietic bone marrow transplantation * Clinically significant active cardiovascular disease, or history of myocardial infarction, or deep vein thrombosis/pulmonary embolism within 6 months prior to enrollment, ongoing cardiomyopathy, or current prolonged QT interval \> 440 ms based on triplicate electrocardiogram (ECG) average * History of Grade \>= 2 CNS hemorrhage or history of any CNS hemorrhage within 28 days of study entry * History of any drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome or Stevens Johnsons syndrome (SJS) or who are allergic to tovorafenib (DAY101) or any of its components * CTCAE version (V.) 5.0 Grade 3 symptomatic creatinine kinase (CPK) elevation (\> 5 x ULN) * Female patients who are pregnant are ineligible. A pregnancy test is required for female patients of childbearing potential * Lactating females who plan to breastfeed their infants are ineligible * Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation are ineligible. Women of childbearing potential must use non-hormonal contraception during tovorafenib treatment and for at least 28 days after the last dose. Men should use effective contraception and must not father a child while taking tovorafenib and for 14 days after the last dose
PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Bone Marrow Biopsy, PROCEDURE: Computed Tomography, PROCEDURE: Echocardiography Test, PROCEDURE: FDG-Positron Emission Tomography and Computed Tomography Scan, PROCEDURE: Lumbar Puncture, PROCEDURE: Multigated Acquisition Scan, DRUG: Tovorafenib
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
I'm interested
Share via email
Show 112 locations

Study Locations

Hide all locations
Location Contacts
Albany Medical Center Albany, New York
Alfred I duPont Hospital for Children Wilmington, Delaware Site Public Contact - (Allison.bruce@nemours.org)
Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Arkansas Children's Hospital Little Rock, Arkansas
Arnold Palmer Hospital for Children Orlando, Florida Site Public Contact - (Jennifer.spinelli@orlandohealth.com)
BI-LO Charities Children's Cancer Center Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Blank Children's Hospital Des Moines, Iowa Site Public Contact - (samantha.mallory@unitypoint.org)
British Columbia Children's Hospital Vancouver, British Columbia
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL) Québec, Site Public Contact - (rechclinique@crchudequebec.ulaval.ca)
Cardinal Glennon Children's Medical Center St Louis, Missouri
Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec Site Public Contact - (yvan.samson@umontreal.ca)
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Sherbrooke, Quebec Site Public Contact - (crcinformation.chus@ssss.gouv.qc.ca)
Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia Site Public Contact - (Olivia.Floyd@choa.org)
Children's Hospital London, Ontario
Children's Hospital Colorado Aurora, Colorado Site Public Contact - (josh.b.gordon@nsmtp.kp.org)
Children's Hospital Los Angeles Los Angeles, California
Children's Hospital New Orleans New Orleans, Louisiana
Children's Hospital and Medical Center of Omaha Omaha, Nebraska
Children's Hospital of Alabama Birmingham, Alabama Site Public Contact - (oncologyresearch@peds.uab.edu)
Children's Hospital of Orange County Orange, California Site Public Contact - (oncresearch@choc.org)
Children's Hospital of Philadelphia Philadelphia, Pennsylvania Site Public Contact - (CancerTrials@email.chop.edu)
Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania Site Public Contact - (jean.tersak@chp.edu)
Children's Hospital of San Antonio San Antonio, Texas Site Public Contact - (bridget.medina@christushealth.org)
Children's Hospital of Wisconsin Milwaukee, Wisconsin Site Public Contact - (MACCCTO@mcw.edu)
Children's Hospital of the King's Daughters Norfolk, Virginia Site Public Contact - (CCBDCresearch@chkd.org)
Children's Hospitals and Clinics of Minnesota - Minneapolis Minneapolis, Minnesota Site Public Contact - (pauline.mitby@childrensmn.org)
Children's National Medical Center Washington D.C., District of Columbia Site Public Contact - (OncCRC_OnCall@childrensnational.org)
Connecticut Children's Medical Center Hartford, Connecticut
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Dayton Children's Hospital Dayton, Ohio
Dell Children's Medical Center of Central Texas Austin, Texas Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org)
Duke University Medical Center Durham, North Carolina
East Carolina University Greenville, North Carolina Site Public Contact - (eubankss@ecu.edu)
East Tennessee Childrens Hospital Knoxville, Tennessee
El Paso Children's Hospital El Paso, Texas Site Public Contact - (ranjan.bista@ttuhsc.edu)
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Golisano Children's Hospital of Southwest Florida Fort Myers, Florida Site Public Contact - (molly.arnstrom@leehealth.org)
Hackensack University Medical Center Hackensack, New Jersey
Hospital for Sick Children Toronto, Ontario Site Public Contact - (ask.CRS@sickkids.ca)
IWK Health Centre Halifax, Nova Scotia Site Public Contact - (Research@iwk.nshealth.ca)
Kaiser Permanente Downey Medical Center Downey, California
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York Site Public Contact - (CancerTrials@nyulangone.org)
Loma Linda University Medical Center Loma Linda, California
Lucile Packard Children's Hospital Stanford University Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
Lurie Children's Hospital-Chicago Chicago, Illinois
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
Maimonides Medical Center Brooklyn, New York
McMaster Children's Hospital at Hamilton Health Sciences Hamilton, Ontario
Memorial Health University Medical Center Savannah, Georgia Site Public Contact - (Lorraine.OHara@hcahealthcare.com)
Memorial Sloan Kettering Cancer Center New York, New York
Mercy Hospital Saint Louis St Louis, Missouri
Methodist Children's Hospital of South Texas San Antonio, Texas Site Public Contact - (Vinod.GidvaniDiaz@hcahealthcare.com)
Michigan State University East Lansing, Michigan
Mission Hospital Asheville, North Carolina Site Public Contact - (NCDV.ResearchRegulatory@HCAHealthcare.com)
Montefiore Medical Center - Moses Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, New York Site Public Contact - (cancerclinicaltrials@cumc.columbia.edu)
NYP/Weill Cornell Medical Center New York, New York
Nationwide Children's Hospital Columbus, Ohio Site Public Contact - (Melinda.Triplet@nationwidechildrens.org)
Nemours Children's Clinic - Pensacola Pensacola, Florida Site Public Contact - (helpdesk@childrensoncologygroup.org)
Nemours Children's Clinic-Jacksonville Jacksonville, Florida Site Public Contact - (Allison.bruce@nemours.org)
Nemours Children's Hospital Orlando, Florida Site Public Contact - (Allison.bruce@nemours.org)
New York Medical College Valhalla, New York
Nicklaus Children's Hospital Miami, Florida
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
Perth Children's Hospital Perth, Western Australia Site Public Contact - (helpdesk@childrensoncologygroup.org)
Primary Children's Hospital Salt Lake City, Utah
Prisma Health Richland Hospital Columbia, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington Site Public Contact - (HopeBeginsHere@providence.org)
Queensland Children's Hospital South Brisbane, Queensland
Rainbow Babies and Childrens Hospital Cleveland, Ohio
Riley Hospital for Children Indianapolis, Indiana
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center Denver, Colorado Site Public Contact - (PSGResearchSharedMailbox@HCAHealthcare.com)
Royal Children's Hospital Parkville, Victoria Site Public Contact - (Jordan.Hansford@rch.org.au)
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick, New Jersey
Saint Christopher's Hospital for Children Philadelphia, Pennsylvania
Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida Site Public Contact - (jennifer.manns@baycare.org)
Saint Joseph's Regional Medical Center Paterson, New Jersey Site Public Contact - (HallL@sjhmc.org)
Saint Jude Midwest Affiliate Peoria, Illinois
Scott and White Memorial Hospital Temple, Texas
Seattle Children's Hospital Seattle, Washington
Sinai Hospital of Baltimore Baltimore, Maryland
State University of New York Upstate Medical University Syracuse, New York
Summerlin Hospital Medical Center Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Sydney Children's Hospital Randwick, New South Wales
The Children's Hospital at TriStar Centennial Nashville, Tennessee
The Steven and Alexandra Cohen Children's Medical Center of New York New Hyde Park, New York
UCSF Benioff Children's Hospital Oakland Oakland, California Site Public Contact - (PedOncRschOAK@ucsf.edu)
UCSF Medical Center-Mission Bay San Francisco, California Site Public Contact - (cancertrials@ucsf.edu)
UF Health Cancer Institute - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
University of Alberta Hospital Edmonton, Alberta Site Public Contact - (pedsoncologyresearch@ahs.ca)
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota
University of Mississippi Medical Center Jackson, Mississippi
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Texas Health Science Center at San Antonio San Antonio, Texas Site Public Contact - (phoresearchoffice@uthscsa.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Children's Hospital Madera, California Site Public Contact - (Research@valleychildrens.org)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Wake Forest University Health Sciences Winston-Salem, North Carolina
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
West Virginia University Charleston Division Charleston, West Virginia
Yale University New Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

ctrrecruit@vcu.edu

NCT05112601
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients with measurable or non-measurable (detectable) recurrent endometrial cancer * Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined per RECIST 1.1 criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \>= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI * Non-measurable (detectable) disease in a patient is defined in this protocol per RECIST 1.1 criteria as one who does not have measurable disease but has at least one of the following conditions: * All other lesions (or sites of disease), including small lesions (longest diameter \<10 mm or pathological lymph nodes with \>= 10 to \< 15 mm short axis), are considered non-measurable disease * Ascites and/or pleural effusion attributed to tumor * Solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions * Patients must have endometrial cancer with deficient mismatch repair system. All patients must have institutional immunohistochemistry (IHC) and/or microsatellite instability (MSI) testing to determine mismatch repair (MMR) status. MMR deficiency is defined as lack of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6, EPCAM) by immunohistochemistry and/or presence of microsatellite instability high using the National Cancer Institute (NCI)-5plex and Promega v1.2 assays, or institutional standards (e.g. next-generation sequencing \[NGS\] panel) * Method(s) of detection of MMR deficiency will be recorded for each patient. An institutional pathology report, and additional reports if available, documenting these results must be submitted. Patients with "equivocal" results on MMR testing by immunohistochemistry may be eligible if they have documented evidence of microsatellite instability by MSI testing or by next generation sequencing assays. MMR testing by IHC may be used to resolve equivocal/indeterminate MSI results * Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, mucinous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.) * Patients may have received 1-2 prior lines of systemic therapy: * Prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings. Patients must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition * Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration * Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to registration * Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, biologic agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C) * Age \>= 18 * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Platelets \>= 100,000/mcl * Absolute neutrophil count (ANC) \>= 1,500/mcl * Creatinine =\< 1.5 x institutional/laboratory upper limit of normal (ULN) * Total serum bilirubin level =\< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =\<3 x ULN may be enrolled) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN * Adequate oxygen saturation via pulse oximeter (CTCAE v.5.0 hypoxia \< grade 2 within 28 days prior to registration) * Thyroid-stimulating hormone (TSH) within normal limits (TSH \< ULN allowed in euthyroid patients on thyroid replacement therapy). TSH testing is only required if clinically indicated * Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy. At least 4 weeks must have elapsed since major surgery * As clinically indicated, patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better and have a corrected QT (QTc) interval \< 450 msec * The effects of nivolumab, and ipilimumab on the developing human fetus are unknown. For this reason and because nivolumab and ipilimumab are known to be teratogenic, women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial * Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and the patient is stable off steroids for at least one month * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information * Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible * Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
Exclusion Criteria:
* Patients with a diagnosis of endometrial serous carcinoma or carcinosarcoma * Patients who received prior anti-PD1/PD-L1 therapy and had grade 3-4 or recurring grade 2 immune-related toxicities that led to dose delay or discontinuation of immunotherapy due to those toxicities * Patients who received anti-CTLA-4 therapy or other immunotherapeutic agents * Patients on chronic steroid therapy except those on replacement therapy at a daily dose of 10mg or less prednisone or equivalent * Patients on immunosuppressive therapy, with the exception of: * Intra-nasal, inhaled, topical or local steroid injections * Premedication for hypersensitivity reaction * Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease * Patients with known immune impairment who may be unable to respond to anti-CTLA-4 antibody * Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Women who are pregnant or unwilling to discontinue nursing * Prior therapy with CTLA-4 inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways * History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, and/or ipilimumab including severe hypersensitivity reactions to any monoclonal antibody
PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, BIOLOGICAL: Ipilimumab, PROCEDURE: Magnetic Resonance Imaging, BIOLOGICAL: Nivolumab
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
I'm interested
Share via email
Show 120 locations

Study Locations

Hide all locations
Location Contacts
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Arnold Palmer Cancer Center Medical Oncology Norwin N. Huntingdon, Pennsylvania Site Public Contact - (ClinicalResearchServices@upmc.edu)
Augusta University Medical Center Augusta, Georgia Site Public Contact - (ga_cares@augusta.edu)
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Carle BroMenn Medical Center Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Cancer Institute Normal Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Cleveland Clinic Cancer Center/Fairview Hospital Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Foundation Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Duke University Medical Center Durham, North Carolina
Duke Women's Cancer Care Raleigh Raleigh, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center-South University Clinic Fargo, North Dakota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fred Hutchinson Cancer Center Seattle, Washington
Geauga Hospital Chardon, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Good Samaritan Hospital - Cincinnati Cincinnati, Ohio Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Henrico Doctor's Hospital Richmond, Virginia
Hillcrest Hospital Cancer Center Mayfield Heights, Ohio Site Public Contact - (TaussigResearch@ccf.org)
IRMC Cancer Center Indiana, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
IU Health North Hospital Carmel, Indiana Site Public Contact - (iutrials@iu.edu)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana Site Public Contact - (iutrials@iu.edu)
Intermountain Health West End Clinic Billings, Montana
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Miami Valley Hospital South Centerville, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miller-Dwan Hospital Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Nebraska Methodist Hospital Omaha, Nebraska
Northwest Cancer Center - Hobart Hobart, Indiana
Northwest Cancer Center - Main Campus Crown Point, Indiana
Northwest Cancer Center - Valparaiso Valparaiso, Indiana Site Public Contact - (CancerResearch@COMHS.org)
Northwest Oncology LLC Dyer, Indiana
Northwest Wisconsin Cancer Center Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
Oklahoma Cancer Specialists and Research Institute-Tulsa Tulsa, Oklahoma
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Memorial Hospital Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Roswell Park Cancer Institute Buffalo, New York
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon
Saint Catherine Hospital Indianapolis, Indiana Site Public Contact - (Roster@nrgoncology.org)
Saint Francis Regional Medical Center Shakopee, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Mary Medical Center Hobart, Indiana Site Public Contact - (CancerResearch@COMHS.org)
Saint Vincent Frontier Cancer Center Billings, Montana
State University of New York Upstate Medical University Syracuse, New York
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The Community Hospital Munster, Indiana
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UH Seidman Cancer Center at Saint John Medical Center Westlake, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UPMC Cancer Center at UPMC Horizon Farrell, Pennsylvania Site Public Contact - (Roster@nrgoncology.org)
UPMC Cancer Center at UPMC McKeesport McKeesport, Pennsylvania
UPMC Cancer Center at UPMC Northwest Seneca, Pennsylvania
UPMC Cancer Center-Natrona Heights Natrona Heights, Pennsylvania
UPMC Cancer Center-Washington Washington, Pennsylvania Site Public Contact - (Roster@nrgoncology.org)
UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania Site Public Contact - (ClinicalResearchServices@upmc.edu)
UPMC Hillman Cancer Center - New Castle New Castle, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center - Part of Frick Hospital Mount Pleasant, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center - Passavant - Cranberry Cranberry Township, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania Site Public Contact - (ClinicalResearchServices@upmc.edu)
UPMC Hillman Cancer Center at Butler Health System Butler, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center in Coraopolis Moon Township, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC West Mifflin-Cancer Center Jefferson West Mifflin, Pennsylvania
UPMC-Heritage Valley Health System Beaver Beaver, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC-Johnstown/John P. Murtha Regional Cancer Center Johnstown, Pennsylvania
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania
UPMC-Mercy Hospital Pittsburgh, Pennsylvania
UPMC-Passavant Hospital Pittsburgh, Pennsylvania
UPMC-Saint Clair Hospital Cancer Center Pittsburgh, Pennsylvania
UPMC-Saint Margaret Pittsburgh, Pennsylvania
UT Southwestern Clinical Center at Richardson/Plano Richardson, Texas Site Public Contact - (Suzanne.cole@utsouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Fort Worth Fort Worth, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University Cancer and Blood Center LLC Athens, Georgia Site Public Contact - (research@universitycancer.com)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Site Public Contact - (gingerreeves@uabmc.edu)
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Rochester Rochester, New York
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Wilmot Cancer Institute at Webster Webster, New York Site Public Contact - (WCICTOresearch@urmc.rochester.edu)
Women and Infants Hospital Providence, Rhode Island
Women's Cancer Center of Nevada Las Vegas, Nevada
Women's Diagnostic Center - Munster Munster, Indiana Site Public Contact - (mnicholson@comhs.org)

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

ctrrecruit@vcu.edu

NCT05675410
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must be 5 to 60 years of age at the time of enrollment * Patients with newly diagnosed untreated histologically confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified \[NOS\]) with stage I or II disease * Patients must have bidimensionally measurable disease (at least one lesion with longest diameter \>= 1.5 cm) * Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained * Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease. * Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality. * Patients \>= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2 * Patients =\< 17 years of age must have a Lansky performance score of \>= 50 * Pediatric patients (age 5-17 years): A serum creatinine based on age/sex as follows (within 28 days prior to enrollment): * 2 to \< 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female) * 6 to \< 10 years (age): 1 mg/dL (male), 1 mg/dL (female) * 10 to \< 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female) * 13 to \< 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female) * \>= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine creatinine clearance \>= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment) OR a glomerular filtration rate (GFR) \>= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) * Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility * For adult patients (age 18 years or older) (within 28 days prior to enrollment): Creatinine clearance \>= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight * Total bilirubin =\< 2 x upper limit of normal (ULN) (within 28 days prior to enrollment) * Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome * Aspartate aminotransferase (AST) =\< 3 x ULN (within 28 days prior to enrollment) * Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome * Alanine aminotransferase (ALT) =\< 3 x ULN (within 28 days prior to enrollment) * Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome * Shortening fraction of \>= 27% by echocardiogram (ECHO), multigated acquisition scan (MUGA), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of \>= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment) * Diffusion capacity of the lung for carbon monoxide (DLCO) \>= 50% of predicted value as corrected for hemoglobin by pulmonary function test (PFT) (within 28 days prior to enrollment). If unable to obtain PFTs, the criterion is: a pulse oximetry reading of \> 92% on room air * Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
* Patients with nodular lymphocyte predominant Hodgkin lymphoma * Patients with a history of active interstitial pneumonitis or interstitial lung disease * Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients * Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, autoimmune conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills * Patients with a condition requiring systemic treatment with either corticosteroids (defined as equivalent to \> 10 mg daily predniSONE for patients \>= 18 years or \> 0.5 mg/kg \[up to 10 mg/day\] for patients \< 18 years) or other immunosuppressive medications within 14 days prior to enrollment * Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=\< 10 mg daily for patients \>= 18 years or =\< 0.5 mg/kg \[up to 10 mg/day\] predniSONE equivalents) are permitted in the absence of active autoimmune disease * Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1 * Short term use of corticosteroids for premedication or treatment of an allergy or hypersensitivity is considered an acceptable use of corticosteroids. * Patients with peripheral neuropathy \> grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome * Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen * Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL * Prior solid organ transplant * Prior allogeneic stem cell transplantation * Live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette Guerin \[BCG\], oral polio vaccine, and oral typhoid). Administration of messenger ribonucleic acid (mRNA) vaccines are permitted * Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test within 28 days prior to enrollment is required for female patients of childbearing potential * Lactating females who plan to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last treatment * Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method for the duration of their study drug therapy. Following therapy, patients will be advised to use contraception as per institutional practice or as listed below for investigational agents, whichever is longer * Men and women of childbearing potential (WOCBP) must use effective contraception during the study and for 2 months for WOCBP and 4 months for men, after last dose of brentuximab vedotin * WOCBP must continue contraception for a period of at least 5 months after the last dose of nivolumab * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
PROCEDURE: Biospecimen Collection, BIOLOGICAL: Bleomycin Sulfate, DRUG: Brentuximab Vedotin, PROCEDURE: Computed Tomography, DRUG: Cyclophosphamide, DRUG: Dacarbazine, DRUG: Doxorubicin Hydrochloride, DRUG: Etoposide, DRUG: Etoposide Phosphate, OTHER: Fludeoxyglucose F-18, RADIATION: Involved-site Radiation Therapy, PROCEDURE: Magnetic Resonance Imaging, BIOLOGICAL: Nivolumab, PROCEDURE: Positron Emission Tomography, DRUG: Prednisolone, DRUG: Prednisone, DRUG: Procarbazine Hydrochloride, OTHER: Questionnaire Administration, DRUG: Vinblastine Sulfate, DRUG: Vincristine Sulfate
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
I'm interested
Share via email
Show 385 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
AdventHealth Orlando Orlando, Florida Site Public Contact - (FH.Cancer.Research@flhosp.org)
Advocate Children's Hospital-Oak Lawn Oak Lawn, Illinois
Advocate Children's Hospital-Park Ridge Park Ridge, Illinois Site Public Contact - (helpdesk@childrensoncologygroup.org)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Albany Medical Center Albany, New York
Alberta Children's Hospital Calgary, Alberta Site Public Contact - (research4kids@ucalgary.ca)
Alfred I duPont Hospital for Children Wilmington, Delaware Site Public Contact - (Allison.bruce@nemours.org)
Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Arkansas Children's Hospital Little Rock, Arkansas
Arnold Palmer Hospital for Children Orlando, Florida Site Public Contact - (Jennifer.spinelli@orlandohealth.com)
Ascension Saint Vincent Indianapolis Hospital Indianapolis, Indiana Site Public Contact - (research@stvincent.org)
Atrium Health Navicent Macon, Georgia Site Public Contact - (andrew.weatherall@atriumhealth.org)
Augusta University Medical Center Augusta, Georgia Site Public Contact - (ga_cares@augusta.edu)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BI-LO Charities Children's Cancer Center Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Beacon Kalamazoo Cancer Center Kalamazoo, Michigan
Blank Children's Hospital Des Moines, Iowa Site Public Contact - (samantha.mallory@unitypoint.org)
Bronson Battle Creek Battle Creek, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Broward Health Medical Center Fort Lauderdale, Florida Site Public Contact - (Allison.bruce@nemours.org)
C S Mott Children's Hospital Ann Arbor, Michigan
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL) Québec, Site Public Contact - (rechclinique@crchudequebec.ulaval.ca)
CTCA at Western Regional Medical Center Goodyear, Arizona
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado Site Public Contact - (ctsucontact@westat.com)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan Site Public Contact - (connie.szczepanek@crcwm.org)
CancerCare Manitoba Winnipeg, Manitoba Site Public Contact - (ctu_web@cancercare.mb.ca)
Cardinal Glennon Children's Medical Center St Louis, Missouri
Carilion Children's Roanoke, Virginia Site Public Contact - (wpmccarty@carilionclinic.org)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Cedars Sinai Medical Center Los Angeles, California
Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec Site Public Contact - (yvan.samson@umontreal.ca)
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Sherbrooke, Quebec Site Public Contact - (crcinformation.chus@ssss.gouv.qc.ca)
Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia Site Public Contact - (Olivia.Floyd@choa.org)
Children's Hospital London, Ontario
Children's Hospital Colorado Aurora, Colorado Site Public Contact - (josh.b.gordon@nsmtp.kp.org)
Children's Hospital Los Angeles Los Angeles, California
Children's Hospital Medical Center Of Akron Akron, Ohio
Children's Hospital New Orleans New Orleans, Louisiana
Children's Hospital Of Eastern Ontario Ottawa, Ontario
Children's Hospital and Medical Center of Omaha Omaha, Nebraska
Children's Hospital of Alabama Birmingham, Alabama Site Public Contact - (oncologyresearch@peds.uab.edu)
Children's Hospital of Michigan Detroit, Michigan Site Public Contact - (helpdesk@childrensoncologygroup.org)
Children's Hospital of Orange County Orange, California Site Public Contact - (oncresearch@choc.org)
Children's Hospital of Philadelphia Philadelphia, Pennsylvania Site Public Contact - (CancerTrials@email.chop.edu)
Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania Site Public Contact - (jean.tersak@chp.edu)
Children's Hospital of San Antonio San Antonio, Texas Site Public Contact - (bridget.medina@christushealth.org)
Children's Hospital of Wisconsin Milwaukee, Wisconsin Site Public Contact - (MACCCTO@mcw.edu)
Children's Hospital of the King's Daughters Norfolk, Virginia Site Public Contact - (CCBDCresearch@chkd.org)
Children's Hospitals and Clinics of Minnesota - Minneapolis Minneapolis, Minnesota Site Public Contact - (pauline.mitby@childrensmn.org)
Children's Mercy Hospitals and Clinics Kansas City, Missouri Site Public Contact - (COGResearchGroup@cmh.edu)
Children's National Medical Center Washington D.C., District of Columbia Site Public Contact - (OncCRC_OnCall@childrensnational.org)
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio Site Public Contact - (cancer@cchmc.org)
City of Hope Antelope Valley Lancaster, California Site Public Contact - (becomingapatient@coh.org)
City of Hope Comprehensive Cancer Center Duarte, California Site Public Contact - (becomingapatient@coh.org)
City of Hope Corona Corona, California Site Public Contact - (becomingapatient@coh.org)
City of Hope Newport Beach Newport Beach, California
City of Hope Seacliff Huntington Beach, California
City of Hope South Bay Torrance, California
City of Hope South Pasadena South Pasadena, California Site Public Contact - (becomingapatient@coh.org)
City of Hope Upland Upland, California Site Public Contact - (becomingapatient@coh.org)
City of Hope at Irvine Lennar Irvine, California
City of Hope at Long Beach Elm Long Beach, California
Cleveland Clinic Foundation Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Connecticut Children's Medical Center Hartford, Connecticut
Cook Children's Medical Center Fort Worth, Texas Site Public Contact - (CookChildrensResearch@cookchildrens.org)
Cooper Hospital University Medical Center Camden, New Jersey
Corewell Health Beaumont Troy Hospital Troy, Michigan
Corewell Health Children's Royal Oak, Michigan
Corewell Health Dearborn Hospital Dearborn, Michigan
Corewell Health Farmington Hills Hospital Farmington Hills, Michigan
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health William Beaumont University Hospital Royal Oak, Michigan
Covenant Children's Hospital Lubbock, Texas Site Public Contact - (mbisbee@providence.org)
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana-Farber Cancer Institute Boston, Massachusetts
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Dayton Children's Hospital Dayton, Ohio
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dell Children's Medical Center of Central Texas Austin, Texas Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org)
Driscoll Children's Hospital Corpus Christi, Texas Site Public Contact - (Crystal.DeLosSantos@dchstx.org)
Duke University Medical Center Durham, North Carolina
East Carolina University Greenville, North Carolina Site Public Contact - (eubankss@ecu.edu)
East Tennessee Childrens Hospital Knoxville, Tennessee
Eastern Maine Medical Center Bangor, Maine
Edward Hospital/Cancer Center Naperville, Illinois
Edward Hospital/Cancer Center?Plainfield Plainfield, Illinois Site Public Contact - (Cancerresearch@edward.org)
Edwards Comprehensive Cancer Center Huntington, West Virginia Site Public Contact - (Christina.Cole@chhi.org)
El Paso Children's Hospital El Paso, Texas Site Public Contact - (ranjan.bista@ttuhsc.edu)
Elmhurst Memorial Hospital Elmhurst, Illinois Site Public Contact - (Jrohde@emhc.org)
Emory Proton Therapy Center Atlanta, Georgia Site Public Contact - (allyson.anderson@emory.edu)
Emory Saint Joseph's Hospital Atlanta, Georgia
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Glens Falls Hospital Glens Falls, New York
Golisano Children's Hospital of Southwest Florida Fort Myers, Florida Site Public Contact - (molly.arnstrom@leehealth.org)
Grady Health System Atlanta, Georgia
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
HSHS Saint Elizabeth's Hospital O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Hackensack University Medical Center Hackensack, New Jersey
Hematology Oncology Associates of CNY at Camillus Camillus, New York
Hematology Oncology Associates of Central New York-East Syracuse East Syracuse, New York
Henry Ford Hospital Detroit, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Medical Center-Columbus Novi, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford West Bloomfield Hospital West Bloomfield, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Hospital for Sick Children Toronto, Ontario Site Public Contact - (ask.CRS@sickkids.ca)
Hunterdon Medical Center Flemington, New Jersey
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
IWK Health Centre Halifax, Nova Scotia Site Public Contact - (Research@iwk.nshealth.ca)
Inova Fairfax Hospital Falls Church, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
Iowa Methodist Medical Center Des Moines, Iowa
Jersey City Medical Center Jersey City, New Jersey Site Public Contact - (ctsucontact@westat.com)
Jersey Shore Medical Center Neptune City, New Jersey
Jim Pattison Children's Hospital Saskatoon, Saskatchewan Site Public Contact - (Jessica.Marien@saskhealthauthority.ca)
Johns Hopkins All Children's Hospital St. Petersburg, Florida Site Public Contact - (Ashley.Repp@jhmi.edu)
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Site Public Contact - (jhcccro@jhmi.edu)
Kaiser Permanente Downey Medical Center Downey, California
Kaiser Permanente Downtown Commons Sacramento, California Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Fresno Orchard Plaza Fresno, California
Kaiser Permanente San Leandro San Leandro, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fremont Fremont, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Modesto Modesto, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Francisco San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California Site Public Contact - (Kpoct@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California Site Public Contact - (Kpoct@kp.org)
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York Site Public Contact - (CancerTrials@nyulangone.org)
Legacy Emanuel Children's Hospital Portland, Oregon
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Loma Linda University Medical Center Loma Linda, California
Loyola University Medical Center Maywood, Illinois
Lurie Children's Hospital-Chicago Chicago, Illinois
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
Maine Children's Cancer Program Scarborough, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Cancer Care and IV Therapy - South Portland South Portland, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mary Bridge Children's Hospital and Health Center Tacoma, Washington Site Public Contact - (research@multicare.org)
Mayo Clinic in Rochester Rochester, Minnesota
McMaster Children's Hospital at Hamilton Health Sciences Hamilton, Ontario
MedStar Georgetown University Hospital Washington D.C., District of Columbia
Medical Center of the Rockies Loveland, Colorado
Medical City Dallas Hospital Dallas, Texas
Medical University of South Carolina Charleston, South Carolina Site Public Contact - (hcc-clinical-trials@musc.edu)
Memorial Health University Medical Center Savannah, Georgia Site Public Contact - (Lorraine.OHara@hcahealthcare.com)
Memorial Hospital East Shiloh, Illinois Site Public Contact - (dschwab@wustl.edu)
Memorial Hospital North Colorado Springs, Colorado
Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida Site Public Contact - (OHR@mhs.net)
Memorial Sloan Kettering Cancer Center New York, New York
Mercy Cancer Center - Carmichael Carmichael, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Elk Grove Elk Grove, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Rocklin Rocklin, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Sacramento Sacramento, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Saint Louis St Louis, Missouri
Mercy San Juan Medical Center Carmichael, California Site Public Contact - (OncologyResearch@DignityHealth.org)
Methodist Children's Hospital of South Texas San Antonio, Texas Site Public Contact - (Vinod.GidvaniDiaz@hcahealthcare.com)
Michigan State University East Lansing, Michigan
Miller Children's and Women's Hospital Long Beach Long Beach, California
Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mission Hospital Asheville, North Carolina Site Public Contact - (NCDV.ResearchRegulatory@HCAHealthcare.com)
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Montefiore Medical Center - Moses Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Morristown Medical Center Morristown, New Jersey
Mount Sinai Hospital New York, New York Site Public Contact - (CCTO@mssm.edu)
Mount Sinai Hospital Medical Center Chicago, Illinois Site Public Contact - (suhi@sinai.org)
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, New York Site Public Contact - (cancerclinicaltrials@cumc.columbia.edu)
NYP/Weill Cornell Medical Center New York, New York
NYU Langone Hospital - Long Island Mineola, New York Site Public Contact - (cancertrials@nyulangone.org)
Natalie Warren Bryant Cancer Center at Saint Francis Tulsa, Oklahoma
Nationwide Children's Hospital Columbus, Ohio Site Public Contact - (Melinda.Triplet@nationwidechildrens.org)
Naval Medical Center - Portsmouth Portsmouth, Virginia
Naval Medical Center -San Diego San Diego, California
Nebraska Medicine-Bellevue Bellevue, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
Nebraska Medicine-Village Pointe Omaha, Nebraska
Nemours Children's Clinic - Pensacola Pensacola, Florida Site Public Contact - (helpdesk@childrensoncologygroup.org)
Nemours Children's Clinic-Jacksonville Jacksonville, Florida Site Public Contact - (Allison.bruce@nemours.org)
Nemours Children's Hospital Orlando, Florida Site Public Contact - (Allison.bruce@nemours.org)
Newark Beth Israel Medical Center Newark, New Jersey Site Public Contact - (Christine.Kosmides@rwjbh.org)
Nicklaus Children's Hospital Miami, Florida
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
Northwestern Medicine Cancer Center Delnor Geneva, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois
Northwestern Medicine Orland Park Orland Park, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
Norton Children's Hospital Louisville, Kentucky Site Public Contact - (CancerResource@nortonhealthcare.org)
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Penn State Children's Hospital Hershey, Pennsylvania
Phoenix Childrens Hospital Phoenix, Arizona
Poudre Valley Hospital Fort Collins, Colorado
Presbyterian Hospital Albuquerque, New Mexico
Primary Children's Hospital Salt Lake City, Utah
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Richland Hospital Columbia, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio Site Public Contact - (PCIOncResearch@promedica.org)
Providence Alaska Medical Center Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington Site Public Contact - (HopeBeginsHere@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Rady Children's Hospital - San Diego San Diego, California
Rainbow Babies and Childrens Hospital Cleveland, Ohio
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Renown Regional Medical Center Reno, Nevada Site Public Contact - (research@sncrf.org)
Rhode Island Hospital Providence, Rhode Island
Riley Hospital for Children Indianapolis, Indiana
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rush-Copley Healthcare Center Yorkville, Illinois Site Public Contact - (Cancer.Research@rushcopley.com)
Rush-Copley Medical Center Aurora, Illinois Site Public Contact - (RCMC_Cancer_Research@rush.edu)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick, New Jersey
Sacred Heart Hospital Pensacola, Florida
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Barnabas Medical Center Livingston, New Jersey Site Public Contact - (joanne.loeb@rwjbh.org)
Saint Christopher's Hospital for Children Philadelphia, Pennsylvania
Saint Francis Cancer Center Greenville, South Carolina Site Public Contact - (Heather_Rich@bshsi.org)
Saint Francis Hospital Federal Way, Washington Site Public Contact - (Heather_Rich@bshsi.org)
Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida Site Public Contact - (jennifer.manns@baycare.org)
Saint Joseph's Regional Medical Center Paterson, New Jersey Site Public Contact - (HallL@sjhmc.org)
Saint Jude Midwest Affiliate Peoria, Illinois
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Hospital Chesterfield, Missouri
Saint Mary's Medical Center West Palm Beach, Florida
Saint Peter's University Hospital New Brunswick, New Jersey Site Public Contact - (kcovert@saintpetersuh.com)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Santa Barbara Cottage Hospital Santa Barbara, California
Scott and White Memorial Hospital Temple, Texas
Seattle Children's Hospital Seattle, Washington
Sinai Hospital of Baltimore Baltimore, Maryland
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Westerly Westerly, Rhode Island Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Long Ridge Stamford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Derby Care Center Derby, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut Site Public Contact - (canceranswers@yale.edu)
Southern Illinois University School of Medicine Springfield, Illinois
State University of New York Upstate Medical University Syracuse, New York
Stony Brook University Medical Center Stony Brook, New York
Swedish Covenant Hospital Chicago, Illinois
T C Thompson Children's Hospital Chattanooga, Tennessee
Tampa General Hospital Tampa, Florida Site Public Contact - (syapchanyk@tgh.org)
The Children's Hospital at TriStar Centennial Nashville, Tennessee
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The Montreal Children's Hospital of the MUHC Montreal, Quebec Site Public Contact - (info@thechildren.com)
The Steven and Alexandra Cohen Children's Medical Center of New York New Hyde Park, New York
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus Elizabeth, New Jersey
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California Site Public Contact - (ucstudy@uci.edu)
UCHealth Greeley Hospital Greeley, Colorado Site Public Contact - (ctsucontact@westat.com)
UCHealth Memorial Hospital Central Colorado Springs, Colorado
UCHealth University of Colorado Hospital Aurora, Colorado
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California Site Public Contact - (ucstudy@uci.edu)
UF Health Cancer Institute - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UMC Cancer Center / UMC Health System Lubbock, Texas
UMass Memorial Medical Center - University Campus Worcester, Massachusetts Site Public Contact - (cancer.research@umassmed.edu)
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
USA Health Strada Patient Care Center Mobile, Alabama
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
UW Health Carbone Cancer Center Rockford Rockford, Illinois Site Public Contact - (lkline@uwhealth.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University Pediatric Hospital San Juan,
University of Alberta Hospital Edmonton, Alberta Site Public Contact - (pedsoncologyresearch@ahs.ca)
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan Health - West Wyoming, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota
University of Mississippi Medical Center Jackson, Mississippi
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Rochester Rochester, New York
University of Texas Health Science Center at San Antonio San Antonio, Texas Site Public Contact - (phoresearchoffice@uthscsa.edu)
University of Vermont and State Agricultural College Burlington, Vermont Site Public Contact - (rpo@uvm.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Medical Center Renton, Washington Site Public Contact - (research@valleymed.org)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Wake Forest University Health Sciences Winston-Salem, North Carolina
Walter Reed National Military Medical Center Bethesda, Maryland
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Wayne State University/Karmanos Cancer Institute Detroit, Michigan Site Public Contact - (ctoadmin@karmanos.org)
Weisberg Cancer Treatment Center Farmington Hills, Michigan Site Public Contact - (ctoadmin@karmanos.org)
Wesley Medical Center Wichita, Kansas Site Public Contact - (WesleyResearch@wesleymc.com)
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
West Virginia University Charleston Division Charleston, West Virginia
Wilmot Cancer Institute at Webster Webster, New York Site Public Contact - (WCICTOresearch@urmc.rochester.edu)
Woodland Memorial Hospital Woodland, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Yale University New Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)
Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Toll Free Number - Trialsites@msd.com

NCT06079879
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Has a diagnosis of ET per WHO 2016 diagnostic criteria for myeloproliferative neoplasms (confirmed by a central pathologist) * Has a centrally assessed bone marrow fibrosis score of Grade 0 or Grade 1, as per a modified version of the European Consensus Criteria for Grading Myelofibrosis * Has a history of inadequate response to or intolerance of hydroxyurea based on modified European LeukemiaNet (ELN) criteria for hydroxyurea resistance or intolerance * Has an inadequate or loss of response to their most recent prior ET therapy, requiring a change of cytoreductive therapy * Has a platelet count \> 450 × 10\^9/L (450k /μL) assessed up to 72 hours before first dose of study intervention * Has an absolute neutrophil count (ANC) ≥0.75 × 10\^9/L assessed up to 72 hours before first dose of study intervention * Participants may have received up to 3 prior ET-directed cytoreductive agents including hydroxyurea
Exclusion Criteria:
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to bomedemstat or lysine demethylase or monoamine oxidase inhibitor (LSDi or MAOi) or the chosen best available therapy (including anagrelide, interferon alfa/pegylated interferon, ruxolitinib, or busulfan) that contraindicates participation * History of any illness/impairment of GI function that might interfere with drug absorption (eg, chronic diarrhea or history of gastric bypass surgical procedure), confound the study results or pose an additional risk to the individual by participation in the study * Evidence at the time of Screening of increased risk of bleeding * History of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder * Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
DRUG: Bomedemstat, DRUG: Anagrelide, DRUG: Busulfan, DRUG: Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, DRUG: Ruxolitinib
Essential Thrombocythemia
essential thrombocythemia, ET, bomedemstat, IMG-7289
I'm interested
Share via email
Show 159 locations

Study Locations

Hide all locations
Location Contacts
Addenbrooke's Hospital ( Site 3303) Cambridge, Cambridgeshire
Affiliated Hospital of Nantong University ( Site 3527) Nantong, Jiangsu
Albert Schweitzer Ziekenhuis, locatie Dordwijk-Internal Medicine ( Site 2302) Dordrecht, South Holland
Anhui Provincial Hospital ( Site 3513) Hefei, Anhui
Ankara Bilkent Şehir Hastanesi ( Site 3201) Ankara,
Ankara UTF Cebeci Arastırma ve Uygulama Hastanesi ( Site 3210) Ankara,
Antalya Egitim ve Arastırma Hastanesi ( Site 3207) Antalya,
Aotearoa Clinical Trials ( Site 0050) Auckland,
Arcispedale Santa Maria Nuova ( Site 0301) Reggio Emilia,
Asan Medical Center ( Site 0603) Seoul,
Azienda Ospedaliera Universitaria Careggi ( Site 0030) Florence, Tuscany
Azienda Ospedaliero Universitaria Pisana-UO Ematologia UNIV ( Site 0309) Pisa, Tuscany
Azienda Ospedaliero Universitaria delle Marche ( Site 0302) Ancona,
Azienda Ospedaliero Universitaria di Ferrara ( Site 0304) Cona, Ferrara
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 0034) Alessandria, Ancona
Boston Pilgrim Hospital ( Site 3301) Boston, Lincolnshire
C.I.C.E. 9 de Julio ( Site 1001) San Miguel de Tucumán, Tucumán Province
CHUS - Hospital Clinico Universitario ( Site 0421) Santiago de Compostela, La Coruna
Calvary Mater Newcastle ( Site 0505) Waratah, New South Wales
Carmel Hospital ( Site 0906) Haifa,
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois-HEMATOLOGY ( Site 0407) Vandœuvre-lès-Nancy, Lorraine
Centre Hospitalier Régional Universitaire de Tours - Hôpital-Hématologie et Thérapie Cellulaire ( Site 0413) Tours, Indre-et-Loire
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Hématologie Clinique et Thérapie Cellu ( Site 1701) Limoges, Limousin
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 0417) Rennes, Ille-et-Vilaine
Centre Hospitalier de Roubaix ( Site 1703) Roubaix, Nord
Chang Gung Medical Foundation-Linkou Branch ( Site 3103) Taoyuan District,
Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 3104) Kaohsiung City,
Chang Gung Memorial Hospital- Chiayi ( Site 3102) Chiayi City, Chiayi
Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0707) Debrecen,
Duke University Health System (DUHS) ( Site 0016) Durham, North Carolina
Ege Universitesi Hastanesi ( Site 3202) Izmir,
Ehime University Hospital ( Site 3612) Tōon, Ehime
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 2201) Milan, Lombardy
Fujita Health University Hospital ( Site 3613) Toyoake, Aichi-ken
Fukushima Medical University Hospital ( Site 3616) Fukushima,
Fundacion Colombiana de Cancerología Clinica Vida ( Site 1403) Medellín, Antioquia
GenesisCare - Windsor ( Site 3309) Windsor, Windsor And Maidenhead
Gloucestershire Royal Hospital ( Site 3302) Gloucester, Gloucestershire
Guy's & St Thomas' NHS Foundation Trust ( Site 3305) London, London, City of
HOSPITAL CLÍNIC DE BARCELONA ( Site 2800) Barcelona, Catalonia
Hacettepe Universite Hastaneleri-Department of Hematology ( Site 3204) Ankara,
Hadassah Medical Center ( Site 0904) Jerusalem,
Henan Cancer Hospital-hematology department ( Site 3504) Zhengzhou, Henan
Henry Ford Hospital ( Site 3413) Detroit, Michigan
Hokkaido University Hospital ( Site 3601) Sapporo, Hokkaido
Hospital Costa del Sol-Hematology Service ( Site 0412) Marbella, Malaga
Hospital General Universitario de Albacete ( Site 0408) Albacete,
Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 0409) Badalona, Barcelona
Hospital Italiano de Buenos Aires ( Site 0105) ABB, Buenos Aires F.D.
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0404) Barcelona,
Hospital Universitario 12 de Octubre ( Site 2806) Madrid,
Hospital Universitario Austral ( Site 0104) Pilar, Buenos Aires
Hospital Universitario Doctor Peset ( Site 0411) Valencia,
Hospital Universitario Ramón y Cajal-Hematology ( Site 2803) Madrid, Madrid, Comunidad de
Hospital Universitario Virgen de la Victoria ( Site 0418) Málaga,
Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 0419) Salamanca,
Hospital del Mar ( Site 2807) Barcelona, Catalonia
Huashan Hospital, Fudan University ( Site 3529) Shanghai, Shanghai Municipality
Hôpital Saint Antoine-Service d'Hématologie et de Thérapie Cellulaire ( Site 1702) Paris, Île-de-France Region
Hôpital Saint-Louis-Centre d'Investigations Cliniques ( Site 0405) Paris,
IMAT S.A.S ( Site 1401) Montería, Departamento de Córdoba
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0308) Meldola, Forli-Cesena
Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 2801) L'Hospitalet Del Llobregat, Barcelona
Institute of hematology&blood disease hospital ( Site 3501) Tianjin, Tianjin Municipality
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 0414) Porto,
Istituto Oncologico Veneto IRCCS-Oncoematologia ( Site 0306) Castelfranco Veneto, Veneto
Jiangsu Province Hospital ( Site 3507) Nanjing, Jiangsu
Jinan Central Hospital ( Site 3523) Jinan, Shandong
Juntendo University Hospital ( Site 3611) Bunkyo-ku, Tokyo
Kanazawa University Hospital ( Site 3614) Kanazawa, Ishikawa-ken
Kansai Medical University Hospital ( Site 3607) Hirakata, Osaka
Karolinska Universitetssjukhuset Huddinge ( Site 2900) Huddinge, Stockholm County
Kindai University Hospital ( Site 3600) Sakai, Osaka
King's College Hospital ( Site 3308) London, London, City of
Kobe City Medical Center General Hospital ( Site 3603) Kobe, Hyōgo
Kocaeli Üniversitesi-Hematology ( Site 3205) Kocaeli,
Korea University Anam Hospital ( Site 0604) Seoul,
Kyushu University Hospital ( Site 3605) Fukuoka,
Lincoln County Hospital ( Site 3310) Lincoln, Great Britain
Liverpool Hospital-Haematology ( Site 0501) Liverpool, New South Wales
Los Angeles Cancer Network ( Site 3491) Glendale, California
Los Cobos Medical Center ( Site 1404) Bogotá, Bogota D.C.
Martini Ziekenhuis ( Site 2300) Groningen,
Medical University of South Carolina-Hollings Cancer Center ( Site 3426) Charleston, South Carolina
Medipol Mega Universite Hastanesi-oncology ( Site 3203) Istanbul,
Mie University Hospital ( Site 3615) Tsu, Mie-ken
Monash Health-Haematology Research ( Site 0006) Clayton, Victoria
National Cancer Center Hospital East ( Site 3610) Kashiwa, Chiba
National Cheng Kung University Hospital-Clinical Trial Center ( Site 3105) Tainan,
National Hospital Organization Sendai Medical Center ( Site 3617) Sendai, Miyagi
National Taiwan University Hospital ( Site 3101) Taipei,
Nippon Medical School Hospital ( Site 3608) Bunkyo-ku, Tokyo
North Shore Hospital-Department of Haematology ( Site 0051) Auckland,
Okayama University Hospital ( Site 3604) Okayama,
Ondokuz Mayıs Universitesi-hematology ( Site 3206) Samsun,
Ospedale Mauriziano ( Site 0305) Torino,
Ospedale di Circolo e Fondazione Macchi Varese ( Site 2200) Varese,
Peking Union Medical College Hospital ( Site 3531) Beijing, Beijing Municipality
Peking University Third Hospital-Hematology ( Site 3502) Beijing, Beijing Municipality
Petz Aladar Egyetemi Oktato Korhaz ( Site 2000) Győr, Győr-Moson-Sopron
Pratia Onkologia Katowice ( Site 0702) Katowice, Silesian Voivodeship
Queen Mary Hospital ( Site 1901) Hksar,
Rabin Medical Center ( Site 0905) Petah Tikva,
Rambam Health Care Campus ( Site 2102) Haifa,
Roswell Park Cancer Institute ( Site 3421) Buffalo, New York
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0001) Adelaide, South Australia
Royal Gwent Hospital ( Site 3304) Gwent, Newport
Royal North Shore Hospital ( Site 0003) St Leonards, New South Wales
Royal Perth Hospital-Haematology ( Site 0504) Perth, Western Australia
Royal Prince Alfred Hospital ( Site 1100) Camperdown, New South Wales
Semmelweis Egyetem-Belgyógyászati és Hematológiai Klinika ( Site 0708) Budapest,
Seoul National University Bundang Hospital-Hematology ( Site 0605) Seongnam, Kyonggi-do
Shaanxi provincial people's hospital ( Site 3516) Xi'an, Shaanxi
Sheba Medical Center ( Site 2101) Ramat Gan,
Soroka Medical Center ( Site 2100) Beersheba,
Sourasky Medical Center ( Site 0902) Tel Aviv,
Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 3511) Guangzhou, Guangdong
Spaarne Gasthuis - Hoofddorp-Oncology ( Site 2301) Hoofddorp, North Holland
Stanford Cancer Institute ( Site 0107) Stanford, California
Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 3524) Guangzhou, Guangdong
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 2504) Kielce, Świętokrzyskie Voivodeship
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór-Haematológia osztály ( Site 0706) Nyíregyháza, Szabolcs-Szatmár-Bereg
The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0606) Seoul,
The Christie NHS Foundation Trust ( Site 3307) Manchester,
The First Affiliated hospital of Xiamen University ( Site 3515) Xiamen, Fujian
The First Afflilated Hospital of Bengbu Medical College ( Site 3509) Bengbu, Anhui
The First Hospital of Hebei Medical University ( Site 3510) Shijiazhuang, Hebei
The First Hospital of Jilin University-Hematology ( Site 3526) Changchun, Jilin
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3505) Nanchang, Jiangxi
The Lundquist Institute ( Site 3423) Torrance, California
The Moncton Hospital-Oncology ( Site 1500) Moncton, New Brunswick
The Second Affiliated Hospital Of Fujian Medical University ( Site 3525) Quanzhou, Fujian
The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3508) Hangzhou, Zhejiang
Trakya University Medical Faculty Hospital-Hematology ( Site 3200) Edirne,
Tufts Medical Center ( Site 3408) Boston, Massachusetts
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 2600) Lisbon,
Unidade Local de Saude de Braga - Hospital de Braga ( Site 0415) Braga,
Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 0402) Dresden, Saxony
Universitetssjukhuset Örebro ( Site 0403) Örebro, Örebro County
University College London Hospital ( Site 3300) London, London, City of
University Medical Center Groningen ( Site 2304) Groningen,
University of Colorado Anschutz Medical Campus ( Site 3425) Aurora, Colorado
University of Michigan ( Site 0008) Ann Arbor, Michigan
University of Miyazaki Hospital ( Site 3609) Miyazaki,
University of Virginia ( Site 3422) Charlottesville, Virginia
University of Yamanashi Hospital ( Site 3606) Chūō, Yamanashi
Universitätsklinikum Aachen ( Site 1801) Aachen, North Rhine-Westphalia
Universitätsklinikum Halle ( Site 0401) Halle, Saxony-Anhalt
VCU Health Adult Outpatient Pavillion ( Site 3416) Richmond, Virginia
VM Medical Park Mersin Hastanesi ( Site 3208) Mersin,
Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400) Winston-Salem, North Carolina
West China Hospital, Sichuan University ( Site 3518) Chengdu, Sichuan
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0502) Melbourne, Victoria
Wuhan Union Hospital ( Site 3500) Wuhan, Hubei
Yitzhak Shamir Medical Center. ( Site 0901) Ẕerifin,
ZAS Cadix ( Site 1200) Antwerp,
Zhejiang University School of Medicine-The Fourth Affiliated Hospital ( Site 3517) Yiwu, Zhejiang
Zhongshan Hospital,Fudan University-Hematology ( Site 3530) Shanghai, Shanghai Municipality
centre hospitalier lyon sud ( Site 0406) Pierre-Bénite, Rhone

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO)

ABBVIE CALL CENTER - abbvieclinicaltrials@abbvie.com

NCT06158841
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. * Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol. * Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment: * Serum M-protein \>= 0.5 g/dL (\>= 5 g/L). * Urine M-protein \>= 200 mg/24 hours. * In participants without measurable serum or urine M protein, serum free light chain (FLC) \>= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio. * Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb). * Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.
Exclusion Criteria:
* Clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months. * Clinically significant conditions such as but not limited to the following: neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that would adversely affect the participant's participation in the study. * Central nervous system involvement of MM. * Has received B-cell maturation antigen (BCMA)-targeted therapy.
DRUG: Etentamig, DRUG: Carfilzomib, DRUG: Pomalidomide, DRUG: Elotuzumab, DRUG: Selinexor, DRUG: Bortezomib, DRUG: Dexamethasone
Multiple Myeloma
Cervino, Multiple Myeloma, Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
I'm interested
Share via email
Show 164 locations

Study Locations

Hide all locations
Location Contacts
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 256808 Turin, Piedmont
AOU Policlinico G. Rodolico - San Marco /ID# 256814 Catania,
ASST Ovest Milanese /ID# 256813 Legnano, Milano
AZ Sint-Jan Brugge /ID# 245345 Bruges, West-Vlaanderen
Addenbrookes Hospital /ID# 261104 Cambridge, Cambridgeshire
Alberts Cellular Therapy /ID# 245725 Pretoria, Gauteng
Alexandra General Hospital /ID# 240591 Athens, Attica
Algemeen Ziekenhuis klina /ID# 260856 Brasschaat, Antwerpen
Alta Bates Summit Medical Center for Research /ID# 261438 Berkeley, California
Anjo Kosei Hospital /ID# 263434 Anjo, Aichi-ken
Antalya Egitim Ve Arastirma Hastanesi /ID# 261674 Antalya,
Atrium Health Levine Cancer Institute /ID# 246199 Charlotte, North Carolina
Auxilio Mutuo Cancer Center /ID# 272565 San Juan,
Azienda Ospedaliero Universitaria delle Marche /ID# 256812 Ancona,
Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 256810 Rome, Roma
Baptist Memorial Hospital /ID# 270910 Memphis, Tennessee
Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891 Lansing, Michigan
Beijing Chaoyang Hospital,Capital Medical University /ID# 245533 Beijing, Beijing Municipality
Beth Israel Deaconess Medical Center /ID# 271535 Boston, Massachusetts
Box Hill Hospital /ID# 262784 Melbourne, Victoria
CH Henri Duffaut /ID# 261844 Avignon, Vaucluse
Calvary Mater Newcastle /ID# 261804 Waratah, New South Wales
Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230 Jacksonville, Florida
Cedars-Sinai Medical Center /ID# 261008 Los Angeles, California
Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 263637 Bethesda, Maryland
Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 261854 Orléans,
Centre Hospitalier du Mans /ID# 261852 Le Mans, Sarthe
Centrum fuer Haematologie und Onkologie Bethanien /ID# 271982 Frankfurt am Main,
Ch Saint Quentin /Id# 261856 Saint-Quentin, Aisne
Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 260689 Berlin,
Chiba University Hospital /ID# 262006 Chiba, Chiba
China Medical University Hospital /ID# 245483 Taichung,
Chugoku Central Hospital /ID# 263431 Fukuyama, Hiroshima
Cleveland Clinic Main Campus /ID# 246183 Cleveland, Ohio
Complejo Hospitalario Universitario Ourense /ID# 246400 Ourense, Ourense
Constantiaberg Haematology /ID# 261320 Cape Town, Western Cape
Dana-Farber Cancer Institute /ID# 261554 Boston, Massachusetts
Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 261646 Budapest,
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 261672 Ankara,
Duke University Medical Center /ID# 259694 Durham, North Carolina
Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 262488 London, Greater London
Eastchester Center for Cancer Care /ID# 262952 The Bronx, New York
Fakultni Nemocnice Ostrava /ID# 245686 Ostrava, Ostrava-mesto
Fakultní Nemocnice Brno - Jihlavská /ID# 245689 Brno, Brno-mesto
Fakultní nemocnice Hradec Králové - Sokolská /ID# 245690 Hradec Králové, Hradec Kralove
Falu Lasarett /ID# 262231 Falun,
First Affiliated Hospital of China Medical University /ID# 245547 Shenyang, Liaoning
Fujian Medical University Union Hospital /ID# 245558 Fuzhou, Fujian
Fundacao Champalimaud /ID# 246258 Lisbon, Lisbon District
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 240596 Athens,
General University Hospital of Thessaloniki AXEPA /ID# 240595 Thessaloniki,
Gifu Municipal Hospital /ID# 263321 Gifu, Gifu
Gunma University Hospital /ID# 262580 Maebashi, Gunma
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 261648 Győr, Győr-Moson-Sopron
Haemalife Inc. /ID# 245724 Kuils River, Western Cape
Helsingborgs Lasarett /ID# 262513 Helsingborg, Skåne County
Hematology And Oncology Institute /ID# 272531 Manatí,
Henan Cancer Hospital /ID# 245536 Zhengzhou, Henan
Henry Ford Hospital /ID# 262704 Detroit, Michigan
Hospital General Universitario Gregorio Maranon /ID# 246401 Madrid,
Hospital Universitario de Salamanca /ID# 262218 Salamanca,
Hospital Universitario y Politecnico La Fe /ID# 261625 Valencia,
Hospital de Leon /ID# 261624 León,
Hyogo Prefectural Amagasaki General Medical Center /ID# 265696 Amagasaki, Hyōgo
Institute of Hematology and Blood Diseases Hospital /ID# 265702 Tianjin, Tianjin Municipality
Instituto Catalan de Oncologia (ICO) Badalona /ID# 246398 Badalona, Barcelona
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE /ID# 246257 Porto,
Istanbul Florence Nightingale Hospital /ID# 271543 Şişli,
Japanese Red Cross Medical Center /ID# 261717 Shibuya-ku, Tokyo
Karmanos Cancer Institute - Detroit /ID# 266298 Detroit, Michigan
Klinik Ottakring /ID# 245829 Vienna, Vienna
Klinikum Chemnitz - Flemmingstraße /ID# 273108 Chemnitz, Saxony
Kyushu University Hospital /ID# 264704 Fukuoka, Fukuoka
Leeds Teaching Hospitals NHS Trust /ID# 261101 Leeds, West Yorkshire
Liverpool Hospital /ID# 262159 Liverpool, New South Wales
Mayo Clinic - Rochester /ID# 246228 Rochester, Minnesota
Mayo Clinic Hospital - Phoenix /ID# 263326 Phoenix, Arizona
Mayo Clinic Hospital Jacksonville /ID# 263324 Jacksonville, Florida
Medical University of South Carolina /ID# 259692 Charleston, South Carolina
Medizinische Universitaet Graz /ID# 261908 Graz, Styria
Miyagi Cancer Center /ID# 265094 Natori-shi, Miyagi
Monash Health - Monash Medical Centre /ID# 262158 Clayton, Victoria
Nagoya City University Hospital /ID# 263320 Nagoya, Aichi-ken
Naha City Hospital /ID# 263972 Naha, Okinawa
Nancy W. Knowles Cancer Center /ID# 271361 Elmhurst, Illinois
National Taiwan University Hospital /ID# 245482 Taipei City, Taipei
New York Cancer & Blood Specialists - Bay Shore /ID# 261524 Bay Shore, New York
New York Cancer & Blood Specialists - Lake Success Medical Oncology /ID# 262953 New Hyde Park, New York
New York Cancer and Blood Specialists - New York /ID# 262951 New York, New York
Northwest Medical Specialties Tacoma /ID# 276281 Tacoma, Washington
Nottingham City Hospital /ID# 261105 Nottingham, Nottinghamshire
Odense University Hospital /ID# 260924 Odense, Region Syddanmark
Ordensklinikum Linz GmbH Elisabethinen /ID# 245609 Linz, Upper Austria
Oregon Medical Research Center /ID# 262335 Portland, Oregon
Our Lady Of The Lake Regional Medical Center /ID# 272780 Baton Rouge, Louisiana
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 245545 Beijing, Beijing Municipality
People's Hospital of Henan Province /ID# 260918 Zhengzhou, Henan
Princess Alexandra Hospital /ID# 261810 Woolloongabba, Queensland
Providence - St. Jude Medical Center /ID# 262031 Fullerton, California
Rabin Medical Center. /ID# 245498 Petah Tikva,
Regents of the University of Michigan /ID# 261577 Ann Arbor, Michigan
Rocky Mountain Cancer Centers - Lone Tree /ID# 278320 Lone Tree, Colorado
Rush University Medical Center /ID# 265690 Chicago, Illinois
Saitama Prefectural Cancer Center /ID# 262586 Kitaadachi-gun, Saitama
Samsung Medical Center /ID# 245492 Seoul, Seoul Teugbyeolsi
Second Affiliated Hospital of Xian Jiaotong University /ID# 261255 Xi'an, Shaanxi
Semmelweis Egyetem /ID# 261647 Budapest,
Seoul National University Hospital /ID# 245491 Seoul, Seoul Teugbyeolsi
Shaare Zedek Medical Center /ID# 245681 Jerusalem, Jerusalem
Shanghai Tongji Hospital /ID# 245539 Shanghai, Shanghai Municipality
Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 260882 Hangzhou, Zhejiang
Springfield Clinic - First /ID# 262266 Springfield, Illinois
St George Hospital /ID# 261806 Kogarah, New South Wales
St Vincent's Hospital Melbourne /ID# 261808 Fitzroy Melbourne, Victoria
Staedtisches Klinikum Karlsruhe /ID# 272377 Karlsruhe, Baden-Wurttemberg
Sun Yat-Sen University Cancer Center /ID# 245542 Guangzhou, Guangdong
Taichung Veterans General Hospital /ID# 261142 Taichung,
Tel Aviv Sourasky Medical Center /ID# 245495 Tel Aviv, Tel Aviv
Texas Oncology - Northeast Texas /ID# 278304 Tyler, Texas
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 245493 Seoul, Seoul Teugbyeolsi
The Chaim Sheba Medical Center /ID# 245497 Ramat Gan, Tel Aviv
The Christie Hospital /ID# 261102 Manchester,
The First Affiliated Hospital of Nanchang University /ID# 245537 Nanchang, Jiangxi
The First Affiliated Hospital of Soochow University /ID# 245544 Suzhou, Jiangsu
The First Affiliated Hospital of Wenzhou Medical University /ID# 245550 Wenzhou, Zhejiang
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883 Hangzhou, Zhejiang
The Royal Marsden NHS Foundation Trust /ID# 262470 London,
The University of Osaka Hospital /ID# 263974 Suita-shi, Osaka
The West Clinic /ID# 262444 Memphis, Tennessee
Tianjin Medical University General Hospital /ID# 260851 Tianjin, Tianjin Municipality
Tokyo Metropolitan Komagome Hospital /ID# 277567 Bunkyo Ku, Tokyo
Trakya University Medical Facu /ID# 261673 Edirne, Istanbul,
Uddevalla sjukhus /ID# 262034 Uddevalla, Västra Götaland County
Ulsan University Hospital /ID# 245490 Ulsan, Ulsan Gwang Yeogsi
Unidade Local de Saude de Santa Maria, EPE /ID# 246255 Lisbon,
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 245549 Wuhan, Hubei
Universitaetsklinikum Freiburg /ID# 262147 Freiburg im Breisgau, Baden-Wurttemberg
Universitaetsklinikum Hamburg-Eppendorf /ID# 260651 Hamburg,
Universitaetsklinikum Krems /ID# 261509 Krems, Lower Austria
University General Hospital Attikon /ID# 240592 Athens, Attica
University Health Network_Princess Margaret Cancer Centre /ID# 261566 Toronto, Ontario
University Hospital Kyoto Prefectural University of Medicine /ID# 262585 Kyoto, Kyoto
University Of Cincinnati Medical Center /ID# 246415 Cincinnati, Ohio
University of Alabama at Birmingham - Main /ID# 261434 Birmingham, Alabama
University of Fukui Hospital /ID# 264222 Yoshida-gun, Fukui
University of Illinois Hospital and Health Sciences System /ID# 246349 Chicago, Illinois
University of Missouri Hospital /ID# 261553 Columbia, Missouri
University of North Carolina /ID# 259854 Chapel Hill, North Carolina
University of Tennessee Health Science Center /ID# 261622 Memphis, Tennessee
University of Yamanashi Hospital /ID# 262912 Chuo-shi, Yamanashi
Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie /ID# 260168 Lublin, Lublin Voivodeship
Uniwersytecki Szpital Kliniczny We Wroclawiu /ID# 260172 Wroclaw, Lower Silesian Voivodeship
Uniwersyteckie Centrum Kliniczne /ID# 260169 Gdansk, Pomeranian Voivodeship
VA Loma Linda Healthcare System /ID# 261015 Loma Linda, California
VCU Massey Cancer Center: Dalton Oncology Clinic /ID# 261944 Richmond, Virginia
Vanderbilt University Medical Center /ID# 261621 Nashville, Tennessee
Vejle Sygehus /ID# 260923 Vejle, Region Syddanmark
Virginia Cancer Specialists - Fairfax /ID# 262792 Fairfax, Virginia
Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 278314 Norfolk, Virginia
Vseobecna fakultni nemocnice v Praze /ID# 245691 Prague, Praha 17
Western General Hospital - NHS Lothian /ID# 261106 Edinburgh, Edinburgh, City of
Winship Cancer Institute of Emory University /ID# 262525 Atlanta, Georgia
Yonsei University Health System Severance Hospital /ID# 245489 Seoul,
Zhongda Hospital Southeast University /ID# 245563 Nanjing, Jiangsu

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Study Director - clinicaltrials@beonemed.com

NCT06742996
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Histologically locally confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC) * Ability to provide archival or fresh tumor tissue for retrospective central confirmation of MCL diagnosis * Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator * Relapsed or refractory disease after the last line of therapy * Measurable disease defined as ≥ 1 nodal lesion that is \> 1.5 cm in longest diameter, or ≥ 1 extranodal lesion that is \> 1 cm in longest diameter * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 * Adequate organ function
Exclusion Criteria:
* Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i) * Prior therapy with BTK degraders * Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to failure of BTKi therapy are ineligible. * Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug * Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug * Known central nervous system involvement by lymphoma * Clinically significant cardiovascular disease * History of stroke or intracranial hemorrhage within 6 months before first dose of study drug Note: Other protocol defined Inclusion/Exclusion criteria may apply.
DRUG: Sonrotoclax, DRUG: Zanubrutinib, DRUG: Placebo
Mantle Cell Lymphoma, B Cell Lymphoma
mantle cell lymphoma, MCL, relapsed/refractory mantle cell lymphoma, sonrotoclax, BGB-11417
I'm interested
Share via email
Show 148 locations

Study Locations

Hide all locations
Location Contacts
Aichi Cancer Center Hospital Clinical Oncology Nagoya, Aichi-ken
Aidport Sp Z O O Skorzewo,
Antalya Memorial Hospital Dokuma,
Asan Medical Center Seoul,
Atrium Health Levine Cancer Institute (Lci) Charlotte, North Carolina
Atrium Health Wake Forest Baptist Charlotte, North Carolina
Auxilio Mutuo Cancer Center San Juan,
Azienda Sanitaria Universitaria Giuliano Isontina Trieste,
Beatson West of Scotland Cancer Centre Glasgow,
Beijing Cancer Hospital Beijing, Beijing Municipality
Beijing Hospital Beijing, Beijing Municipality
Box Hill Hospital Box Hill,
Centre Hospitalier Universitaire Nantes Hotel Dieu Nantes,
Centroricerche Cliniche Di Verona Srl Verona,
Chiba Cancer Center Chiba, Chiba
Christchurch Hospital Christchurch,
Chu Hopital Lyon Sud PierreBenite,
Chu Montpellier Hopital Saint Eloi Montpellier,
Chu Tours Hopital Bretonneau Tours,
Churchill Hospital Oxford University Hospital Nhs Trust Headington,
Clatterbridge Cancer Centre Metropolitan Borough of Wirral,
Cleveland Clinic Florida Weston, Florida
Cleveland Clinic Foundation Cleveland, Ohio
Concord Repatriation General Hospital Concord,
Dana Farber Cancer Institute Longwood Medical Center Boston, Massachusetts
Dept of Medicine Iii, University Hospitallmu München,
Derriford Hospital Plymouth,
Dokkyo Medical University Saitama Medical Center Koshigaya, Saitama
Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii Wroclaw,
Duke University Durham, North Carolina
Dunedin Hospital Dunedin,
Etlik City Hospital Ankara,
FUNDALEU Caba,
Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana
Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality
Fujian Medical University Union Hospital Fuzhou, Fujian
Fundacao Pio Xii Hospital de Amor de Barretos Barretos,
Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude Petrópolis,
GenesisCare North Shore St Leonards, New South Wales
H Puerta de Hierro Majadahonda Majadahonda,
Harbin Medical University Cancer Hospital Harbin, Heilongjiang
Hattiesburg Hematology and Oncology Clinic Hattiesburg, Mississippi
Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular São Paulo,
Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital Hiroshima, Hiroshima
Hokkaido University Hospital Sapporo,
Hospital Aleman CABA,
Hospital Clinic de Barcelona Barcelona,
Hospital Do Cancer de Pernambuco Recife,
Hospital Erasto Gaertner Curitiba, Paraná
Hospital Felício Rocho Belo Horizonte,
Hospital Santa Rita de Cassia Afecc Vitória,
Hospital Universitario Fundacion Jimenez Diaz Madrid,
Hospital Universitario de Cordoba Córdoba,
Hospital de Clínicas de Porto Alegre Porto Alegre, Rio Grande do Sul
Ico H Duran I Reynals Barcelona,
Institute of Science Tokyo Hospital Tokyo, Bunkyo-ku,
Instituto Joinvilense De Hematologia e Oncologia Joinville, Santa Catarina
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst Meldola,
Jiangsu Province Hospital Nanjing, Jiangsu
Jiangxi Province Cancer Hospital Nanchang, Jiangxi
Kagoshima University Hospital Kagoshima, Kagoshima,
Kanagawa Cancer Center Yokohama,
Klinikum Chemnitz gGmbH Chemnitz,
Kobe City Medical Center General Hospital Hyōgo,
Kocaeli Universitesi Tip Fakultesi Kocaeli,
Kurashiki Central Hospital Okayama, Kurashiki,
Liaoning Cancer Hospital and Institute Shenyang, Liaoning
Linear Clinical Research Nedlands, Western Australia
Linyi Cancer Hospital Linyi, Shandong
MD Anderson Cancer Center Madrid,
Matsuyama Red Cross Hospital Matsuyama,
Mayo Clinic Phoenix Phoenix, Arizona
Mayo Clinic Rochester Rochester, Minnesota
McGlinn Cancer Institute West Reading, Pennsylvania
Medical University Vienna Oncology Vienna,
Memorial Cancer Institute, Memorial Healthcare System Pembroke Pines, Florida
Mission Cancer and Blood Waukee, Iowa
Monash Health Clayton, Victoria
Nanfang Hospital of Southern Medical University Guangzhou, Guangdong
National Hospital Organization Okayama Medical Center Okayama,
Nebraska Cancer Specialists Omaha, Nebraska
Nebraska Cancer Specialists St Francis Grand Island Grand Island, Nebraska
North Shore Hospital Auckland,
Northwest Cancer Specialist, Pc(Us Oncology Research) Vancouver, Washington
Ogaki Municipal Hospital Ōgaki, Gifu
Ohio Health Research Institute Columbus, Ohio
Ohio State University Comprehensive Cancer Center Columbus, Ohio
One Clinical Research Nedlands, Western Australia
Ordensklinikum Linz GmbH Elisabethinen Linz,
Osaka Metropolitan University Hospital Osaka, Osaka
Osaka Red Cross Hospital Osakashi, Osaka
Ospedale Vito Fazzi, Asl Lecce Leece,
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania
Perth Blood Institute West Perth, Western Australia
Policlinico Sorsola Malpighi, Aou Di Bologna Bologna,
Pratia MCM Kraków Krakow, Lesser Poland Voivodeship
Pusan National University Hospital Busan,
Rockingham Hospital Cooloongup, Western Australia
Rush University Medical Center Chicago, Illinois
Samsung Medical Center Seoul,
Seoul National University Bundang Hospital Seongnam-si,
Seoul National University Hospital Seoul,
Severance Hospital Yonsei University Health System SeodaemunGu, Seoul Teugbyeolsi
Shaanxi Provincial Peoples Hospital Xi'an, Shaanxi
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital Chengdu, Sichuan
Stauferklinikum Schwabisch Gmund Kliniken Ostalb Mutlangen,
Sun Yat Sen University Cancer Center Guangzhou, Guangdong
Sunshine Coast Hospital and Health Service Birtinya, Queensland
Tauranga Hospital Tauranga,
Tennesse Oncology Chattanooga Downtown Chattanooga, Tennessee
Tennessee Oncology Nashville, Tennessee
Texas Oncology Austin Midtown Round Rock, Texas
The Affiliated Hospital of Qingdao University Branch West Coast Qingdao, Shandong
The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu
The Cancer and Hematology Centers Grand Rapids, Michigan
The Catholic University of Korea, Seoul St Marys Hospital SeochoGu, Seoul Teugbyeolsi
The Catholic University of Korea, Yeouido St Marys Hospital Yeongdeungpo-gu, Seoul Teugbyeolsi
The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality
The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang
The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan
The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan Hangzhou, Zhejiang
The Royal Bournemouth and Christchurch Hospitals Nhs Foundation Bournemouth,
The Valley Hospital, Inc Paramus, New Jersey
Tohoku University Hospital Miyagi, Sendai,
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei
Toyohashi Municipal Hospital Toyohashishi, Aichi-ken
Uk St Poelten Sankt Pölten,
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei
Universidade de Campinas Centro de Hematologia E Hemoterapia Campinas,
Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg Salzburg,
University College Hospital London,
University Hospitals Cleveland, Ohio
University of Alabama at Birmingham Hospital Birmingham, Alabama
University of Maryland Greenebaum Comprehensive Cancer Center Baltimore, Maryland
University of Michigan Ann Arbor, Michigan
University of Virginia Charlottesville, Virginia
Universitätsklinikum Halle Halle,
Universitätsklinikum Hamburg Eppendorf Hamburg,
Uniwersytecki Szpital Kliniczny Nr W Lublinie Lublin,
VCU Massey Cancer Center Richmond, Virginia
Virgina Cancer Specialists Gainesville, Virginia
Washington University School of Medicine St Louis, Missouri
Wellington Regional Hospital (Ccdhb) Wellington,
Westmead Hospital Westmead, New South Wales
Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi Lodz,
Yale University, Yale Cancer Center New Haven, Connecticut
Yokohama Municipal Citizens Hospital Yokohama,
hospital Italiano de Buenos Aires CABA,